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Abstract 
Human urine is an abundant source of the main nutrients (N, P, and K), while in the modern 
age it may contain traces of pharmaceutical and hormonal compounds. In many parts of the 
world, urine is collected into sewers, mixed with other wastewaters and treated at centralized 
wastewater treatment plants. Recently, the source separation of urine has been considered as 
a way to promote nutrient recovery from households as concentrated streams which could 
promote its use as fertilizer. The presence of pharmaceuticals and estrogens in urine has 
raised questions regarding its safe agricultural use, thus leading to a need to monitor the 
presence of pharmaceutically active compounds in urine. As a minimum, six-month storage 
before agricultural use is recommended for urine for hygienic reasons. The objective of this 
thesis was to develop and facilitate the use of source-separated urine by making the 
characterization of urine easier and faster, to gain more understanding regarding 
pharmaceutical and estrogenic behavior during urine storage, and to evaluate the suitability of 
human urine in microalgal cultivations as a nutrient source.  
An analytical liquid chromatographic method, which had the advantage of simultaneous 
analysis of eight pharmaceuticals in a short six-minute analysis time, was developed as no 
such method previously existed (Paper I). The method was validated, proven repeatable, and 
the obtained pharmaceutical recoveries were acceptable (81.6–109.2%). The limit of detection 
for the pharmaceuticals in urine was 39–1 610 µg/L. In addition, a previously developed 
bioluminescent yeast cell biosensor Saccharomyces cerevisiae (BMAEREluc/ERα) was 
applied on urine samples, as prior to this thesis no information was available on the use of 
yeast biosensor in estrogenic activity assessment from source-separated human urine (Paper 
II). The biosensor produced repeatable results in the estrogenic activity testing of fresh and 
stored human urine with the limit of detection corresponding to 0.28–35 µg/L of estrogens. To 
enhance the signal, incubation with β-glucuronidase enzyme was used. The biosensor gave a 
cumulative signal for estrogenic activity (estrogens and estrogen-like compounds), thus 
enabling the assessment of overall estrogenic activity during urine storage.  
The method presented in Paper I was subsequently used in monitoring spiked pharmaceutical 
concentrations in urine during six-month storage (Paper III). Each pharmaceutical (three 
antivirals and four antibiotic compounds) was tested in laboratory storage both individually and 
in therapeutic groups, as well as in therapeutic groups either with feces or urease inhibitor 
amendment. During storage, the overall concentration reductions of <1% to >99% were 
detected, and in assays with amendments, concentrations reductions remained <50%, except 
for rifampicin (>99%). Four of the pharmaceuticals had reduced concentrations after a six-
month storage, suggesting biological or chemical degradation and/or precipitation of the 
compounds.  
Human urine was tested as nutrient source for biomass production from microalga Chlorella 
vulgaris (Paper IV). Biomass yield in diluted urine was comparable with growth in artificial 
growth medium and urine could be utilized up to 1:25-dilutions without inhibition to algal growth. 
The highest biomass production (0.6 g/L) was achieved in 1:100-diluted urine. C. vulgaris used 
32.5–78.7% of N and 35.1–99.0% of P available in urine. At the beginning of cultivation, the 
majority of the biomass consisted of algal cells, while towards the end the share of living algal 
cells decreased, indicating accumulation of bacteria and algal cell debris.  
In conclusion, the results obtained in this thesis indicated that the pharmaceutical 
concentrations did not reduce enough in order to safely use urine. The yeast biosensor 
demonstrated that during storage, the estrogenic activity changes most likely due to bacterial 
enzyme activity, but some activity is still present after five months. The urine is a viable nutrient 
source for microalgal biomass production, thus having potential for sustainable use and 
recycling of nutrients.   
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Tiivistelmä 
Ihmisen virtsa sisältää runsaasti pääravinteita (N, P ja K), mutta nykyaikana se voi myös 
sisältää jäämiä lääkeaineista ja hormoniyhdisteistä. Suuressa osassa maailmaa virtsa 
kerätään viemäreihin, sekoitetaan muiden kotitalous- ja teollisuusjätevesien kanssa ja 
käsitellään jätevedenpuhdistamoilla. Virtsan erilliskeräys kotitalouksissa on kiinnostava 
vaihtoehto tälle käytännölle, sillä tällöin ravinteiden kierrätystä voidaan edistää ja näin 
edesauttaa virtsan lannoitekäyttöä. Virtsan sisältämät lääkeaineet ja hormonit ovat herättäneet 
kysymyksiä turvallisesta lannoitekäytöstä, jonka vuoksi on tarve seurata ja tutkia erittyvien 
aktiivisten lääkeaineiden esiintymistä ja pitoisuuksia virtsassa. Virtsan hygienisoimiseksi 
ennen lannoitekäyttöä suositellaan minimissään kuuden kuukauden varastointia. Tämän 
väitöstyön tarkoituksena oli kehittää ja edistää erilliskerätyn virtsan käyttöä tekemällä virtsan 
sisältämien ainesosien tutkimisesta nopeampaa ja helpompaa, lisätä tietoa lääkkeiden ja 
hormonien käyttäytymisestä virtsan varastoinnin aikana, sekä arvioida virtsan soveltuvuutta 
halpana ja uusiutuvana ravinnelähteenä mikrolevien kasvatukseen. 
 
Työssä kehitettiin uusi nestekromatografinen menetelmä kahdeksan lääkeaineen 
samanaikaiseen tutkimiseen kuuden minuutin analyysiajassa (Julkaisu I). Menetelmä 
validoitiin, se oli toistettava ja lääkeaineiden saannot olivat hyväksyttäviä (81,6–109,2 %). 
Lääkeaineiden määritysraja virtsassa oli 39–1610 µg/L. Lisäksi, aiemmin kehitettyä 
bioluminesoivaa hiivasolubiosensoria Saccharomyces cerevisiae (BMAEREluc/ERα) käytettiin 
virtsan estrogeeniaktiivisuuden tutkimiseen (Julkaisu II). Biosensori tuotti vertailukelpoiset 
tulokset tuoreen ja seisotetun virtsan estrogeeniaktiivisuusmittauksissa määritysrajan 
vastatessa 0,28–35 µgestrogeeneja/L. Näytteiden signaalin vahvistamiseksi suoritettiin inkubointi 
β-glukuronidaasi-entsyymillä. Biosensori tuotti kumulatiivisen estrogeeniaktiivisuussignaalin 
(estrogeenit ja estrogeenien kaltaiset yhdisteet), joka mahdollistaa kokonaisestrogeeni-
aktiivisuuden mittaamisen virtsan varastoinnin aikana. 
 
Julkaisussa I esitettyä menetelmää käytettiin virtsaan lisättyjen lääkeaineiden pitoisuuksien 
tutkimiseen kuuden kuukauden varastoinnin aikana (Julkaisu III). Jokaista lääkeainetta 
(kolme viruslääkettä ja neljä antibioottiyhdistettä) tutkittiin yksittäin, terapeuttisissa ryhmissä 
sekä terapeuttisissa ryhmissä, joihin oli lisätty ulostetta tai ureaasi-inhibiittoria. Pitoisuudet 
vähenivät kaikissa kokeissa varastoinnin aikana <1–99 %, ja kokeissa, joissa käytettiin 
ulostetta tai ureaasi-inhibiittoria, pitoisuuksien vähenemät jäivät alle 50 % (paitsi rifampisiinilla 
yli 99 %). Pitoisuuksien selvät vähenemät neljällä yhdisteellä osoittivat biologista tai kemiallista 
hajoamista ja/tai saostumista. 
 
Ihmisvirtsaa käytettiin ravinnelähteenä Chlorella vulgaris –mikrolevän biomassatuotannossa 
(Julkaisu IV). Biomassan saanto laimennetussa virtsassa oli vertailukelpoinen 
biomassatuotantoon keinotekoisessa kasvumediassa kasvatetun levän kanssa, ja virtsaa 
voitiin käyttää jopa 1:25-laimennettuna ilman levän kasvun inhiboitumista. Korkein 
biomassasaanto (0,6 g/L) saavutettiin 1:100-laimennetulla virtsalla. C. vulgaris käytti virtsassa 
olevasta typestä 32,5–78,7 % ja fosforista 35,1–99,0 %. Kasvatuksen alussa suurin osa 
biomassasta koostui leväsoluista, kun taas loppua kohden elävien leväsolujen osuus pieneni 
osoittaen bakteerien ja kuolleiden leväsolujen kertymistä kasvatukseen. 
 
Tässä työssä saadut tulokset osoittivat, että lääkeaineiden pitoisuudet eivät alene varastoinnin 
aikana tarpeeksi, jotta virtsaa voisi turvallisesti käyttää. Hiivabiosensori osoitti, että 
varastoinnin aikana estrogeeniaktiivisuus virtsassa muuttuu todennäköisimmin bakteerien 
entsyymitoiminnan vuoksi, mutta aktiivisuutta on vielä jäljellä viiden kuukauden varastoinnin 
jälkeen. Ihmisen virtsa on myös käyttökelpoinen ravinnelähde mikroleväbiomassan 
tuotannossa, mikä edesauttaa ravinteiden kestävää käyttöä ja kierrätystä.   
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1 Introduction 
Humans produce urine on a daily basis, as it has been from the beginning of times, and the 
composition and quantity of urine vary by the person and diet. There are currently over 7.3 
billion people in the world and each and every one of them produces approximately 1.2 L of 
urine per day, containing 11.5 gN/p/d and 1.2 gP/p/d (Kujala-Räty et al. 2008). Thus, the 
amount of urine in the world reaches 8.85 billion m3/d with 84·103 tons N and 8.8·103 tons P. 
As a reference, the world inorganic fertilizer (as NPK) consumption in years 2005–2007 was 
166·106 tons with division of 57% N, 25% P, and 18% K (FAO 2012). The estimation for 
fertilizer consumption in year 2050 has been projected as 263·106 tons (FAO 2012). 
Human urine contributes approximately 80–90%, 50–65%, and 50–80% of the N, P and K, 
respectively, arriving at typical centralized wastewater treatment plants (WWTPs), while it is 
only 0.4–1.0% of the volume (Höglund et al. 2002, Heinonen-Tanski and van Wijk-Sijbesma 
2005, Pronk et al. 2006; Vinnerås et al. 2008, Winker et al. 2008a, Jana et al. 2012b). 
Centralized WWTPs have been developed from stormwater sewers which were originally 
constructed to prevent flooding of urban areas and further used to transport human excreta in 
response to the need to ensure hygiene and health in urban areas (Wilsenach and van 
Loosdrecht 2004). Along the development, the flush toilet was introduced and it became of a 
symbol for cleanliness (Medilanski et al. 2006). Nowadays in many cases, domestic 
wastewaters (toilet, kitchen, personal hygiene) are mixed together in the sewers with rainwater 
and infiltration water, in addition to with e.g. industrial and hospital wastewaters (Kümmerer 
2001, Medilanski et al. 2006), and are treated in a centralized WWTP (Remy and Jekel 2012). 
Meanwhile, the centralized system has received criticism, as it is not considered sustainable 
(Wilsenach and van Loosdrecht 2004). Therefore, other systems, such as the source 
separation of urine, have been shown to have environmental benefits in environmental life-
cycle studies (Jönsson 2002, Maurer et al. 2003, Spångber et al. 2014). Separating urine from 
other domestic wastewaters can reduce the organic and nutrient load arriving at WWTPs.  
Human excreta, including urine, could be considered as a resource rather than a waste as 
urine contains essential nutrients, already in a form available to plants (Sundin et al. 1999, Lind 
et al. 2001, Golder et al. 2007, Yang et al. 2015). Source separation and use of human excreta 
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as a fertilizer is even claimed to be more energy-efficient and have less impact on global 
warming than the enhanced reduction of nitrogen and phosphorus at a WWTP, complemented 
with the use of chemical fertilizers (Spångberg et al. 2014). However, urine may contain 
microorganisms, pharmaceuticals, and hormones and thus, their fate and removal during urine 
storage and re-use need to be addressed before urine may be regarded as safe. Therefore, 
separating urine from other wastewaters could help to lessen the pharmaceutical and 
hormonal burden of both WWTPs and the environment, in addition to recycling nutrients in a 
more sustainable way. As pharmaceuticals and hormones enter the environment, they pose a 
threat to e.g. aquatic life by increasing the occurrence of hermaphroditic fish near WWTPs 
(Larsson et al. 1999), by re-entering the water cycle (Kujawa-Roeleveld et al. 2008), or by 
accumulating in soils and plants (Pronk et al. 2006), and concerns have risen about the 
potential effects of these compounds on aquatic organisms and human health during long-
term, continuous exposure (Escher et al. 2006). The presence of pharmaceuticals and 
estrogenic hormones in urine-based fertilizer products is also a matter of concern.  
Pharmaceuticals have been detected from municipal WWTPs with varying daily loads (Sim et 
al. 2011). As pharmaceuticals, hormones, and hormone-like ingredients cover a wide variety 
of compounds, detecting them in collected urine in order to monitor the effectiveness of urine 
treatment techniques has been gaining interest, as have their concentrations in the 
environment and in urine-based fertilizer products (Ronteltap et al. 2007). A necessity has 
risen to develop simple and rapid analytical techniques to facilitate the re-use of urine. 
Resulting from a faster urine analysis, the utilization of urine in fertilization applications 
becomes simpler since the presence of harmful substances is rapidly discovered. Thus, the 
suitability of urine in microalgal cultivation and biomass production, for instance, can be more 
simply assessed. 
The objective of this thesis was to develop and facilitate the use of source-separated urine by 
developing and assessing the feasibility of analytical tools in urine monitoring, by evaluating 
the behavior of pharmaceuticals during urine storage, and by assessing the feasibility of urine 
as a nutrient source in microalgal cultivation and biomass production. In the following chapters, 
the composition and uses of human urine, as well as techniques used in source-separated 
urine treatment are discussed (Chapters 2.1.1-2.1.4). Related to pharmaceutical excretion, a 
short summary on pharmaceutical metabolism in human body is given (Chapter 2.2.1), and 
the fate of pharmaceutical compounds in urine treatment processes and at WWTPs is 
discussed (Chapter 2.2.2). As pharmaceuticals and estrogens have environmental relevance 
and need to be monitored from environmental and urine samples, an insight on analytical 
techniques for their detection is given (Chapter 2.3). Afterwards, the aims of the thesis are 
presented (Chapter 3) and the materials and methods used are shortly described (Chapter 
4). Subsequently, the results and discussion related to analytical development, pharmaceutical 
and estrogenic monitoring, as well as results from urine storage and its effects on 
pharmaceutical behavior in urine, and a description of the algal cultivation experiments 
conducted in urine are given (Chapter 5). Thereafter, conclusions, based on findings 
presented in the thesis, are summarized (Chapter 6).  
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2  Background 
2.1 Human Urine 
2.1.1 Composition of Human Urine  
Human urine is a complex water solution, containing nutrients as diluted compounds. Main 
compounds are sodium chloride (NaCl, 9-16 g/d) and urea [CO(NH2)2] (25 g/d), which is the 
major source of total nitrogen (80–90%) in fresh urine (up to 9 gN/L). Also potassium (K, 50–
80%), calcium (Ca), sulphate (SO4) and phosphorus (approximately 0.7 gP/L, 50–65%) are 
present (Table 2.1). Urine contains an excess of ammonium relative to phosphate, but it is 
deficient in magnesium. Phosphorus is available as phosphates (H2PO4- or HPO42-) and 
potassium as an ionic component (K+). Urine contains organic compounds which are 
breakdown products of biomolecules and food, such as hydroxyindoles, ethyl mercaptan and 
other sulphides, phenols and cresols, as well as substituted benzoic and phenylacetic acids 
(Escher et al. 2005 end references therein). Urine also contains uric acid, chlorides, oxalates, 
and small amounts of minerals, vitamins, hormones, amino acids, and enzymes. (Harper et al. 
1979, Lind et al. 2001, Heinonen-Tanski and van Wijk-Sijbesma 2005, Ganrot et al. 2007a, 
Winker et al. 2009). The nutrient and chemical composition of urine, reported in the literature, 
is presented in Table 2.2. 
The quantity and composition of urine depend on age, water intake, diet, and external 
temperature. Normally, an adult produces 0.6 to 2.5 L of urine daily (average being 1.2 L). 
Urine is normally acid, with pH ranging from 4.7 to 8.0 (average pH 6.0). Normal color of urine 
is pale yellow or amber, the determining pigment being urochrome, but color varies with its 
concentration; also pharmaceuticals can cause colored urine. (Harper et al. 1979). Each year, 
one person produces approximately 500 kg of urine (Heinonen-Tanski and van Wijk-Sijbesma 
2005) which includes 2.5–5.7 kgN, 0.3–1.0 kgP and 0.1–1.2 kgK per person per year 
(Kirchmann and Pettersson 1995, Heinonen-Tanski and van Wijk-Sijbesma 2005, Mihelcic et 
al. 2011).  
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TABLE 2.1.  Composition of urine (modified from Harper et al. 1979). 
Urine property/component Unit In urine  
specific gravity kg/L 1.003–1.030 
pH  -  4.7–8.0 
volume mL 600–2500 
acidity (as 0.1 N NaOH) mL  250–700 
total solids g/L 30–70 
   
Inorganic constituents (per 24 h) 
g 9–16 chlorides (NaCl) 
Sodium (varies with intake) g  4 
Phosphorous g 2–2.5 
Potassium (varies with intake) g 2 
Sulfur (as SO3) g 0.7–3.5 
Calcium g 0.1–0.2 
Magnesium g 0.05–0.2 
Iodine µg 50–250 
   
Organic constituents (per 24 h) 
g 25–35 nitrogenous (total) 
urea (varies with diet) g  25–30 
creatinine g 1–1.8 
ammonia g 0.3–1 
uric acid g 0.5–0.8 
undetermined N (amino acids etc.) gN-eq 0.5 
protein, e.g. albumin g 0–0.2 
creatine mg 60–150 
   
Other organic constituents (per 24 h) 
g 
 
hippuric acid 0.1–1 
15–20 oxalic acid mg 
indican mg 4–20 
coproporphyrins µg 60–280 
purine bases mg 10 
ketone bodies mg 3–15 
allatoin mg 30 
phenols (total) g 0.2–0.5 
   
ascorbic acid mg 15–50 
Ureases (urea amidohydrolases) are a group of enzymes widely synthesized in nature by 
plants, bacteria, fungi, algae, and invertebrates; they also occur in soils as a soil enzyme 
(Krajewska 2009). When urine is left standing, urea is hydrolyzed to ammonia and carbamate 
by urease, and the latter compound decomposes spontaneously to carbonic acid and another 
molecule of ammonia; the process is called ureolysis (Eq. 1.1, Udert et al. 2003). Without 
urease, urea is a very stable compound, with a half-life time of 3.6 years at 38oC (Hotta and 
Funamizu 2008 and references therein).  
ܰܪଶ(ܥܱ)ܰܪଶ + 2 ∙ ܪଶܱ → ܰܪଷ +ܰܪସା +ܪܥܱଷି   (1.1) 
Due to the ammonia release, pH increases (Udert et al. 2003). During ureolysis precipitates 
are formed, of which struvite (MgNH4PO4·6H2O) is the most commonly studied and dominates 
precipitation at high pH (Udert et al. 2003). Struvite is an orthophosphate, which contains 
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magnesium, ammonium, and phosphate in equal molar concentrations (Ronteltap et al. 2007). 
Ureolysis thus leads to phosphorus and magnesium precipitation.  
TABLE 2.2.  Nutrients and chemical composition of human urine reported in the literature. 
Composition Unit Storeda Storedb 
Stored, 
undiluted Fresh Fresh Stored Fresh 
Ntot g/L 1.795 2.610 9.2 8.83 - - - 
NH4-N g/L 1.117 1.726 - 
8.1 
- 
0.463 
0.254 1.720 0.438 
NH3aq-N g/L 0.574 0.773 - - - 
urea g/L - - -  - 5.810 0.0073 4.450 
amino acid –N g/L 0.104 0.110 - - - - - 
NO3-N µg/L 45 45 - 
0 
- 
- 
- - - 
NO2-N µg/L 10 20 - - - 
pH - 8.96 8.90 9.1 6.2 7.2 9.0 5.6 
conductivity mS/cm 13.4 19.0 - - - - 22.6 
redox potential mV -90 +236 - - - - - 
COD g/L - - - - 8.150 1.650 7.660 
Macronutrients                
P g/L 0.210 0.200 0.540 0.8-2.0 0.367 0.076 0.388 
K g/L 0.875 1.150 2.2 2.737 2.170 0.770 1.870 
SO4-S g/L 0.225 0.175 0.505 1.315 0.748 0.292 0.878 
Na g/L 0.982 0.938 2.6 3.45 2.670 0.837 3.240 
Cl g/L 2.500 2.235 3.8 4.97 3.830 1.400 6.620 
Micronutrients                
Ca mg/L 15.75 13.34 0 0.233 129 28 89.2 
Mg mg/L 1.63 1.5 0 0.119 77 1 45.4 
Mn mg/L 0 0 - 0.0019 - - - 
Fe mg/L 0.205 0.165 - - - - - 
B mg/L 0.435 0.440 - 0.097 - - - 
Al mg/L 0.210 0.185 - - - - - 
Reference  
Kirchmann and 
Perttersson (1995) 
Maurer et al. 
(2006) 
Udert et al. 
 (2003) 
Etter et al. 
(2011) 
Note: a stored 0–3 months; b stored 6 months; - data not reported 
Some bacteria that inhabit the urinary tract excrete ureases that take part in ammonium 
formation and pH rise (Krajewska 2009). One example of these microorganisms is Proteus 
mirabilis, which is also responsible for producing urinary stones (Krajewska 2009), and 
blocking urinary tract catheters in hospitals and urine pipelines in urine diversion systems 
(Udert et al. 2003, Maurer et al. 2006) due to struvite precipitation. Ureases have an optimum 
pH range from pH 6 to pH 9, while also acid ureases exist (pH optimum 2–4.5) (Krajewska 
2009). 
Human urine may contain pathogens (e.g. Salmonella typhi, S. paratyphi, Mycobacterium 
tuberculosis, and Leptospira interrogans) and few enteric microorganisms, viruses (e.g. 
Cytomegalovirus), protozoa (e.g. Microsporidia), or helminth and parasitic eggs (e.g. 
Schistosoma haematobium) which can be emitted in urine (Höglund 2001, Höglund et al. 2002, 
Heinonen-Tanski and van Wijk-Sijbesma 2005, Vinnerås et al. 2008). Urine has been shown 
to contain none or only low levels of the infectious human immunodeficiency virus (HIV) but 
does not appear to be an important source of virus transmission (Levy 1993). In urine, 
ammonia concentration of 40 mM, which can be formed during storage, has been established 
as an inactivation threshold for pathogenic microorganisms (Vinnerås et al. 2008). When in the 
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bladder, human urine is sterile (Höglund 2001). However, collected human urine is not totally 
sterile, as it contains fecal contamination which in source-separated urine is mainly due to 
misplaced feces: the average contamination is 9.1 mgfeces/L urine (Schönning et al. 2002) and 
can be measured by monitoring the concentration of fecal sterols (Sundin et al. 1999).  
Urine also contains heavy metals in a ppb-range (Vinnerås et al. 2008, Table 2.3), while the 
differences in heavy metal concentrations vary depending on the time of storage and possible 
precipitation of metals. Urine may also contain pharmaceuticals, as approximately 60–70% of 
human pharmaceuticals and hormones are excreted in urine (Lienert et al. 2007), the topic of 
which will be discussed in more detail in Chapter 2.2. Urine may also contain traces of the 
chemicals that humans are exposed to on a daily basis, such as plastic softeners and flame 
retardants (Breithaupt 2014). 
TABLE 2.3.  Reported heavy metal contents of urine. 
Heavy metal (µg/L)  
Urine, stored 3–6 
months Urine, hydrolyzed 
Cd 0.2 5.0 
Cr 2.0–4.0 11.0 
Co 1.0–12.0 13.8 
Cu 155 88.4 
Hg 0.44–0.55 - 
Ni 15–227 8.1 
Pb 2.0 27.2 
Zn 70–110 - 
Al 185–210 - 
As - 151 
Reference 
Kirchmann and 
Perttersson (1995) 
Ronteltap et al. 
(2007) 
Note:  - data not found 
 
2.1.2 Source Separation, Storage, and Treatment of Urine 
Source separation basically means the separation and separate collection of urine from feces 
in the toilet, thus enabling the (re-)use of collected urine as such in different applications. 
Different techniques for source separation of urine have been proposed; e.g. urine diverting 
toilets (NoMix toilets, Medilanski et al. 2006) and waterless urinals, which are used to collect 
little diluted urine (Udert et al. 2003). NoMix toilets, depending on the model, use 0.2–0.8 L of 
flushing water (Udert et al. 2003) compared with the 2.5–4 L in the conventional double-flush 
toilets. Separating toilets typically consist of a bowl divided into two parts: the front bowl collects 
the urine and the rear bowl the feces (Schönning et al. 2002, Kvarnström et al. 2006, Larsen 
et al. 2009). After separation urine is collected in a storage tank in or near the household, and 
treated on-site or transported further to a centralized treatment unit (Borsuk et al. 2008, Larsen 
et al. 2009). 
Source separation of urine has been studied in a larger scale for instance in a pilot village in 
Sweden (Kvarnström et al. 2006, Johansson et al. 2009), in office-scale in Germany (23 
waterless urinals and 43 NoMix-toilets, Blume and Winker 2011; Schürmann et al. 2012), and 
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in a university in Australia (Abeysuriya et al. 2013). A larger field study conducted in the 
eThekwini Municipality in South Africa with 700 households (i.e. the VUNA project, Valorization 
of Urine Nutrients in Africa) has demonstrated the applicability of urine diverting dry toilets in 
collecting material for fertilizer production (Etter et al. 2014a, 2014b, Rhonton et al. 2014). A 
lot of information is available for different separation techniques and related issues, such as 
maintenance of toilets and user opinions (e.g. Johansson 2000, Kvarnström et al. 2006, Borsuk 
et al. 2008, Larsen et al. 2009, Lienert and Larsen 2009, Larsen et al. 2010, Blume and Winker 
2011). 
During urine storage, ureolysis (Eq. 1.1) causes ammonia losses due to volatilization. 
Pathogenic contamination and infections from enteric viruses present in urine are mainly 
dependent on the fecal cross-contamination and storage time as well as temperature. The 
recommended storage time at 20oC is at least six months, after which urine is considered safe 
to use as a fertilizer for any crop since pathogenic microorganisms have assumed to be dead 
and/or inactivated. (Höglund et al. 2002, WHO 2006, Winker et al. 2009). The enteric micro-
organisms usually die off in two months’ time, which is why shorter than six-month storage 
periods are commonly applied (Akpan-Idiok et al. 2012).  
Different urine treatment techniques can be applied on the collected urine and are based on 
separation processes, e.g. membranes or precipitation, and elimination processes, e.g. 
oxidation or adsorption (Maurer et al. 2006), and have been discussed in the literature (Table 
2.4) for e.g. hygienization, volume reduction, stabilization, and nutrient removal and recovery 
perspectives, and also for pharmaceutical removal (for a review, see Maurer et al. 2006, 
Tettenborn et al. 2007). The technologies exist and the separation process of nutrients and 
pharmaceuticals is relevant to the production of a urine-based fertilizer, whereas the 
pharmaceuticals must be eliminated for environmental pollution control (Maurer et al. 2006). 
Some of these techniques can be used in pharmaceutical concentration reduction, which will 
be discussed further in Chapter 2.2. Only urine storage has been investigated thoroughly 
enough for its ability to reduce the amount of pathogens in source-separated urine, while many 
of the other treatment steps will probably also have an effect on the hygienic properties (Maurer 
et al. 2006). For example, the nitrification/distillation process introduced by Udert et al. (2015) 
stabilizes nutrients by biological treatment and additionally improves the quality of the liquid 
fertilizer by inactivating pathogens and removing pharmaceuticals with post-nitrification 
distillation and advanced treatment, respectively (Bischel et al. 2015).  
Some of these treatment techniques (ozonation, nanofiltration, electrodialysis, distillation) are 
high-tech processes and consume energy for e.g. heating, pressure provision, etc. (Gulyas et 
al. 2007, Tettenborn et al. 2007, Udert and Wächter 2012). Based on the comparison 
performed by Dodd et al. (2008), the energy requirements for urine pre-treatment may be lower 
than those required to achieve similar effluent quality via enhanced wastewater treatment, 
based on the energy savings derived from upstream resource recovery.  
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TABLE 2.4.  Different urine treatment processes and their aims described in the literature. 
Note: UV - ultraviolet 
Urine treatment 
process 
Aim of treatment Application scale Reference 
acidification stabilization (prevention 
of precipitation, 
degradation and 
volatilization) 
laboratory  Maurer et al. (2006) 
adsorption ammonia and 
phosphate removal from 
urine with e.g. zeolite  
laboratory  Tettenborn et al. (2007) 
crystallization crystal formation, 
fertilizer product 
laboratory  Tettenborn et al. (2007) 
electrochemical 
oxidation on graphite 
ammonia removal laboratory Udert et al. (2015) 
Zöllig et al. (2015) 
electrodialysis salt concentration,  
pharmaceutical 
concentration reduction 
laboratory,  
pilot tests 
Dodd et al. (2008). 
Escher et al. (2006)  
Pronk et al. (2007) 
evaporation volume reduction and 
concentration of 
nutrients, 
pharmaceutical 
concentration reduction 
laboratory, 
pilot, 18 L of concentrate 
from 1 m3 of urine  
Tettenborn et al. (2007) 
freeze-thaw volume reduction laboratory  Maurer et al. (2006) 
ion exchange nitrogen recovery laboratory  Maurer et al. (2006) 
microbial electrolysis 
cell 
hydrogen production 
ammonium recovery 
laboratory Kuntke et al. (2014) 
 
microbial fuel cells  energy production 
nitrogen recovery 
ammonium recovery 
nitrogen and 
phosphorus removal 
pharmaceutical removal 
laboratory 
 
Ieropoulos et al. (2013) 
Kuntke et al. (2012) 
Ledezma et al. (2015) 
Santoro et al. (2013a) 
Santoro et al. (2013b) 
Wang et al. (2015) 
micro- and nanofiltration turbidity removal,  
separation of nutrients 
from pharmaceuticals, 
pharmaceutical 
concentration reduction 
laboratory  Pronk et al. (2006, 2007) 
nitrification/distillation  nutrient recovery  
partial degradation of 
pharmaceuticals 
laboratory,  
pilot tests 
 
Bischel et al. (2015) 
Fumasoli et al. (2016) 
Udert et al. (2015) 
Udert and Wächter (2012) 
ozonation pharmaceutical 
concentration reduction, 
additional treatment 
laboratory,  
pilot tests 
Dodd et al. (2008) 
Escher et al. (2006) 
Tettenborn et al. (2007)  
Pronk et al. (2007) 
precipitation solid fertilizer, mainly 
struvite 
pilot  Escher et al. (2006) 
Maurer et al. (2006)  
Ronteltap et al. (2007) 
Tettenborn et al. (2007) 
reverse osmosis volume reduction laboratory  Maurer et al. (2006) 
steam stripping nitrogen recovery, 
pharmaceutical 
concentration reduction 
laboratory,  
pilot plant, >2 m3 
Tettenborn et al. (2007) 
storage hygienization pilot and technical  Maurer et al. (2006) 
UV-radiation pharmaceutical 
concentration reduction, 
additional treatment 
laboratory  Tettenborn et al. (2007) 
9 
 
In the future, urine treatment would most probably consist of a combination of treatment 
processes, e.g. by removing phosphate and ammonium by struvite precipitation followed by a 
biological process to eliminate organic pollutants and nitrogen (Maurer et al. 2006) either at 
the source or at centralized treatment units. One of the novel techniques include the use of 
microbial fuel cells (MFCs) to recover nitrogen while simultaneously producing electricity 
(Kuntke et al. 2012, Santoro et al. 2013); the objective being energy-positive wastewater 
treatment (Ledezma et al. 2015). MFCs can also be utilized in micropollutant (i.e. trace organic 
compounds) removal from wastewater (for a review, see Wang et al. (2015)). 
2.1.3 Use of Human Urine  
As urine is rich in nutrients, it has inspired research in the field of fertilizer use in different 
applications. According to the European Union (EU), the concept of urine as a fertilizer is 
unknown: only chemically pure urea is accepted in fertilizer use on agricultural fields and it is 
regarded as inorganic fertilizer (Regulation No 2003/2003). Regarding manure, instructions on 
its use are given in a Council regulation, but (human) urine is not involved (Regulation No 
1069/2009). Legislation dealing with organic farming in the EU denies the use of human urine 
in agricultural fields (Council Regulation 834/2007). However, World Health Organization has 
introduced guidelines for safe re-use of human excreta (WHO 2006); next, a short summary 
of source-separated urine as a fertilizer is given.   
Urine as a Fertilizer in Agri- and Aquaculture    
As discussed in the previous section, human urine contains nutrients that are needed for plant 
growth, thus making it an appealing fertilizer alternative (Paruch 2012). Human urine has also 
been recognized as a potential aquacultural nutrient source. 
Traditionally, urine as such has been and can be used in liquid form which can be applied with 
conventional equipment available at farms, or it can be precipitated as struvite which is a rather 
pure mineral (Winker et al. 2009). Struvite crystallizes when human urine is treated with 
magnesium (Mg2+) (Maurer et al. 2006) and can then be used as a slow-release phosphatic 
fertilizer (nutrient becomes available gradually over time, Ronteltap et al. 2010) (Antonini et al. 
2012). Human urine releases plant nutrients faster than sources such as livestock/avian 
excreta, green manure, compost manure, or similar (Akpan-Idiok et al. 2012). In developing 
countries, the use of human urine could be a solution as a low-cost, easily available and safe 
fertilizer (Jana et al. 2012a). Human urine has been used to fertilize edible plants (Table 2.5) 
with no considerable changes in taste and with better yields than with artificial fertilizers 
(Heinonen-Tanski et al. 2007, Pradhan et al. 2007, Tidåker et al. 2007, Pradhan et al. 2009, 
Pradhan et al. 2010, Akpan-Idiok et al. 2012).  
The prevention of ammonia loss during storage and soil application of urine is an important 
aspect for efficient fertilizer use (e.g. Kirchmann and Pettersson 1995, Watson et al. 2008). 
Indeed, urine infiltrates soil quite quickly and thereafter ammonia emissions end. Therefore, 
the application technique has to be adjusted to the high ammonia content of urine (i.e., close 
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to soil preferably in combination with soil incorporation) (Winker et al. 2009). By using a struvite 
fertilizer, ammonia volatilization is minimized compared with direct urine application into soil 
(Heinonen-Tanski and van Wijk-Sijbesma 2005, Watson et al. 2008). 
Soil ureases (Krajewska 2009) rapidly hydrolyze urea, leading to ammonia emissions when 
urine is applied into the soil (Watson et al. 2008, Saggar et al. 2013, Singh et al. 2013). In order 
to prevent the loss of ammonia from urea during soil application, the use of urease inhibitors 
has been studied (Watson et al. 2008). The most promising urease inhibitor in different 
laboratory and field studies has been N-(n-butyl) thiophosphoric triamide (nBPT), a structural 
analogue of urea, which is effective in low concentrations, non-toxic, stable, and inexpensive 
(Watson et al. 2008, Saggar et al. 2013), as well as available commercially as e.g. Agrotain® 
(Zaman and Blennerhassett 2010, Singh et al. 2013) and StabilureN® (Agra Group 2015). 
Granular urea amended with nBPT reduced ammonia losses under laboratory conditions from 
11% to 1.9% of urea-N applied and no evidence of nBPT efficiency decline was detected after 
repeated applications on the same soil over a three-year period (Watson et al. 1998). 
Use of urine in aquaculture, such as in hydroponic cultivation of plants or growing zoo- and 
phytoplankton, is another way to potentially use the renewable nutrient source (Table 2.5). 
One of the issues associated with fresh urine use in aquaculture is the high concentration of 
ammonia and high pH which can be harmful to aquatic species (Jana et al. 2012a). Therefore, 
aeration of urine is usually used in urine-fed aquacultural systems as it transforms ammonia 
to nitrate more rapidly via nitrification (Jana et al. 2012a). Another advantage of aeration is the 
reduction of anaerobic pathogens which may be present in urine-fed culture systems (Jana et 
al. 2012a). However, the toxicity of urine at higher concentrations can pose risks to e.g. 
zooplankton survival, which is why urine needs to be highly diluted (Golder et al. 2007). It has 
been demonstrated that human urine can be used in aquaculturing of microalgae, zoo- and 
phytoplankton, and tomatoes (Adamsson 2000, Golder et al. 2007, Jana et al. 2012b), as well 
as fish and prawns (Jana et al. 2012a) and water spinach (Yang et al. 2015). In most cases, 
cultivation in diluted urine led to similar or higher yields than in nutrient solution or compared 
with other nutrient sources used (cow urine, vermi-compost etc., Table 2.5).
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TABLE 2.5.  Studies reported in the literature on ways to utilize human urine as a fertilizer. 
Agricultural applications Scale of cultivation Urine application  Main observation Reference 
fertilization with fresh human urine     
cabbage outdoor cultivation 180 kgN/ha growth and biomass were slightly 
higher with urine than with a 
mineral fertilizer  
Pradhan et al. (2007)  
cucumbers outdoor cultivation 233 
kgN/ha(urine)a 
34 kgN/ha 
(mineral)a 
the cucumber yield with urine was 
similar or slightly better than the 
yield obtained with a mineral 
fertilizer 
Heinonen-Tanski et al. (2007) 
red beet outdoor cultivation 
urine only, urine+ash 
133 kgN/ha urine and ash, and only urine 
fertilizer produced 1720 
and 656 kg/ha more root biomass 
than mineral fertilizer, respectively 
Pradhan et al. (2010) 
wheat life cycle analysis - - Tidåker et al. (2007) 
 climate chamber, 21 days, 
pot trials (freeze-concentrated 
urine, urine-equilibrated zeolite, 
urine-equilibrated activated 
carbon, struvite) 
0.45-0.65 gN/kgb  the struvite/adsorbent mixtures 
showed better nutrient availability 
than struvite alone, but nutrients 
weren’t enough for wheat growth 
during 21 days  
Ganrot et al. (2007b) 
okra greenhouse and field  0, 45.8, 68.7 or 
91.6 kgN/hac 
91.6 kgN/ha significantly 
increased the growth and yield 
relative to inorganic fertilizer; 68.7 
kgN/ha had similar effect as 
inorganic fertilizer 
Akpan-Idiok et al. (2012) 
fertilization with stored human urine    
tomato greenhouse experiment 135 kgN/ha urine fertilization resulted in  
equal amounts of tomato fruits as 
mineral fertilizer and 4.2 times 
more fruits than non-fertilized 
plants 
Pradhan et al. (2009) 
fertilization with struvite     
maize, ryegrass greenhouse pot 
experiment 
0.17 gN/kgd  struvite fertilizers induced similar 
or significantly higher biomass 
yields than those generated by a 
commercial mineral fertilizer 
Antonini et al. (2012) 
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TABLE 2.5. Continues. 
Aquacultural applications Scale of cultivation Urine 
concentration  
Main observation Reference 
fresh and stored urine     
indian carp and freshwater prawn holding tanks, 120 days 0.01% 0.01% urine produced fish yield 
lower than cow manure or cow 
manure mixed with human urine  
Jana et al. (2012a) 
microalgae 
zooplankton 
tomato 
hydroponic cultivation, 
114 days 
2%, 2%+Fe culturing algae, zooplankton and 
tomatoes in an aquaculture 
system using only diluted human 
urine with iron amendment is 
possible 
Adamsson (2000) 
phytoplankton 5000 L tanks, 16 weeks 0.02% primary production of 
phytoplankton was the highest 
with highest phosphate 
concentration (stored urine) 
Jana et al. (2012b) 
zooplankton 4500 L tanks, 10 days 0.01% the best zooplankton growth 
was obtained in diluted human 
urine 
Golder et al. (2007) 
water spinach hydroponic cultivation, 
21 days  
10%, 5%, 3.3%, 2%  2% urine produced comparable 
growth characteristics to those 
in nutrient solution 
Yang et al. (2015) 
Note: areported as gN/m2; b180-260 mgN per 0.4 kg pot;  creported as L/ha; d1530 mgN per 9 kg pot 
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2.1.4 Urine in Cultivation of Microalgae  
Microalgal cultivation for biofuel and bioenergy feedstock purposes has become increasingly 
relevant as new energy sources are explored for. After harvesting, microalgal biomass can be 
utilized e.g. in anaerobic digestion to produce methane (for a review, see e.g. Sialve et al. 
2009), in biodiesel production by extracting the algal lipids (Griffiths and Harrison 2009, for a 
review, see Chisti 2007), or as another type of products, such as nutritional supplements, 
natural pigments, or aquaculture feed (Vandamme et al. 2013). When using urine for algae 
cultivation, factors such as light intensity, possible water source, cultivation strategies (batch 
vs. continuous, open pond vs. closed photobioreactor, etc.), climate conditions, existing 
infrastructure and logistic considerations, additional supply of carbon dioxide (CO2), algal 
harvesting, and biomass post-processing affect the cultivation system (e.g. sustainability) 
(Chisti 2007, Cho et al. 2013, Rawat et al. 2013, for a review, see e.g. Lam and Lee 2012a). 
One of the main issues affecting the economics of algal cultivation, i.e. the capital and 
operating costs as well as well as the viability of commercial production (Jegathese and Farid 
2014), is the source of phosphorus and nitrogen; micronutrients are also required at lower 
concentrations. Sustainability issues impact on the cultivation of algal biomass for biofuel 
production: on one hand, nitrogen fertilizer manufacturing process is energy-demanding and 
causes greenhouse gas emissions, on the other hand the world’s phosphorus reserves are 
depleting due to phosphate rock mining (Dawson and Hilton 2011, Hilton and Dawson 2012, 
Canter et al. 2015).  
Microalgal Nutrient Sources 
Different types of recyclable sources of nutrients in microalgal cultivation have been suggested 
(Table 2.6), and studied, mainly in laboratory scale. Microalgal cultivation in wastewater can 
be used to remove nutrients from the wastewaters and simultaneously grow biomass for further 
uses (e.g. Li et al. 2011, Lam and Lee 2012a). Suggestions to integrate algal cultivation to 
wastewater treatment with CO2 supplementation have been made (Cho et al. 2013, Soares et 
al. 2013) as microalgae can fix CO2 from industrial exhaust gases in the form of soluble 
carbonates (Sydney et al. 2010). On the other hand, life cycle analyses have demonstrated 
(e.g. Clarens et al. 2010, Medeiros et al. 2015) that cultivation of microalgae in wastewater still 
has its pressure points (the use of electricity, fertilizers etc.) that need to be addressed. 
Wastewater has been considered as an attractive and economic alternative for microalgal 
fertilizer source, but it is susceptible to virus and bacterial contamination, and in the worst-case 
scenario the whole microalgal colony could be devastated by other microorganisms thus 
leading to annihilation of microalgal population (Lam and Lee 2012a).  
The use of human urine in microalgal cultivation has only been studied quite recently (Table 
2.6). Human urine contains sufficient nutrients (especially N and P, Table 2.2) to support algal 
growth in addition to being a renewable resource. It has been hypothesized that urine used in 
cultivations should be nitrified (Feng et al. 2008) or stored (Jana et al. 2012b) to lessen the 
effect of ammonium inhibition or to inactivate microorganisms. Stored urine has less 
Escherichia coli than fresh urine (Jana et al. 2012b), whereas nitrification requires constant 
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pH-adjustment which increases expenses (Feng et al. 2008). During nitrification, ammonia 
volatilization can occur, affecting negatively on the ammonium-N concentration, which is why 
dilution of nitrified urine would be needed (Feng et al. 2007, Jana et al. 2012a). However, as 
urine quickly undergoes hydrolysis, leading to ammonium formation and precipitation of key 
nutrients (Zhang et al. 2014), the use of fresh urine is the most promising nutrient source in 
algal cultivation. Source-separated, hydrolyzed urine (urine was diluted to 3.5%) has been 
compared to other bioenergy feedstocks for algal cultivation (Clarens et al. 2010), but 
hydrolyzed urine needs excessive dilution, making it more water intensive than coupling algal 
cultivation with wastewater treatment. In addition, some microalgal strains are not able to re-
grow efficiently in recycled water due to the susceptible contamination by fungus and bacteria 
(Lam and Lee 2012b). 
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TABLE 2.6.  Different recyclable nutrient sources for microalgal cultivation, algal strains used, and the experimental scale. 
Microalgal nutrient source Algal strain Cultivation volume and type Reference 
    
wastewater - - Pittman et al. (2011) 
agricultural Botryococcus braunii  
Chlorella vulgaris 
Chlamydomonas mexicana 
Nitzschia cf. pusilla 
Scenedesmus obliquus 
Ourococcus multisporus 
500 mL, bubble-column, piggery 
250 mL, batch, piggery 
An et al. (2003) 
Abou-Shanab et al. (2013) 
industrial Chlorella vulgaris 
Chlorella vulgaris 
Chlorella vulgaris 
40 L, high rate algae pond, textile 
500 mL, photobioreactor, dairy waste 
250 mL batch, oil industry waste  
Lim et al. (2010) 
Abreu et al. (2012) 
Wang et al. (2013) 
municipal Chlorella sp. 
Chlorella sp. 
Chlorella vulgaris 
Chlorella vulgaris 
Chlorella sorokiniana 
Chlorella vulgaris 
250 mL, batch 
25 L, coil reactor 
500 mL, batch 
1000 mL, semi-continuous 
 
2 L, tubular photobioreactor  
Li et al. (2011) 
 
Choi and Lee (2012) 
de-Bashan et al. (2004) 
 
He et al. (2013a) 
anaerobic digestion effluent Chlorella sp. 
Nannochloropsis salina 
- 
Muriellopsis sp. 
Pseudokirchinella subcapitata 
250 mL, batch, dairy manure  
2 L, batch, semi-continuous 
- 
300 mL, bubble column 
Wang et al. (2010) 
Cai et al. (2013) 
Sialve et al. (2009) 
Morales-Amaral et al. (2015) 
food waste hydrolysate Schizochytrium mangrovei 
Chlorella pyreidinosa 
Chlorella vulgaris 
2 L, batch  
 
150 mL, batch, darkness 
Pleissner et al. (2013) 
 
Lau et al. (2014) 
hydrothermal liquefaction 
aqueous by-product 
Chlorella vulgaris 
Nannochloropsis gaditana 
Phaeodactylum tricornutum 
Scenesdesmus almeriensis 
Desmodesmus sp. 
500 mL, batch 
 
 
 
2 L, batch  
Barreiro et al. (2015) 
 
 
 
Alba et al. (2013) 
 
Note: - review study, not reported 
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TABLE 2.6.  Continues. 
Microalgal nutrient source Algal strain Cultivation scale Reference 
struvite Chlorella vulgaris 10 L, batch, photobioreactor Moed et al. (2015) 
human urine Spirulina platensis 1.2 L, batch, bubble column 
1 L, batch, photobioreactor  
1.2 L, bubble column 
1.2 L, batch, bubble column 
1.2 L, photobioreactor 
Feng et al. (2007) 
Yang et al. (2008) 
Feng et al. (2008) 
Chang et al. (2013) 
Feng and Wu (2006) 
 Chlorella sorokiniana microtiter plate 
1 L, photobioreactor 
6 L, photobioreactor 
Tuantet et al. (2014a) 
Tuantet et al. (2014b) 
Zhang et al. (2014) 
 Scenedesmus acuminatus 40 L, greenhouse culture Adamsson (2000) 
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2.2 Pharmaceuticals and Estrogenic Hormones in Urine 
To make utilization of urine possible, besides factors such as the varying collection, storage, 
and transportation methods, also the possible occurrence of harmful substances in urine and 
their fate must be considered. Pharmaceutical residues and hormones are excreted through 
human urine and therefore, use of urine is associated with potential transfer of pharmaceutical 
residues to the environment, agricultural fields, crop plants and thus, humans (Winker 2010). 
The effect of estrogenic compounds on endocrine and reproductive systems of wildlife (e.g. 
fish feminization, Larsson et al. 1999) has been noted (Soto et al. 1995, Routledge et al. 1998), 
and female sex-hormones and synthetic steroids are the most potent estrogenic compounds 
regarding their endocrine-disrupting properties (Rodriguez-Mozaz et al. 2004b). In addition, 
many compounds that are found in the environment have estrogenic properties: certain 
pesticides and herbicides, some polychlorinated biphenyls (PCBs), plasticizers, breakdown 
products of surfactants, and phthalates (Routledge and Sumpter 1996, Beck et al. 2006). In a 
wastewater treatment system, conjugated pharmaceuticals and hormones can transform back 
into their (biologically) active forms by microbial metabolism already in the sewer network or 
at the WWTP (Desbrow et al. 1998, Jelíc et al. 2015) and be transported to watersheds.  
Pharmaceutically active ingredients comprise a large variety of chemical compounds (more 
than 3 000 registered in the EU alone) which have different therapeutic modes of action, 
different physico-chemical properties and susceptibilities to (biological) degradation (Kujawa-
Roeleveld et al. 2008, Kümmerer 2009). Thus, one important factor in pharmaceutical and 
estrogenic monitoring is the use of applicable detection methods. Next, more insight is given 
on specific compounds and estrogenic hormones (Chapter 2.2.1), their fate in urine and 
wastewater treatment processes (Chapter 2.2.2), and the analytical methods for detecting and 
monitoring them in urine (Chapter 2.3). 
2.2.1 Pharmaceuticals, Estrogens, and Their Excretion in Urine 
Pharmaceuticals and hormones, as well as nutrients (Table 2.2) are excreted to a large extent 
into urine (Winker et al. 2008a, 2008b, Table 2.7), the production of which is 1.2 L/person/day 
on average. Nutrients, hormones, and microorganisms (bacteria, viruses) are naturally present 
in collected urine, as described in Chapter 2.1, while pharmaceuticals and the transformation 
products have been present in urine largely since the 1970’s, when the concept of 
medicalization entered the modern society (Becker and Nachtigall 1992). Many 
pharmaceutical compounds go through a structural change in the human body, due to 
organisms in the gut or by human enzymes (Pelkonen and Ruskoaho 2003). This structural 
change turns the compounds into metabolites, which do not make a difference between 
biochemical processes, bacterial activity, or hydrolysis (Längin et al. 2008, Kümmerer 2009). 
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At the beginning of the 21st century, several groups of pharmaceuticals considered 
environmentally relevant were listed (Kümmerer 2001, Jain et al. 2013 and references therein): 
(i) antiviral compounds, due to their transportation in the food chain, their escapement of 
degradation at WWTPs, and interference with the natural biological systems of living 
organisms, (ii) antibiotics, because of their pronounced bacterial toxicity and their potential of 
fostering resistance, and (iii) hormones, because of their high efficiency/low effect threshold. 
Compounds from all of these pharmaceutical groups can be detected in human urine.  
The antibiotic (ii) resistance reported at WWTPs is widely recognized (Xu et al. 2015), whereas 
antiviral drugs (i) have lately been gaining attention as possible environmental pollutants and 
possibly inducing antiviral drug resistance among influenza viruses (Prasse et al. 2010, Jain 
et al. 2013). Antibiotics can also negatively affect plant growth and soil microbial and enzymatic 
activities (Liu et al. 2009). Studies have shown that irrigation with pharmaceutical-containing 
reclaimed water leads to presence and accumulation of pharmaceuticals in soil (Kinney et al. 
2006) and urine fertilization may lead to e.g. carbamazepine transportation into the roots and 
aerial plant parts of ryegrass (Winker et al. 2010). Steroidal estrogenic hormones (iii) have 
been recognized as environmental pollutants already a few decades ago (Shore et al. 1993) 
and they have been detected in surface and wastewaters (Vermeirssen et al. 2005) while 
evidence of their presence in the environment is continuous (e.g. soils, Goeppert et al. 2015). 
The following list presents some selected compounds from the three previously described 
categories i-iii (studied in this thesis), considered of environmental concern due to their poor 
degradability, bacterial or viral resistance, and low threshold effect in the environment (see 
Tables 2.7 and 4.3 for more information): 
 (i) nevirapine (NVP), lamivudine (3TC), and zidovudine (ZDV), that are commonly 
prescribed as antivirals to treat HIV infections (therapeutic group of antiviral 
compounds),  
 (ii) rifampicin (RMP) and ciprofloxacin (CIP) that are widely used to treat tuberculosis 
(therapeutic group of anti-tuberculotics),  
 (ii) trimethoprim (TRI) and sulfamethoxazole (SMX) that are used in combination with 
HIV drugs to prevent infectious diseases in HIV patients (therapeutic group of 
antibiotics), 
 carbamazepine (CBZ), one of the most important antiepileptic drugs (Bertilsson and 
Tomson 1986), and 
 (iii) estogens, namely estriol (E1), 17β-estradiol (E2), synthetic 17α-ethinylestradiol 
(EE2) and estrone (E3).  
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TABLE 2.7.  Selected pharmaceuticals (studied in this thesis), their uses and excretion as a parent compound and metabolites in urine. 
Pharmaceutical Use Excretion in urine 
as a parent 
compound (%) 
Reference 
Lamivudine (3TC) treatment of HIV, antiretrovirals a 
 
70 Atkinson et al. (2007) 
Zidovudine (ZDV) 14–20 Johnson et al. (1999) 
Nevirapine (NVP) 2.7 Smith et al. (2001) 
Sulfamethoxazole (SMX) sulphonamide antibacterials, used in treating urinary tract infections, 
pneumonia, bronchitis, meningitis, or toxoplasmosis, and in 
veterinary medicine. Also called co-trimoxazoleb, TRI and SMX are 
most likely used to treat HIV-related pneumonia.  
14–48 Fernandez-Torres et al. (2010)  
Johnson et al. (1999) 
Pérez et al. (2005) 
Patel and Welling (1980) 
Trimethoprim (TRI) 37–81 
Ciprofloxacin (CIP) fluoroquinole antibacterial used e.g. in tuberculosis treatment 
(commonly associated with HIV infection). Also an effective 
antibiotic against Proteus mirabilis, a common bacterium in the 
urinary tract that can cause urinary infections and formation of 
urinary crystals. 
40–50 Vance-Bryan et al. (1990) 
Rifampicin (RMP) rifamycin antibacterial. Used in the treatment of tuberculosis, 
caused by Mycobacterium tuberculosis. 
13–24 Burman et al. (2001) 
Carbamazepine (CBZ) c antiepileptic. CBZ is a persistent pharmaceutical and is not 
subjected to any degradation or adsorption neither in wastewater 
treatment nor in soils. 
3 Clara et al. (2004) 
Gibson et al. (2010) 
Estrogens Use Elimination as 
glucuronides (%) 
Reference 
Estrone (E1) estrone is produced primarily in the ovaries, placenta, and in 
peripheral tissues (especially adipose tissue) 
85–89 DrugBank (2015) 
Roche Diagnostics GmbH (2014) 
 17β-Estradiol (E2) estradiol is the most potent form of estrogenic steroids. In humans, 
it is produced primarily by the ovaries and the placenta. It is also 
produced by the adipose tissue of men and postmenopausal 
women. 
90–95 
17α-Ethinylestradiol (EE2) semisynthetic and has high estrogenic potency when administered 
orally. EE2 is often used as the estrogenic component in oral 
contraceptives. 
90–95 
Estriol (E3) estriol is a major urinary estrogen, large amounts of which is 
produced by the placenta during pregnancy. 
90–95 
Note: a 3TC, ZDV and NVP are used in combination in HIV treatment as a fixed-dose combination tablets (Marier et al. 2007). b Co-trimoxazole is also effective 
against P. mirabilis. c CBZ has been used as a marker for a non-biodegradable substance and it has been detected in many WWTP effluents. 
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After administration or production and/or synthetization in the human body, pharmaceuticals 
and estrogens are metabolized and excreted mostly in urine via kidneys (or through bile and 
via faeces), partially as parent compounds and as a number of inactive and active metabolites 
with modified chemical structures (Pelkonen and Ruskoaho 2003, Kujawa-Roeleveld et al. 
2008, Schürmann et al. 2012). The excretion varies for the previously presented compounds 
(Table 2.7) in the range of 2.7–70% as parent compounds; for estrogens, excretion is based 
mainly on glucuronides, which comprise approximately 85–95% of the excreted concentration 
(Table 2.7). As estrogens can be less bioactive in their glucuronide-form, to enhance analysis 
efficiency, the chemical glucuronides must be broken down to release the active, original 
compound (Figure 2.1).   
 
FIGURE 2.1.  Chemical structures of the four estrogens (DrugBank 2015) and the conjugated forms 
of estradiol as examples of urinary estrogen conjugates (ChEBI 2013, MolDB 2013). 
 
 
FIGURE 2.2.  An overview of the metabolism of a parent compound into phase I and phase II 
metabolites (adapted from Halling-Sørensen et al. 1998, Koulu and Tuomisto 2007).  
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In human metabolism (of pharmaceuticals and hormones) four different end-products are 
observed: an active compound results in inactive metabolite (i), an active compound results in 
active metabolite (or both active and inactive metabolites) (ii), an inactive compound results in 
active metabolite (iii), or an inactive compound results in toxic metabolite (iv) (Koulu and 
Tuomisto 2007). As a result of conjugation, the compound gains a glucuronide, glutathione, 
acetyl, or a sulfate group (Pelkonen and Ruskoaho 2003) and is then excreted into urine. 
Metabolism can be divided into two phases describing the water solubility of the metabolite 
(Figure 2.2). Both phase I and phase II reactions depicted in Figure 2.2 change the physical 
behavior of the substance, since metabolism always renders the metabolites more water-
soluble than the parent compound (Halling-Sørensen et al. 1998); phase II metabolites being 
most water-soluble. In the intestine or in urinary bladder de-conjugation reactions can occur, 
which leads to release of parent compound or phase I metabolite into urine (Pelkonen and 
Ruskoaho 2003). The presence of metabolites in urine is essential relating to urine-based 
fertilizers, as metabolites are susceptible to change back to original, active forms of the 
compounds e.g. in the WWTPs and in the soil (Kurisu et al. 2010, Goeppert et al. 2014, Jelíc 
et al. 2015), thus posing a risk to fertilization applications. 
2.2.2 Fate of Pharmaceuticals and Estrogens in Urine Treatment and in 
Wastewater Treatment Plants  
In order to understand the effect of urine removal from municipal wastewater, the presence of 
pharmaceuticals and estrogens at WWTPs and receiving waters needs to be assessed. 
Pharmaceuticals and their metabolites are excreted mainly via urine (only partly via feces), as 
discussed earlier (Chapter 2.2.1) and thus the potential fate of pharmaceuticals and their 
metabolites is defined by the following processes. For example, in the flush sewage systems 
urine is led into municipal WWTPs, while in other systems urine may be discharged directly 
into environment (Escher et al. 2005, 2006). One major difference between source-separating 
urine and treating wastewaters at WWTPs is that in the former the urine has a significantly 
higher concentration of pharmaceuticals (µg/L or mg/L vs. ng/L measured at WWTPs) as well 
as bulk organics and nutrients (Kujawa-Roeleveld et al. 2008).  
Finding processes to remove pharmaceuticals and hormonal compounds from urine is of 
notable importance considering its re-use (Gajurel et al. 2007). Among the different techniques 
investigated for urine treatment and pharmaceutical removal (Tables 2.4 and 2.8), 
nanofiltration, struvite precipitation, and electrodialysis are all effective in separating inorganic 
nutrients from pharmaceuticals for further applications, while a supplemental treatment is 
recommended to remove or degrade the pharmaceuticals (Dodd et al. 2008). Ozonation is not 
considered as a process for fertilizer production, but it can be used as an additional urine 
treatment step to break down pharmaceutical compounds (Escher et al. 2006). It is also 
possible, in principle, to remove pharmaceuticals by adsorption to active carbon or other 
adsorbents (Maurer et al. 2006), but the high organics concentration in urine will probably 
interfere with the adsorption process (Quinlivan et al. 2005). 
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TABLE 2.8. Comparison of different urine treatment processes for pharmaceutical elimination. 
Technique Waste product Fertilizer product Estrogenicity removal  Removal of single compounds  Reference  
electrodialysis diluate, drugs concentrate 99.7% EE2 > 98% Escher et al. (2006) 
   86–94% ibuprofen >95% Pronk et al. (2007) 
bioreactor (after 24h) - treated effluent 
(stabilized urine) 
E2 92% 
EE2 73% 
E2 89% 
EE2 55% 
propranolol 0% 
ibuprofen 0% 
Escher et al. (2006) 
nanofiltration concentrate 
drugs 
permeate 53.4% propranolol 59% 
ibuprofen 96% 
diclofenac 96% 
carbamazepine 74% 
EE2 96% 
Escher et al. (2006) 
  - - EE2, diclofenac, ibuprofen, 
propranolol, carbamazepine: at 
pH 5.3, >92% removal; at pH 4.8, 
73% removal 
Pronk et al. (2006) 
struvite precipitation filtrate, drugs struvite >98.1% EE2 and E2 < LOD 
propranolol 99.2% 
ibuprofen >99.9% 
diclofenac >99.9% 
carbamazepine 99.7% 
Escher et al. (2006) a 
  washed struvite  - diclofenac <LOD 
hydrochlorothiazid <LOD 
metoprolol <LOD 
nebivolol <LOD 
Schürmann et al. (2012) 
  washed struvite - E1 97% 
E2 95% 
EE2 100% 
propranolol 94.2% 
ibuprofen 99.6% 
diclofenac 99.9% 
carbamazepine 96.4% 
Ronteltap et al. (2007) 
Note: a struvite dissolved after washing; <LOD - concentration below limit of detection; - not reported 
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TABLE 2.8. Continues. 
Technique Waste product Fertilizer product Estrogenicity removal  Removal of single compounds  Reference  
ozonation - - >99% (1.1 gO3/L) removal <LOD (0.6-0.8 gO3/L) for 
EE2, propranolol, diclofenac, 
carbamazepine and at 1.3 gO3/L 
for ibuprofen 
Escher et al. (2006) 
 - - - ibuprofen 50%, clofibric acid 50%, 
carbamazepine 95%, diclofenac 
95% 
Gulyas et al. (2007) 
 - - - ibuprofen 15–117%, bezafibrate 
17–97%, β-sitostrerol 32–79%, 
carbamazepine 67–92%, 
diclofenac -31–151%, 
pentoxifylline 69% 
Tettenborn et al. (2007)b 
 - - - >99% EE2 at 0.06 gO3/L Dodd et al. (2008) 
steam stripping N-depleted urine  ammonium-
containing 
condensate 
- >99% for ibuprofen, bezafibrate,  
β-sitosterol, diclofenac, 
phenacetin, carbamazepine, 
pentoxifylline 
Tettenborn et al. (2007) 
evaporation distillate concentrate - in 3.5 times concentrated urine 
phenacetin, carbamazepine, 
pentoxifylline, phenazone were 
detected,  50% of bezafibrate, 
30% of diclofenac and ibuprofen,  
Tettenborn et al. (2007) 
UV-radiation - - - ibuprofen 46–93%, bezafibrate 
42–348%, β-sitosterol -58–38%, 
carbamazepine 74–113%, 
diclofenac 37–72%, pentoxifylline 
48–87% 
Tettenborn et al. (2007)c 
 - - - degradation of sulfamethoxazole 
and trimethoprim, formation of 
metabolites of different properties 
Zhang et al. (2015)d 
Note: UV – ultraviolet; O3 - ozone; - not reported; b removal depending on gO3/L supplied; c removal depending on efficiency of UV-radiation; d synthetic fresh and hydrolyzed 
human urine 
 
 
24 
 
While the fate of pharmaceuticals and estrogens in the treatment or use of source-separated 
urine are little investigated, their fate at WWTPs has been intensively studied and in the 
following some general overview of the compounds studied in this thesis is given (Tables 2.9 
and 2.10). Over the years, several studies investigating the pharmaceutical concentration at 
current WWTPs have shown the inconvenient truth: most pharmaceuticals are only partly 
removed during treatment processes (Ternes et al. 2001, Ternes et al. 2004, Blair et al. 2015) 
and some appear quite persistent (Clara et al. 2004). In Tables 2.9 and 2.10, the average 
concentrations reported in the literature for the selected compounds are given. The fate of the 
studied compounds in the WWTP process has varied; e.g. 3TC is reported to be eliminated 
more than 90%, while removal of NVP and ZDV has been negligible (Table 2.9). According to 
a review by Jain et al. (2013), antiviral compound persistence in WWTPs can be observed with 
other antiviral compounds as well. It has been claimed that pharmaceuticals are transformed 
back to their active forms by the WWTP microorganisms (Jelíc et al. 2015), thus explaining the 
larger concentration leaving from the WWTP than what is recorded in the influent. In the case 
of estrogens, the removal percentages at WWTPs have varied from -62.4% to 98.8% in the 
reported investigations (Table 2.10). The natural estrogens E2 and E3 are eliminated by 44–
96%, and E1 is not removed in some cases at all, while the synthetic EE2 used in e.g. 
contraceptives is 34–43% removed. 
TABLE 2.9.  Pharmaceutical concentrations in WWTP influents and effluents, and their removal 
percentages reported in the literature. In some cases, concentrations are from grab 
samples, in others 24-h collection samples. The removal is expressed as a difference 
between the influent and the effluent, while the fate is not presented. The values are 
mean concentrations.  
 At WWTP (ng/L)   
Analyte Influent Effluent Removal (%) Reference  
Lamivudine 210–720  < LOQ 76–93 Prasse et al. (2010) 
Nevirapine 4.8–21.8 7.2–32.1 0 Prasse et al. (2010) 
Zidovudine 310–380 98.2–564 0–68 Prasse et al. (2010) 
Sulfamethoxazole 
- 
580 
144–674 
800–2200 
- 
250 
135–304 
900 
-138–60 
43 
6–55 
40  
Göbel et al. (2007) 
Carballa et al. (2004) 
Lindberg et al. (2005) 
Pérez et al. (2005) 
Trimethoprim 
- 
99–1300 
300–500 
- 
66–1340 
100 
-40–20 
-3–33 
75  
Göbel et al. (2007) 
Lindberg et al. (2005) 
Pérez et al. (2005) 
Ciprofloxacin 
200–600 
<LOD–4230 
102–300 
29–40 
<LOD–130 
7–18 
86–93 
97–100 
93–94 
Vieno et al. (2006) 
Vieno et al. (2007) 
Lindberg et al. (2005) 
Rifampicin - - - - 
Carbamazepine 160–820 
290–400 
290–2440 
380–470 
 -81– -198 
-18– -23 
Vieno et al. (2007) 
Vieno et al. (2006) 
 
Note: A negative value in the elimination-column means that effluent had higher concentration than 
influent. In most cases, the variation is reported between different seasons or different WWTPs and 
sampling sites; - not reported 
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TABLE 2.10.  Estrogen concentrations in surface waters and in WWTP influents and effluents 
reported in the literature. In some cases concentrations are from grab samples, in 
others 24-h collection samples. The values are mean concentrations. 
 Estrone  
E1 
17β-estradiol 
E2 
17α-ethinyl-
estradiol EE2 
Estriol  
E3 
Reference 
surface  
water (ng/L) 
- 
1.1–3.0 
0.1–4.1 
< 0.1–2.9 
2.2–2.6 
1.4–3.0  
0.15–3.6 
< 0.3–5.5 
0.48–0.52 
1.1–2.9  
0.1–5.1 
< 0.1–4.3 
- 
1.0–2.5  
- 
- 
Snyder et al. (1999) 
Cargouët et al. (2004) 
Kuch and Ballschmiter (2001) 
Belfroid et al. (1999) 
WWTP 
influent 
(ng/L) 
- 
19–78 
56.2 
54.8 
9.6–17.6 
0.71 
2.4–26.0 
15.7 
22 
11.1–17.4  
- 
- 
< 0.3 
< 5.0 
4.9–7.1  
- 
- 
26.2 
- 
11.4–15.2  
Snyder et al. (1999) 
Servos et al. (2005) 
Fan et al. (2011) 
Braga et al. (2005) 
Cargouët et al. (2004) 
WWTP 
effluent 
(ng/L) 
- 
1–96 
12.0 
8.1 
4.3–7.2 
0.35–18 
2.4 
0.45-3.66 
0.2–14.7 
1.0 
0.95 
4.5–8.6 
0.15–5.2 
4.4 
0.24–0.76 
- 
< 0.3 
4.5 
2.7–4.5 
0.1–8.9 
- 
- 
- 
0.2 
- 
5.0–7.3 
- 
- 
Snyder et al. (1999) 
Servos et al. (2005) 
Fan et al. (2011) 
Braga et al. (2005) 
Cargouët et al. (2004) 
Kuch and Ballschmiter (2001) 
Carballa et al. (2004) 
removal at 
WWTPs (%) 
85 
-62.4–97.8 
44–59 
96 
39.5–98.8 
43–60 
- 
- 
34–43 
- 
- 
40–67 
Braga et al. (2005) 
Servos et al. (2005) 
Cargouët et al. (2004) 
Note: In most cases the variation is reported between different seasons or different WWTPs and 
sampling sites; - not reported 
 
Pharmaceuticals and Hormones in Soil and Transportation into Agricultural Products 
One of the main concerns in using urine on agricultural purposes on edible plants is the 
leaching of these compounds in the soil and transportation and accumulation of the 
pharmaceuticals and hormones into the plants. Sorption is seen as the major factor influencing 
pharmaceutical behavior in the soil (Winker et al. 2009) when using reclaimed wastewater 
sources while using urine, a much lower concentration is sorbed onto soil particles (Kujawa-
Roeleved et al. 2008). The organic matter content in urine decreases the soil capacity to sorb 
pharmaceuticals (Kujawa-Roeleved et al. 2008) and urine is not only affecting the sorption rate 
but prolongs vertical migration rates as well as hinders microbial degradation (Lucas and Jones 
2009). In soils, the bioavailability is determined by the sorption characteristic by clay minerals 
and soil organic matter as well as soil pH (Carvalho et al. 2014). Behavior of estrogens in soil 
is dependent upon the aqueous matrix type where it is delivered to the soil (Lucas and Jones 
2009). 
The prior exposure of the soil to pharmaceuticals (i.e. has the pharmaceutical already been 
introduced to the soil microorganisms) can influence the degradative ability of the soil microbial 
community and be inhibitory to degradation – additionally, the effect of soil oxygen content 
plays a major role (Xu et al. 2009, Carr et al. 2011). Biological degradation under aerobic 
conditions in the soil can be more rapid or similar in comparison with unexposed soils for 
estrogens and some pharmaceuticals than in prior exposed soils (Carr et al. 2011). Ibuprofen, 
for instance, does not necessarily degrade under lower bacterial concentrations found in soil, 
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but requires high bacterial activity found in activated sludge WWTPs, whereas CIP does not 
degrade at all but is immobilized in the soil (Carr et al. 2011). Under anaerobic conditions, 
influencing factors such as nutrient availability, microbial population, and soil structure could 
have an effect (Carr et al. 2011). In the soil, microbial transformations, sorption, the capillary 
transport of water and pharmaceuticals, and the levels of pharmaceuticals in contact with roots 
may vary both spatially and temporally (Wu et al. 2013). Winker et al. (2010) have 
demonstrated that ryegrass can uptake CBZ on roots and aerial parts of the plant via urine 
fertilization, and the transport was driven by transpiration, while a cucumber can take up CBZ 
which can bioaccumulate at indigenous levels present in wastewater (Shenker et al. 2011). 
The main factors affecting pharmaceutical and hormonal uptake in plants from soil are the acid 
dissociation constant (pKa) and polarity of the compound (i.e. ionization at environmental 
conditions) – pharmaceutical translocation in the plant after root uptake is affected by water 
movement due transpiration, and hydrophilic compounds may have a greater movement 
potential (Herklozt et al. 2010, Wu et al. 2013). The plant uptake of pharmaceuticals during 
irrigation with treated wastewater may affect plant development indirectly by disrupting soil 
communities and soil function by decreasing the number of soil bacteria thus leading to lack 
of food for soil fauna (protozoa, nematodes, micro arthropods) (Fatta-Kassinos et al. 2011). 
Less data is available on pharmaceutical accumulation through urine fertilization but some 
studies have been conducted using e.g. reclaimed wastewater (Shenker et al. 2011) and 
nutrient solutions (Herklotz et al. 2010, Wu et al. 2013). For more information, see Table 2.11 
where some of the accumulation and leaching studies of pharmaceuticals and estrogenic 
hormones in the soil have been grouped.  
The root uptake of pharmaceuticals has been shown to correlate positively with pH-adjusted 
octanol–water partition factor (logKow) for nonionic compounds whereas translocation from 
roots is negatively related (Wu et al. 2013). Ionization of compounds, including 
pharmaceuticals in the soil, is therefore important – weak acids or bases, for instance, undergo 
partial dissociation under environmental pH conditions and are thus present in soils in two or 
more forms, i.e. the neutral molecule and ionized species (Wu et al. 2013). Under soil pH 
conditions below their pKa, organic acids are normally in their neutral and undissociated form, 
which has a higher tendency to sorb to soil organic matter (Xu et al. 2009). For ionizable 
organic compounds, ionization reduces their uptake to the shoots due to the decrease in the 
plant cell membrane permeability (Carvalho et al. 2014). 
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TABLE 2.11.  Studies on pharmaceutical accumulation into plants and leaching of estrogens in the soil as reported in the literature 
Source of 
pharmaceuticals 
and hormones 
Pharmaceutical/
plant 
Soil type (organic matter 
content %) Type of experiment Main observation Reference 
reclaimed 
wastewater 
CBZ/cucumber peat mixture (32.6) 
sandy soil (1.2) 
clay soil (6.5) 
greenhouse, CBZ 
concentration 25 µg/L 
(spiked); 1 µg/L 
(reclaimed incl. 3 µg/L 
indigenous), 5 L pot, 
50-60% water content 
CBZ concentration in the fruit ranged 6.4–
25.6 µg/kg. 
Shenker et al. (2011) 
nutrient solution TRI, CBZ, SMX 
and 13 
others/lettuce, 
cucumber, 
spinach, chili 
pepper 
- hydroponic cultivation, 
21 days, 0.5 and 5 µg/L 
vegetables were taking up 
pharmaceuticals. Among the studied 
pharmaceuticals, TRI (92–270 ng/g) 
accumulated in roots, CBZ in roots (2.9–
67 ng/g) and leaves and stems (23–520 
ng/g).  
Wu et al. (2013) 
nutrient solution SMX, CBZ, 
TRI/cabbage 
Hoagland’s nutrient 
solution 
hydroponic cultivation, 
232.5 µg/L (spiked) 
accumulation of pharmaceuticals in the 
roots (per wet weight): 98.87 ng/g CBZ, 
138.26 ng/g SMX and 91.33 ng/g TRI. 
Herklozt et al. (2010) 
urine CBZ, Ibuprofen 
/ryegrass 
air-dried type 
Meckenheimer Krume 
(1.2) 
greenhouse, 
29 µg CBZ and 422 µg 
Ibuprofen (spiked) per 
pot, 9 kg pot, 80% 
water content 
CBZ in aerial parts 4200–6950 µg/kg dry 
matter, roots 202–426 µg/kg dry matter. 
Ibuprofen was not transferred to the roots 
and probably degraded by soil bacteria. 
Winker et al. (2010) 
fertilized water CIP, metformin, 
narasin/carrot, 
barley, wheat 
and 5 others 
sandy soil (0.73) greenhouse, 4 kg per 
pot, 10 mg/kg (spiked), 
duration 2–3 months, 
concentration in soil 6.5 
mg/kg for CIP 
in barley, CIP accumulated the least, while 
metformin was detected up to 0.1 mg/kg in 
the leafs and 1.5 mg/kg in the seeds. 
Eggen et al. (2011) 
spiked water TRI and 9 
others/carrot, 
lettuce 
loamy sand soil (0.4) greenhouse, 1 µg/kg, 
1.5 kg soil per pot, 20% 
water content 
TRI was detected in lettuce (6 µg/kg), 
carrot (5.3 µg/kg) and carrot peel (1.0 
µg/kg). 
Boxall et al. (2006) 
sheep urine estrone, estradiol sandy clay loam textured 
Eutric Cambisol (2.1); 
sand textured Eutric 
Cambisol (2.7); sandy 
loam textured Haplic 
Podzol (1.2) 
laboratory soil leaching 
study, 50 µg/L (spiked) 
both estrogen and estradiol mineralization 
were significantly reduced in all soils. 
Addition of urine caused significant 
changes in microbial activity and their 
capacity to degrade estrogens. 
Lucas and Jones 
(2009) 
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Pharmaceuticals and Hormones in Microalgal Cultivation 
It has been shown that microalgal species (e.g. Dunaliella tertiolecta, Selenastum 
capricornutum, Microcystis aeruginosa, Pseudokirchneriella subcapitata, and some Chlorella 
sp.) are sensitive to antibacterial agents (Halling-Sørensen 2000, Yang et al. 2008, Qian et al. 
2012) and pharmaceuticals and personal care products (DeLorenzo and Fleming 2008). 
Matamoros et al. (2015) have demonstrated that microalgal (incl. Chlorella sp.) uptake of 
organic compounds (including some pharmaceuticals) was indeed happening in a wastewater 
treatment system based on high-rate algal ponds. The most abundant compounds in the algal 
biomass where those with high logKow > 5 (hydrophobic), and the removal of organic 
compounds from wastewater varied from 32% to 99% (Matamoros et al. 2015). When 
cultivating C. vulgaris with the common estrogens (E1, E2, EE2, E3), it was discovered that up 
to 9% of the hormones were partitioned within the algae (Lai et al. 2002). It was also proposed 
that C. vulgaris can biotransform the steroid estrogens (e.g. E2 to E1) and that some 
bioconcentration can occur (up to factor of 27) (Lai et al. 2002). Other microalgal strains (e.g. 
S. capricornutum and Chladymonas reinhardtii) have also demonstrated E2 and EE2 removal 
efficiency from culture medium while biotransformation products were also observed (Hom-
Diaz et al. 2015). The effect of pharmaceuticals and hormones on algal growth and on biomass 
utilization options (Hom-Diaz et al. 2015) should therefore be studied further. 
2.3  Methods for Pharmaceutical and Estrogenic Characterization in 
Urine  
As described in the previous chapter, pharmaceuticals and hormones have been a rising 
matter of environmental concern, and them entering through urine into WWTPs and receiving 
waters have gained increasing attention. Pharmaceuticals are typically analyzed from waters, 
wastewaters, and urine using techniques that combine liquid chromatography (LC) with mass 
spectrometry (MS) techniques (e.g. Buiarelli et al. 2005, Mistri et al. 2007, Nebot et al. 2007, 
Prasse et al. 2010), providing information about the concentration of the analytes (at quite low 
ng/L concentrations) and also aiding to recognize unknown compounds via compound 
spectrum and mass libraries (Lai et al. 1997). Typically, LC-MS techniques are preceded by 
sample clean-up and concentration in order to reach equipment detection limits (Hao et al. 
2007, Moreno-Bondi et al. 2009). 
High performance (pressure) liquid chromatography (HPLC) analysis alone can provide a 
simple method for quantification of known pharmaceutical compounds in urine, especially at 
analyte concentrations >0.05 mg/L which is considered as a common detection limit for HPLC 
equipment. In the context of urine utilization, the need and interest to develop methods for the 
pharmaceuticals used in HIV treatment (studied in this thesis) rose from the fact that even 
though they are increasingly used globally, their environmental fate is far less studied than e.g. 
compounds such as painkillers, β-blockers, and lipid modifiers, of which a lot of analysis data 
can be found in the literature (e.g. Vieno et al. 2006, 2007, Winker et al. 2008a, 2008b). 
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However, methods for detecting the pharmaceuticals presented in Chapter 2.2.1 are very 
diverse, are not necessarily optimized for urine matrix, and include only few of the compounds 
at a time from a selection of matrices. Therefore, a method able to detect the selected 
compounds in a single run would provide savings in analysis time and consumables. 
Although LC and MS are very sensitive techniques, they are not suitable for screening 
purposes and do not consider the biological effects of a single hormone or chemical mixtures 
(Michelini et al. 2008). Endocrine disrupting compounds (EDCs, e.g. estrogens, estrogen-like 
compounds, plastic softeners, etc.) have several different chemical structures and 
mechanisms of action making their detection complicated using conventional, mainly 
chromatographic methods (Michelini et al. 2008). As the environmental concentrations of 
EDCs are quite low, sample matrices are complex, and the diversity of target compounds is 
vast, robust bioassays have been gaining interest (Salste et al. 2007). The advantage of 
biosensors in monitoring estrogenic activity is their capability to estimate cumulative estrogenic 
effects of a variety of chemicals in an environmental sample (Campbell et al. 2006) that 
correspond the overall activity of all estrogen receptor (ER) -binding chemicals present 
(Rehman et al. 1999). To identify different estrogenic compounds in environmental samples, 
the results from biological assays must be combined with gas chromatography (GC) or LC 
coupled to MS analyses (Salste et al. 2007). 
2.3.1 Pharmaceutical Analysis of Urine with Liquid Chromatography 
As already described, pharmaceuticals can be analyzed in urine with LC-technology. HPLC 
(operating pressure < 400 bar) and ultra-high performance liquid chromatography (UHPLC, 
operating pressure up to 1000–1200 bar) (Wren and Tchelitcheff 2006, Gritti and Guiochon 
2010b, McCalley 2011) are common tools in sample analysis of different environmental and 
biological matrices (e.g. Jin et al. 2010, Núñez et al. 2012). HPLC is one of the main 
techniques, for example, in pharmaceutical development, where it is used to determine purity 
to control the quality and consistency of the active substance and dosage forms (Wren and 
Tchelitcheff 2006).  
Core-Shell Columns vs. Conventional Columns 
The 400-bar pressure limit of the conventional HPLC system has been a bottleneck for faster 
chromatographic analysis (MacNair et al. 1997). As the column particle size decreases, the 
backpressure of the system increases, and pressure in columns packed with 1-µm-diameter 
particles at its optimum flow rate is 125 times higher than in columns packed with 5 µm particles 
(MacNair et al. 1997). Commonly used column particle sizes are 3–5 µm and with complex 
samples, separation times of 30 minutes or longer are not uncommon (Wren and Tchelitcheff 
2006): therefore, reducing separation time without reducing the separation quality has led to 
development of smaller particles which can be used with older HPLC equipment.  
The porosity of the particles affect negatively on column efficiency at high flow rates and under 
high pressure gradients (Gritti and Guiochon 2010a): thus, the use of superficially porous 
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particles (aka core-shell particles) has the advantage of decreasing the thickness of the porous 
layer of the porous column packing material, which decreases the length along which 
molecules have to diffuse (Gritti and Guiochon 2010b, Ruta et al. 2012). Core-shell particles 
decrease the effect of the eddy diffusion (Gritti and Guiochon 2012) as the particle size 
distribution is very narrow (Ruta et al. 2012) and the particles cannot diffuse axially in the solid 
inner core (Ruta et al. 2012). Smaller particles allow higher flow rates while maintaining near-
maximum efficiency (Fekete et al. 2011). 
The use of core-shell columns with older HPLC equipment is well justified, as long as the extra-
column contributions and system dwell volume are minimized (McCalley 2011), no methanol-
water mixtures are used due to their approximately two-fold higher viscosity compared with 
acetonitrile (ACN)-water mixtures, and long columns providing high resolution are not required 
(Ruta et al. 2012). ACN has low viscosity which enables high elution rates (Gritti et al. 2010). 
With conventional HPLC, the performance of core-shell particles is roughly equivalent to that 
of sub-2 µm particles on a typical UHPLC (McCalley 2011). 
Sample Pre-treatment in Chromatography and Simultaneous Analysis of Several 
Pharmaceuticals in Urine  
Sample preparation is a fundamental step in analytical procedures as it helps to achieve 
detection limits as well as to extract, concentrate, and clean up samples (Bakkali et al. 1999, 
Pavlović et al. 2007), or to release the analyte from a conjugate (chemical or enzymatic 
hydrolysis) (Bakkali et al. 1999) with no need to dilute the sample (Fernandez-Torres et al. 
2010). The most popular technique for liquid samples is solid phase extraction (SPE), which is 
extensively used to purify and concentrate samples containing several analytes from complex 
matrices (Fontanals et al. 2007), e.g. environmental and biological samples (Fontanals et al. 
2007) and in toxicological analyses (Logan et al. 1990, Ferrara et al. 1992, Solans et al. 1995).  
SPE sorbents come with different properties, but chemically modified polystyrene-
divinylbenzene sorbents have been studied a lot (Fontanals et al. 2007), although for 
pharmaceuticals with logKow of 1.5-4.0, any reversed phase material should work (Pavlović et 
al. 2007). Matrix effects are a problem when extracting pharmaceuticals from urine, as they 
can influence the recovery efficiency and the extracted quantity (Pavlović et al. 2007). Sample 
pretreatment with SPE is suitable for urine, as it removes the by-products of urine matrix, such 
as inorganic salts and compounds which have low hydrophobicity (Escher et al. 2005).  
As pharmaceutical compounds have a large variety of chemical structures (Pavlović et al. 
2007, Fernandez-Torres et al. 2010), the choice of sorbent is a key factor affecting the 
selectivity, affinity, and sample capacity (Pavlović et al. 2007). Simultaneous analysis of e.g. 
antibiotics (Baranowska et al. 2006, Fernandez-Torres et al. 2010), β-blockers (Maguregui et 
al. 1995), and anti-inflammatory drugs (Hirai et al. 1997, Sun et al. 2003) from human urine 
and serum have been performed, but in several cases compounds have had similar physico-
chemical properties. In many analytical methods, a compromise in the selection of 
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experimental conditions is generally required (Pavlović et al. 2007, Fernandez-Torres et al. 
2010).  
2.3.2 Bioluminescence Measurements of Estrogenic Compounds in Urine 
In this chapter, the basic principle of bioluminescence measurements of estrogens with 
biosensors is given. In addition, the applicability of genetically modified, bioluminescent yeast 
biosensor in estrogen measurements in urine is shortly described. 
Biosensors and Bioluminescence in Estrogenic Monitoring 
Different biosensors include enzyme-, non-enzymatic-, immunochemical-, cell-, and receptor-
based biosensors as well as DNA biosensors (Rodriguez-Mozaz et al. 2006, Rogers 2006). 
Biosensors include genetically modified microorganisms which give an observable response 
to target analytes (Rogers 2006) and are used for environmental monitoring such as toxicity, 
EDCs, biocides, hormones, PCBs, surfactants, antibiotics, and metals (D’Souza 2001, 
Rodriguez-Mozaz et al. 2004a). 
Bioluminescence is light produced in a living organism by a chemical reaction which involves 
an enzyme/substrate system (Roda et al. 2009). Bioluminescent cell-based assays are simple 
to perform and have been used in bioanalytical measurements where high sensitivity is needed 
(Roda et al. 2009). A bioluminescent protein, an enzyme (luciferase, also β-glucuronidase, 
green fluorescent protein and β-galactosidase, Köhler et al. 2000), catalyzes the oxidation of 
the substrate (luciferin): one of the most commonly used proteins is luciferase obtained from a 
firefly Photinus pyralis (Roda et al. 2009). However, the exact reaction mechanism is yet not 
fully understood (Roda et al. 2009). Luciferases are also produced by other microorganisms, 
such as bacteria (e.g. Vibrio fischeri used in toxicity monitoring; for reviews, see e.g. Girotti et 
al. 2008, Roda et al. 2009). 
Biosensors based on ERs provide information of the estrogenic potency of the samples 
(Rodriguez-Mozaz et al. 2004b). The principle of detection is based on the ER capturing the 
estrogen after which the complex is bound with an estrogen-responsive element immobilized 
on the sensor (Rodriguez-Mozaz et al. 2004b), which in turn, in the presence of appropriate 
substrate, produces light. The amount of reporter protein is proportional to the biological activity 
of the sample and can be measured by luminescence measurements (Michelini et al. 2008), 
while the obtained signal represents the sum activity of all estrogen receptor binding 
substances in the sample (Rehmann et al. 1999). Requirements to biosensors include 
simplicity, rapidness, cost-effectiveness, and field-portability, and they appear to be well suited 
to complement standard analytical methods for a number of environmental monitoring 
applications (Rogers 2006, Rodriguez-Mozaz et al. 2007). Biosensor advantages over 
chromatographic techniques include the redundancy of sample pre-treatment or concentration 
and sensitivity to a specific analyte due to biological recognition system (Leskinen et al. 2005, 
Rodriguez-Mozaz et al. 2007). Advantages of bioluminescence over other spectroscopic 
detection methods include higher detectability due to lower non-specific background signal and 
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the absence of interference from excitation light; bioluminescence-exploiting measurements 
also provide high sensitivity when the analyte concentration is low or sample size is very small 
(Roda et al. 2009); the analysis is robust and the sensor organisms can be grown on media 
devoid of steroids (Bovee et al. 2004a) when detecting hormonal compounds.  
The quantitative analysis of all components in a complex sample is not possible (Rodriguez-
Mozaz et al. 2007). Chemical analysis of all estrogenic compounds would be costly, and 
unknown metabolites and other estrogenic compounds can still be present in the 
(environmental) samples (Murk et al. 2002); therefore, knowing the sum of estrogenic activity 
in the sample can be more informative. Due to the great variety of compounds having estrogen-
like activity, the classical instrumental analysis may not be the most suitable tool to assess 
estrogenicity of complex mixtures (Bovee et al. 2004a), such as urine. Biosensors may also 
be useful in a quick screening of endocrine-disrupting chemicals at municipal WWTPs, which 
has been previously performed e.g. by Desbrow et al. (1998) using a selection of sample pre-
treatment steps. 
Genetically Modified Yeast Cells in Estrogenic Monitoring in Urine 
Bioluminescence tests performed on yeast cells are useful in the first stage screening as they 
are easy and inexpensive to perform and are more resistant to environmental contaminants 
than e.g. mammalian cells, which is an advantage when working with complex environmental 
samples (Leskinen et al. 2005), such as urine. A number of yeast tests for estrogenic 
compounds have been published, and many of them use the β-galactosidase enzyme as a 
reporter (Table 2.12). In addition, they take several days to perform due to long incubation 
times and sample pre-treatment requirements. (Routledge and Sumpter 1996, Bovee et al. 
2005, Vermeirssen et al. 2005). However, bioluminescent yeast biosensors have not been 
previously used to detect estrogenic activity from source-separated human urine. Previously, 
human urine has been analyzed with biosensors mainly to produce information on steroid 
abuse (Zierau et al. 2008).  
In vitro yeast estrogen screen (YES) assays utilizing β-galactosidase as a reporter have been 
successfully implemented in assessing estrogenic activity in environmental samples such as 
waters and wastewaters (Routledge and Sumpter 1996, Leskinen et al. 2005, Beck et al. 
2006). A YES-based test battery has also been applied on human urine to detect toxicity of 
certain pharmaceuticals and to monitor the efficiency of wastewater (Escher et al. 2005) and 
urine treatment processes (Escher et al. 2006). YES responds to all substances with receptor-
mediated estrogen activity regardless of the chemical structure, but the assay has a long 
induction time and assay protocol usually includes lysis of cells (Leskinen et al. 2005). The 
yeast biosensor utilizing luciferase as reporter protein (developed by Leskinen et al. 2003) was 
shown to respond to natural hormones and xenoestrogens similarly to the already established 
YES. 
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TABLE 2.12.  Biosensors used in detection of estrogenic activity from different matrices. 
Biosensor Reporter protein Detection Matrix Reference 
ER-CALUXa β-glucuronidase 
from Escherichia 
coli and Helix 
pomatia 
bioluminescence human urine 
surface waters 
Legler et al. (2002) 
   WWTP influent, 
effluent, sludge, 
river water 
Murk et al. (2002) 
E-SCREENb - cell yield E2 in EtOH  Soto et al. (1995) 
Saccharomyces 
cerevisiae  
β-galactosidase fluorescence 
microscopy 
E2 in water Wozei et al. (2006) 
 β-glucuronidase 
 
bioluminescence WWTP effluent Salste et al. (2007) 
 β-galactosidase, 
β-glucuronidase 
green fluorescent 
protein 
optical density 
luminescence 
fluorescence 
standard 
solutions 
Bovee et al. (2004a) 
yeast estrogen 
screen (YES)  
β-galactosidase absorbance/ 
optical density 
river water Vermeirssen et al. 
(2005) 
   surfactants and 
degradation 
products in 
EtOH 
Routledge and 
Sumpter (1996) 
   WWTP influent, 
effluent, sludge, 
river water 
Murk et al. (2002) 
Note: a estrogen-receptor (ER) mediated chemical-activated luciferase gene expression, human cell line; 
b human breast cancer estrogen-sensitive MCF-7 cells; EtOH - ethanol 
The yeast biosensor is an attractive option for ER mediated activity screening in chemicals as 
well as in complex environmental samples and urine (Bovee et al. 2005, 2009, Leskinen et al. 
2005). Androgen receptors have also been studied similarly to ERs in modified yeast cells (e.g. 
Michelini et al. 2008, Bovee et al. 2009). Bioluminescent yeast biosensors can be used to 
calculate the relative estrogenic potencies of estrogenic compounds to gain knowledge on their 
environmental effects (Bovee et al. 2004b, Leskinen et al. 2005). Saccharomyces cerevisiae 
can also be used to monitor non-specific toxicity in environmental samples (Välimaa et al. 
2008). Yeast cells do not normally contain an ER, thus minimizing the concerns rising from 
interference from other gene targets, presence of other steroids, peptide hormones, or growth 
factors (Routledge and Sumpter 1996).   
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3  Aims of the Present Work  
The main general objective of this thesis was to develop the use of source-separated urine. 
The main objective was further concretized to specific objectives of making characterization of 
urine easier and faster, to gain more understanding regarding pharmaceutical and estrogenic 
behavior during urine storage, and to evaluate the suitability of human urine in algal cultivations 
as a low-cost, renewable fertilizer. The specific aims of the present work were: 
 
 To develop and apply analytical methods that make detection and quantification of 
pharmaceuticals and hormones in urine faster by 
o developing a method to detect several pharmaceuticals from human urine in a 
single six-minute analysis instead of analyzing each compound separately 
(Paper I). 
o assessing the feasibility of a yeast-cell-based biosensor in fast estrogenic 
activity detection in urine without any pre-treatment of the sample (Paper II). 
 To assess the effect of the generally recommended six-month storage of urine on 
selected pharmaceuticals (Paper III). 
 To evaluate the effect of urease inhibitor addition and fecal contamination in urine on 
pharmaceutical behavior during six-month storage (Paper III). 
 To evaluate the feasibility of urine as nutrient source in microalgal cultivation and 
biomass production (Paper IV) by 
o comparing microalgal growth in diluted urine with growth in artificial growth 
medium. 
o screening the effect of urine dilution for maximum biomass production. 
 To gain knowledge on microalgae nutrient utilization from urine (Paper IV). 
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4  Materials and Methods 
This chapter describes the methods and analyses used in this thesis. The objectives as well 
as the methods are summarized in Table 4.1.   
TABLE 4.1.  Summary of the objectives and methods used in this thesis. 
Objective Method Paper 
method for analyzing several 
pharmaceuticals simultaneously in urine 
development of an HPLC method able to 
detect eight pharmaceuticals in a single run 
in six minutes 
I 
method for fast estrogenic activity 
detection in both fresh and stored 
human urine 
feasibility assessment of a yeast-cell-based 
biosensor without sample pre-treatment in 
detecting estrogenic activity in urine  
II 
pharmaceutical behavior in urine during 
a six-month storage  
urine storage experiments for six months 
with pharmaceutical spiking and with 
feces/urease inhibitor amendment 
III 
urine as a nutrient source in microalgal 
cultivation 
microalgal cultivation in different urine 
dilutions and as a reference in an artificial 
growth medium  
IV 
 
4.1 Substrate and Inocula 
4.1.1 Urine Collection, Experimental Controls, and Pharmaceuticals Used 
The human urine used in the experiments was collected from volunteers (28–38 years) in the 
Department of Chemistry and Bioengineering (Tampere University of Technology, TUT) as 
well as from four individuals outside TUT (9–38 years). A summary of the collected urine and 
different experimental set-ups are presented in Table 4.2. All volunteers were healthy and 
were taking no medication. 
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TABLE 4.2.  Urine collection for each experiment conducted in this thesis. 
Source of human urine Processing before experiments Reference 
two persons: 
a male and a female 
mixed Paper I 
six persons: 
a female, a female taking oral 
contraceptives, two males, a boy child, a 
girl child 
used individually + mixed 
stored (one or five months) + mixed 
Paper II 
eight persons: both male and female mixed  
 
Paper III 
one person: a male sampled twice: one sample for each 
set-up 
Paper IV 
Urine used in the experimental controls (Papers II-IV) was not autoclaved, although 
autoclaving is often used to prevent biological activity. Preliminary tests indicated that 
autoclaving changed urine composition by transforming urea to ammonium, thus making use 
of such control unfeasible. Filtration of controls through 0.2 µm was excluded as it removes 
beneficial bacteria, and in a large scale, the costs would be high (Papers II, III, IV). 
A method was developed to analyze several pharmaceuticals in urine simultaneously (Paper 
I), and the effect of urine storage on spiked pharmaceuticals was evaluated (Paper III). In 
addition, a bioluminescent whole-cell biosensor was used to determine the estrogenic activity 
from spiked standards and real human urine samples (Paper II). A summary of the physical 
and chemical properties of the pharmaceuticals and estrogens used in the experiments 
(Papers I, II, and III) are described in Table 4.3 (next page).  
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TABLE 4.3.  Physical and chemical properties of the pharmaceuticals, chemicals, and estrogens used in this thesis (Papers I, II, III). 
Paper Compound  Molecular 
weight (g/mol) a 
pKa a,b logKow a,b Water solubility 
(g/L) a,b 
Typical usage 
I, III Pharmaceuticals       
 Lamivudine 3TC 224.26 4.3 -1.29 2.76 antiviral (HIV-treatment) 
 Zidovudine ZDV 267.24 9.96 0.05 16.3 antiviral (HIV-treatment) 
 Nevirapine NVP 266.89 2.8 1.75 0.105 antiviral (HIV-treatment) 
 Sulfamethoxazole SMX 253.28 1.6; 5.7 0.89 0.459 antibiotic 
 Trimethoprim TRI 290.32 7.12 0.91 0.400 antibiotic 
 Ciprofloxacin CIP 331.35 6.09; 8.74 0.28 30 antibiotic (tuberculosis) 
 Rifampicin RMP 822.94 1.7; 7.9 4.24 1.4 antibiotic (tuberculosis) 
 Carbamazepine CBZ 236.27 13.9 2.45 0.0177 antiepileptic 
II Estrogens       
 Estrone E1 270.37 -5.3; 10.33 3.13 0.030 natural hormone 
 17β-Estradiol E2 272.38 -0.88; 10.33 4.01 0.0036 natural hormone 
 17α-Ethinylestradiol EE2 296.40 -1.7; 10.33 3.67 0.0113 synthetic hormone, used in contraceptives 
 Estriol E3 288.38 -3.2; 10.33 2.45 0.0273 natural hormone 
Note: Data collected from a DrugBank (2015); b Toxnet (2015). 
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4.1.2 Microorganism Strains and Cultivation Conditions Used 
The microorganism strains, inoculum cultivation, and growth conditions used in this thesis 
(Papers II and IV) are described in Table 4.4. The yeast biosensor (developed by Leskinen et 
al. 2003, 2005) has been used in detection of estrogenic compounds from different matrices 
such as wastewaters and moisturizing lotions, but it has not been used with urine before 
(Paper II). Preparation of the medium and agar were based on Välimaa et al. (2008) and are 
described in detail in Paper II. C. vulgaris stock and maintenance cultures were grown in 
modified Chu-10 medium (originally by Stein (1973), modified by Acreman, for more detail, see 
Paper IV). 
TABLE 4.4.  Description of the inoculum and cultivation conditions used for Saccharomyces 
cerevisiae and Chlorella vulgaris (Papers II and IV). 
 Estrogenic activity assessment of 
urine 
Microalgal cultivation in urine 
organism used genetically modified bioluminescent 
yeast, Saccharomyces cerevisiae 
BMAEREluc/ERα 
green microalga  
Chlorella vulgaris (SAG 211-11b) 
inoculum origin stored in glycerol stock at -80oC. originally obtained from the Culture 
Collection of Algae (SAG) at the 
University of Göttingen, Germany. 
inoculum cultivation AHL-agar consisting of yeast nitrogen 
base w/o amino acids, agar-agar, 
glucose, and essential amino acids 
adenine, L-histidine and L-leusine (aka 
AHL). 
the alga used had been sustained in 
maintenance cultures, from which 
inoculum were transferred into 
experimental cultivations. 
growth conditions inoculum was grown 48 h at 30oC after 
which one colony was transferred into 
5 mL of liquid medium (AHL-medium 
without agar-agar), where it was 
incubated overnight at 30oC, 300 rpm. 
culture was maintained and 
experiments conducted in 250 mL 
shake flasks at 24±1oC at 135 rpm 
under continuous 29 µmol 
photons/m2/s illumination (5x 
OSRAM L 18W/965 Biolux 
fluorescent lamps) without CO2 
addition. 
notes: both the agar and liquid medium were 
autoclaved before glucose and amino 
acid addition at 121 oC for 15 min. 
alga was grown in modified Chu-10 
medium. 
Reference Paper II Paper IV 
 
4.2 Experimental Set-ups  
4.2.1 Urine Storage Experiments (III) 
For storage experiments, collected urine was combined thrice in a 5-liter volumetric flask, 
mixed and divided into 150 mL portions into sterile 60 plastic (polypropylene) bottles with tight 
lids (Figures 4.1A and 4.1B). After sample division in experimental jars, pharmaceuticals 
(Table 4.3) were spiked into the samples at concentrations which might have be present in 
urine of a medicated person (the pharmaceutical concentration range of 7–140 mg/L/d for 
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antivirals, 43–469 mg/L/d for antibiotics, 60–300 mg/L/d for antituberculotics, and 20 mg/L/d 
for CBZ, Paper III). In short, each pharmaceutical was tested in laboratory storage, in triplicate, 
individually, in therapeutic groups, in therapeutic groups with feces addition, and in therapeutic 
groups with urease inhibitor addition. Urine was also stored without pharmaceuticals but 
amended with either feces or urease inhibitor.  
In the beginning of the experiment and afterwards monthly for a duration of six months, pH and 
conductivity of the samples were measured and a 3 mL portion of the sample was filtrated for 
SPE pre-treatment. After SPE, samples were transferred into HPLC vials and run on Agilent 
1100 HPLC with earlier developed method (both the HPLC method and SPE pre-treatment are 
described in detail in Chapter 4.3.1 and in Paper I).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4.1.  A) experimental set-up in storage experiments; mixed urine (150 mL) in 60 bottles, 
and B) same urine samples after pharmaceutical, feces, and urease inhibitor addition 
(green color is caused by urease inhibitor, orange by the antibiotic agent rifampicin) 
(Paper III). C) microalgal cultivation in batch bottles (Paper IV). The alga was 
cultivated in initial 600 mL of selected medium in 1 L Erlenmeyer shake flasks. 
 
4.2.2 Microalgal Cultivation Experiments (IV) 
Microalgal growth was studied in two experimental set-ups for 21 days each (Paper IV). One 
experiment was performed as triplicate in diluted urine (1:100), in modified Chu-10 medium, 
where the concentrations of N and P were adjusted to match to that of diluted urine, and in 
modified Chu-10 medium in which the N and P sources had been replaced by corresponding 
amount of urine but with all essential nutrients supplied as stock solutions. The other 
A B 
C 
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experiment was conducted as duplicate, in different urine dilutions of 1:25, 1:75, 1:100, 1:150, 
and 1:300. Cultivation experiments took place in 1 L Erlenmeyer shake flasks (Figure 4.1C) in 
similar conditions as with stock and maintenance cultures (temperature, shaking, illumination, 
air supply). 
4.3 Analytical Methods and Method Development 
As eight different pharmaceuticals were analyzed, and many different chromatographic 
techniques were available for the selected individual compounds, there was a need to develop 
an analytical tool to detect all the compounds with a single method instead of having to analyze 
each compound separately. As for the estrogenic activity assessment, application of the yeast 
biosensor was hypothesized to provide rapid overview of the estrogenic activity in urine 
samples without having to perform time-consuming chromatographic analysis that would have 
required extensive sample pre-treatment steps.  
4.3.1 HPLC Method for Simultaneous Detection of Pharmaceuticals in Urine (I) 
A pre-treatment step for urine samples was needed in order to remove interfering substances 
before HPLC analysis. Thus, SPE with vacuum manifold was chosen as a cleaning step (for 
details, see Paper I). The SPE sorbent (Strata-X, 30 mg/33 µm) was conditioned with methanol 
(MeOH), equilibrated with MilliQ-water, and the filtrated (0.2 µm nylon) sample was loaded. 
After drying the sample for 1 minute in vacuum, sorbent was washed with 2% ammonium 
hydroxide to remove interferences, and to collect the fraction containing lamivudine (due to low 
logKow, Table 4.3), sorbent was dried for 1 min in vacuum and the rest of the sample was 
eluted with ACN:MeOH:Acetic acid (50:50:2, v/v/v). Method was validated for human urine by 
performing recovery tests for each pharmaceutical (Paper I). 
An HPLC method was developed to monitor the concentrations of selected pharmaceutical 
compounds in urine during storage. In short, Agilent 1100 HPLC equipped with Kinetex XB-
C18 2.6 µm core-shell column (temperature 40oC) and a 0.2 µm pre-filter C18-cartridge was run 
in a gradient mode: mobile phase consisted of ACN (eluent A) and 10 mM potassium 
phosphate buffer, pH 2.50 (eluent B). Gradient elution took place in 4.0 minutes: an isocratic 
hold from 0 min to 0.5 min at 5% eluent A, linear gradient from 0.5 min to 3.5 min from 5% to 
70% eluent A, and an isocratic hold from 3.5 min to 4.0 min at 70% eluent A. The column was 
left to stabilize for 2.0 min after each sample, leading to a total analysis time of 6.0 min per 
sample. The detection wavelengths were 210 nm and 264 nm (diode array detector) and the 
flow rate used was 2.5 mL/min. The method was validated by performing repeatability and 
robustness tests (Paper I). 
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4.3.2 Estrogenic Activity Detection in Urine (II) 
For the hormonal activity assays, yeast cells were grown to optical density (OD600) of 3.0 and 
afterwards the culture was diluted with AHL-medium to OD600 of 0.8 and used in the assay with 
D-luciferin solution (Paper II, developed by Leskinen et al. (2003)). The D-luciferin solution was 
sterilized by sterile filtration and stored in 4 mL fractions in falcon tubes at -20oC covered with 
aluminum foil due to its light sensitivity. For analysis, one tube was unfrozen and its contents 
diluted with 4 mL of sterilized MilliQ-water to produce a 1 mM luciferin solution. 
 
FIGURE 4.2.  Standards for EE2 and E3, in addition with some spiked and real samples. The more 
red the color, the higher the yeast response to the estrogen. 
In short, to construct a standard curve for all four estrogens (E1, E2, EE2, E3; Table 4.3), aliquots 
of estrogens (0.29–29 640 µg/L) were pipetted into white 96-well plates (Paper II). As blank, 
10% EtOH was used. Aliquots of the yeast culture were subsequently added into the wells 
containing the urine samples and estrogen standards. Plates were incubated at 30oC for 2.5 h 
at 300 rpm on a rotary shaker. After incubation, aliquots of 1 mM D-luciferin were pipetted into 
the wells and bioluminescence was measured using a Victor2 Wallac 1420 Multilabel counter 
(Figure 4.2). In addition to signals from each well, the apparatus also indicated the intensity of 
the signal with colors. 
The fold induction (FI) values were calculated based on signals given by the blank and the 
samples and compared to the estrogen standards to obtain approximation of estrogenic 
concentrations (Paper II). The effect of estrogen glucuronidation on bioavailability was tested 
by performing hydrolysis on the samples by heat-treating them in 80oC for 30 minutes or by 
adding β-glucuronidase enzyme and incubating at 46oC for 45 minutes to break the conjugated 
bonds. 
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4.3.3 Analytical Methods and Calculations 
The analyses conducted during the experiments are summarized in Table 4.5. All standardized 
analyses were, in general, conducted using Finnish standards (SFS). 
TABLE 4.5.  Summary of the analyses used in this work. 
 
 
  
Physicochemical, biological, and 
instrumental analysis 
Analytical method Paper 
bioluminescence luminometer  II 
biomass concentration (dry weight, 
volatile suspended solids, VSS) 
furnace, balance IV 
conductivity electrode II, III, IV 
de-conjugation β-glucuronidase addition, incubation II 
dissolved Na, Mg, K, Ca, Fe atomic adsorption spectrophotometer (AAS):   
SFS 3044, SFS 3018 
II, IV 
dissolved organic carbon (DOC) total organic carbon analyzer: SFS-EN 1484 II, III, IV 
dissolved oxygen electrode IV 
dissolved PO43-, NO2-, NO3-, Cl-, SO42- ion chromatography: SFS-EN ISO 10304-1 II, III, IV 
estrogenic activity yeast bioluminescence assay II 
filtration vacuum or syringe filter with 0.2 or 0.45 µm 
membrane 
I, III, IV 
Ntot, Ptot, NH4+-N colorimetric cuvette test, spectrophotometer IV 
optical density spectrophotometer, @600 nm II, IV 
pH pH-electrode III, IV 
pharmaceutical concentration high performance liquid chromatography I, III 
sample preparation solid phase extraction with vacuum manifold I 
temperature electrode, data logger III, IV 
urea ammonia selective electrode II, III, IV 
   
Microbiological analyses    
algal cell enumeration microscopic counting with cell-counting chamber IV 
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5 Results and Discussion 
5.1 Urine Characteristics 
The characteristics of urine used in different experiments (Papers II–IV) are described in Table 
5.1. Urine was collected several times during years 2012–2014 from volunteers (see Chapter 
4.1.1).  
The pH of fresh urine was in the range of 5.7–6.3 (Papers II–IV) as reported in the literature 
and close to the average pH 6.0 of urine (Harper et al. 1979). As discussed in Chapter 2.1, 
the composition of human urine varies greatly with diet. This can explain the variation in 
different set-ups in e.g. urea concentration (0.89 g/L vs. 6.28 g/L in Papers III and IV, 
respectively) or in DOC (7.3 g/L in Paper II vs. 2.4 g/L in Paper IV), as well as with other 
parameters such as nutrients, anions, and cations. All in all, the nutrients and parameters in 
urine used (Papers II–IV) fall in the range reported in the literature (Table 5.1).   
The pH of urine after storage (5–6 months) had risen well above 9 (Papers II and III), indicating 
ureolysis which is supported by the smaller concentration of urea in the stored urine as well as 
the increased ammonium, bicarbonate and alkalinity content of urine (Table 5.1). The 
decomposition of organic matter, precipitation of Mg and Ca salts (e.g. as struvite) and 
decrease in sulphate and phosphate content are supporting decomposition of urine into 
struvite during storage (Papers II and III). In general, during storage of five to six months, 
changes in conductivity followed the changes in pH. As pH rose, so did the conductivity, 
reaching up to 20–25 mS/cm (Papers II and III), while with lower final pH values the 
conductivity remained approximately at 10–13 mS/cm (Paper III). The increase in conductivity 
in stored urine is directly related to the amount of dissolved ions, e.g. phosphorus, nitrogen, 
and carbon: the higher the conductivity, the more there are ions present in the sample (Lind et 
al. 2001). This is in correlation with the present findings (Papers II and III), since dissolved 
nitrogen, phosphorus, and sulphur as well as cations were present throughout the storage 
period.  
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TABLE 5.1.  Characteristics of the urine used in the experiments (Papers II–IV). 
 Fresh Stored  Fresh Stored 
Fresh/ 
set-up I 
Fresh/ 
set-up II 
Range reported in the 
literature 
Parameter (unit) n = 6 n = 8 n = 1  
pH 5.8 9.4 6.3  9.6  5.8 5.7 5.6–9.1 
conductivity (mS/cm) 9.1 25.9 9.1  25.9  - - 13.4–22.6 
DOC (g/L) 7.29 2.81 3.9  1.5  4.83 2.405 - 
NH4+ + NH3 –N (g/L) 0.57 8.67 0.26  1.04  - - - 
urea (g/L) 4.95 1.05 0.89  0.05  - - 0.007–5.8 
Ntot (g/L) - - - - 6.80 4.32 1.8–9.2 
NO3--N (mg/L) - - - - < 5 < 2 0–0.045 
NO2--N (mg/L) - - - - < 1 < 1 0–0.020 
NH4+-N (mg/L) - - - - 520 275 254–1726 
Norg (g/L) a) - - - - 6.275 4.042 - 
Ptot (g/L) - - - - 0.670 0.355 - 
Anions         
NO3- (g/L) 0.16 b.d. 0.0324  b.d. - - - 
NO2- (g/L) - - 0.04  0.77  - - - 
SO42- (g/L) 1.61 1.28 1.61  0.91  - - 0.175–1.315 (as SO4-S) 
PO42- (g/L) 2.86 1.18 0.93  0.35  - - 0.076–2.0 (as P) 
F- (mg/L) 91.6 55.8 - - - - - 
Cl- (g/L) 2.67 2.40 - - - - 1.4–6.62 
Cations         
Na (g/L) 0.83 1.01 - - 0.710 - 0.837–3.45 
K (g/L) 0.52 1.17 - - 0.717 - 0.770–2.74 
Mg (mg/L) 76.0 b.d. - - 50 - 0–77 
Ca (mg/L) 88.0 3.1 - - 77 - 0–129 
Fe (mg/L)b) - - - - < 1 - 0.165–0.205 
Reference II II III III IV IV Table 2.2 
Note: a Norg - urea; b below AAS detection limit; - not measured; b.d - below detection limit 
5.2 Assessment of Analytical Methods for Urine Characterization 
In this section, the applicability of two analytical methods on urine characterization are 
presented and discussed. Development of a new analytical tool and application of a previously 
published one on a new matrix provided important information on pharmaceutical and 
estrogenic compounds in urine during storage. 
5.2.1  Applicability of the New HPLC Method in Pharmaceutical Detection in 
Urine (I) 
As pharmaceutical analysis of complex matrices requires sample pre-treatment (Fontanals et 
al. 2007) and optimization of the analytical method for best recovery (Pavlović et al. 2007), the 
developed HPLC method provided a novel tool for fast analysis of selected pharmaceuticals. 
The compounds belonged to therapeutic groups which had different physicochemical 
properties (Table 4.3), which resulted in making compromises in the performance (Pavlović et 
al. 2007). As discussed earlier, simultaneous detection of different pharmaceuticals have been 
conducted (Chapter 2.3.1), but many of them have been dealing with compounds with similar 
properties, and prior to development of this method, no such tool existed that enabled 
simultaneous analysis of these eight compounds from one sample. Urine storage experiments 
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(Paper III) included 60 experimental jars (sampled monthly, Chapter 4.2.1), thus making it 
important to take into account the feasibility aspects of the method. Regarding future 
experiments, it was therefore crucial to enable the fast detection of the selected compounds. 
Core-Shell Column Performance 
However, by the time the method development was started, a new core-shell column 
technology was introduced in the analytical field. The column, which was used in this thesis 
(Kinetex XB-C18, Phenomenex), utilized new 2.6 µm core-shell particles, which have a 1.9 µm, 
solid silica core and a 0.35 µm, thick porous silica layer on top, and which have been shown 
to perform well in gradient separations (Gritti and Guiochon 2010b) and under isocratic 
conditions (Gritti et al. 2010). Selection of the column was based on literature 
recommendations demonstrating the efficiency and performance of 2.6 µm core-shell columns 
to be similar or better than fully porous 1.7 µm particles in fast gradient separations (Fekete 
and Fekete 2011). The method development was performed according to recommendations 
given in the literature (Ruta et al. 2012) regarding the use of small system dwell volumes (the 
system volume was minimized e.g. with shorter capillary), ACN–water mixtures (ACN–water-
based buffer mixture was used) and short column lengths (75x4.6 mm column).  
The use of the core-shell technology provided both savings in time and money as the analysis 
time was reduced through application of larger backpressure of the column (>300 bar) and 
high flow rate (2.5 mL/min). As described in the literature (Gritti and Guiochon 2010b), 
operating the HPLC system with pressures under 400 bar was possible even with significantly 
higher mobile phase velocity (2.5 mL/min) than is recommended for porous particle columns. 
Although high flow rate causes faster use of the eluent, the reduced analysis time compensates 
for the increased mobile phase consumption. In a 6-minute sample run, a 15 mL mobile phase 
was consumed, as opposed to 18–21 mL with 1.5 mL/min flow rate and 12–14 minutes of 
analysis time, a starting point from which the method development was begun by using a fully 
porous 5 µm reversed-phase column. In addition, the new method was operated at 40oC as 
increasing the column temperature can cut down analysis time by reducing the mobile phase 
viscosity and thus increase mass transfer (Fekete et al. 2011). Based on method validation 
results, the best performance was achieved at this temperature. 
Solid Phase Extraction Efficiency in Urine Pre-treatment 
A sample pre-treatment was required due to the complex nature of the urine matrix (Escher et 
al. 2005). The SPE sorbent used was Strata-X (Phenomenex) which has been previously used 
e.g. in cleaning up biological samples (plasma, milk), and in enriching pesticides and 
pharmaceuticals from water samples (Fontanals et al. 2007 and references therein, Pavlović 
et al. 2007). Urine not pre-treated with SPE contains compounds that can interfere with the 
pharmaceutical analysis (Figure 5.1), especially with smaller concentrations. 3TC, TRI, CIP, 
and ZDV are the compounds which are most affected by analytics. Urine matrix interference 
especially that of a concentrated or hydrolyzed urine, has been reported previously to affect 
the identification of pharmaceuticals (Lai et al. 1997). Although in Figure 5.1 the 
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pharmaceuticals are all visible, their signal intensity at 10 mg/L is quite different. This comes 
from the selected 210 nm wavelength used for signal recording. This particular wavelength 
has been used previously e.g. in screening a variety of toxicological drugs from serum and 
urine (Lai et al. 1997). Each compound has its own maximum intensity wavelength on which 
the observed signal would be the best. In order to optimize the analysis, 210 nm was used for 
all other compounds except for RMP, to which 264 nm was used.  
 
 
FIGURE 5.1.  A graph showing HPLC-UV signal at 210 nm from filtrated urine (solid line) and 
pharmaceuticals (dashed line). Note the different y-axis scale for pharmaceuticals.  
As the compounds studied were of varying physical and chemical properties, some 
compromises were needed to enable simultaneous analysis. With SPE, the limitations of the 
sorbent (Strata-X, logKow -0.5) affected the analysis of 3TC, which is why a two-step elution 
was needed. Antiviral drugs have been described as difficult to analyze because of the 
differences in their pKa values and high polarity, and the fact that they are difficult to retain on 
common SPE sorbent materials (Prasse et al. 2010). SPE was used to clean up the samples 
and its use also provided savings, as the compounds could be eluted in two subsequent 
elutions from the same SPE tube, thus saving sorbent material. Comparison of different SPE 
sorbents on pharmaceutical recovery has been discussed in Paper I. 3TC performance was 
difficult to optimize in HPLC analysis as well, as it seemed that the linear range of the 
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compound was only up to 100 mg/L after which the compound was flushing out of the column 
with no retention. The injection of small enough sample sizes is therefore important to avoid 
overloading the column (Gritti and Guiochon 2012). The limited sample capacity is directly 
related to the core-shell particle surface area (DeStefano et al. 2012): Kinetex particles are 
61% porous, which reduces the sample loading capacity due to the more straightforward 
movement of the sample in the column as a narrow band (McCalley 2011). 
Method Suitability in Urine Sample Analysis with HPLC 
The LOD (limit of detection) and LOQ (limit of quantification) of the method were somewhat 
high for urine samples. However, keeping in mind the further use of this method (Paper III), 
the LOD and LOQ obtained for the developed method were comparable with other similar 
studies with pharmaceutical detection from biological fluids and water (Table 5.2). As 
previously described, some compromises were needed for the method in order to be able to 
simultaneously analyze all eight compounds. Previously, e.g. antiviral pharmaceuticals have 
been analyzed simultaneously (Mistri et al. 2007), but these compounds all belonged to the 
same therapeutic group with relatively similar logKow’s (Table 4.3). In conclusion, the method 
performed as was expected, with acceptable LOD and LOQ, and after validation it was suitable 
to be used in further studies. 
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TABLE 5.2.  Comparison of the limit of detection (LOD) and limit of quantification (LOQ) for pharmaceuticals from different matrices analyzed with 
HPLC. 
Method Matrix Compound LOD 
(µg/L) 
LOQ 
(µg/L) 
Sample pre-treatment Recovery % Reference 
HPLC-UV urine 
 
3TC 
ZDV 
NVP 
TRI  
SMX 
CIP  
RMP 
CBZ 
1610 
189 
71 
39 
115 
189 
503 
41 
5366 
630 
237 
129 
383 
631 
1676 
136 
SPE 
SPE 
SPE 
SPE 
SPE 
SPE 
SPE 
SPE 
16.7–43.3 
93.2–106.9 
98.5–105.0 
98.7–104.9 
83.0–96.2 
81.6–109.2 
90.7–105.8 
97.8–102.1 
Paper I 
Paper I  
Paper I 
Paper I 
Paper I 
Paper I 
Paper I 
Paper I 
  SMX 
TRI 
120 
180 
420 
570 
SPE 
SPE 
86.4–90.5 
70.2–77.2 
Fernandez-Torres et al. (2010) 
Fernandez-Torres et al. (2010) 
HPLC-FL serum CIP 5 - protein precipitation, enrichment 97.8–107.9 Zotou and Miltiadou (2002) 
  CIP 50 - sample vortexing, protein precipitation 99.4–101.0 Krol et al. (1995) 
  CIP 50 - sample dilution 99.0–104.3 Krol et al. (1995) 
HPLC-MS/MS water TRI 
SMX 
0.00007 
0.00013  
0.00025  
0.00043  
SPE 
SPE 
46 
16 
Nebot et al. (2007) 
Nebot et al. (2007) 
HPLC-MS urine CBZ 2400 - un-treated - Maggs et al. (1997) 
HPLC-MS/MS plasma 3TC 
NVP 
25 
50  
- 
- 
SPE 
SPE 
87.6–90.9 
96.5–99.5 
Mistri et al. (2007) 
Mistri et al. (2007) 
Note: - = not reported; UV - ultraviolet; FL - fluorescence 
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5.2.2 Efficiency of the Yeast Biosensor in Estrogenic Activity Assessment (II) 
The goal of this study was to investigate the applicability of the bioluminescent yeast-cell-based 
biosensor as a fast, stand-alone analytical screening tool in estrogenic activity monitoring in 
urine. Urine samples required no pre-treatment (e.g. filtration, extraction, or centrifugation) and 
the method could be applied to urine as such. 
Hormonal Activity Assay 
The yeast biosensor produced a signal with respect to all of the studied estrogens (E1, E2, EE2, 
E3) in a concentration-dependent way (Figure 5.2A), similarly to Salste et al. (2007) who used 
the same biosensor to study WWTP effluents, thus demonstrating the repeatability of the 
results in a different laboratory and matrix. The yeast assay is specific to estrogenic 
substances. Studies have demonstrated that the estrogenic analysis with a yeast biosensor is 
not interfered by the presence of androgens or gestagen progesterone, and no interference is 
observed screening at low estrogen levels (Bovee et al. 2005, Salste et al. 2007). Mainly the 
response was obtained with estrogen range from 0.29 to 29 640 µg/L. The highest response 
with the biosensor was obtained with the synthetic EE2. In order to estimate the overall 
estrogenic concentration, an average of four estrogens was taken (Figure 5.2B) to 
approximate concentrations in urine.  
 
FIGURE 5.2.  A) Standard curves for estrone (E1), 17β-estradiol (E2), 17α-ethinylestradiol (EE2), 
and estriol (E3). B) A standard curve calculated as the average of four estrogens from 
Figure 5.2A for the estimation of estrogenic concentration. The error bars represent 
the standard errors from three measurements. Estrogenic concentration 
determination: FI < FILOD: estimated from average estrogen curve; FI > FILOD: 
calculated from average estrogen curve; FI > average estrogen curve FI: calculated 
from EE2 standard curve. (Paper II) 
The estrogen LODs for the biosensor and the LOD determined from the average concentration 
curve were as presented in Table 5.3, in which a comparison of different yeast-cell-based 
bioassays and their detection limits for the current bioassay is also presented. Many studies 
have measured estrogen equivalents or used the bioassay only to demonstrate estrogenic 
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activity, and in those cases concentrations have been measured with chromatographic 
methods, requiring sample enrichment before analysis if the matrix has been some other than 
a standard solution (EtOH etc.). The LOD was practical in monitoring of real urine samples. 
Compared with the sample preparation and clean-up needed before chromatographic analysis 
(e.g. Escher et al. 2005), use of the biosensor was justifiable in simple and rapid monitoring. 
Compared with analysis using MS, which normally has a low LOD of only few ng/L (e.g. 
Desbrow et al. 1998), the obtained LODs were higher, but compared with conventional LC in 
combination with urine sample pre-treatment which has a LOD around 0.1–0.2 µg/L, the results 
are comparable (Zou et al. 2012). A comparison of different yeast-cell-based bioassays and 
their detection limits to chromatographic techniques is presented in Table 5.4. 
Leskinen et al. (2005) have already proven that yeast estrogen strains have behaved and 
responded to hormones (two androgens, E2) and xenoestrogens similarly with yeast estrogen 
screen. Urine always contains estrogens (even urine of males); thus, having urine blank is not 
possible. Stored men’s urine has a low estrogenic background which is still higher than in fresh 
urine: this difference has been explained by the fact that majority of estrogens are excreted as 
conjugates which may be hydrolyzed in non-sterile urine storage (Escher et al. 2006). Even 
though urine stored long enough might be devoid of estrogens, the composition of the sample 
would be different and it might still contain estrogen-like compounds that induce a signal with 
the biosensor.  
As discussed previously (Chapter 4.1), no filtration or sterilization of the urine samples was 
conducted as their costs would not be feasible in practice in a large scale – all the bacteria 
responsible for estrogenic degradation would be removed – and it was not considered 
significant related to the use of the biosensor in this thesis.  
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TABLE 5.3.  Comparison of yeast-cell-based bioassays (Paper II).  
Bioassay Reporter protein Matrix Sample pre-
treatment 
Time needed for 
analysis 
Limit of detection 
LOD (µg/L) 
Reference 
Saccharomyces 
cerevisiae 
BMAEREluc/ERα 
luciferase pure 
compound in 
10% EtOH 
not needed  2.5-h incubation 0.008 (E2)a 
 
Leskinen et al. (2005) 
Saccharomyces 
cerevisiae (yEGFP) 
green fluorescent 
protein 
spiked calf 
urine 
solid phase 
extraction, de-
conjugation 
de-conjugation 
overnight, plate drying 
overnight, 24-hour 
incubation 
1.0 (E2 and EE2)a Bovee et al. (2005) 
Saccharomyces 
cerevisiae 
β-galactosidase pure 
compound in 
EtOH 
not needed  three-day incubation 0.0015 (E2) Routledge and Sumpter 
(1996) 
yeast estrogen 
screen (YES) 
β-galactosidase river water solid phase 
extraction 
pre-treatment 120-
150+ min, three-day 
incubation 
0.0001 estrogen 
equivalents (EE2)  
Vermeirssen et al. (2005) 
Saccharomyces 
cerevisiae 
BMAEREluc/ERα 
luciferase wastewater 
effluent 
solid phase 
extraction 
solid phase extraction 
20+ min, freeze drying 
4.5 h, chromatographic 
fractionation 28 min, 
LC-MS/MSb 15 min, 
2.5-h incubation 
LOD was not 
determined for 
yeast assay 
Salste et al. (2007) 
Saccharomyces 
cerevisiae 
BMAEREluc/ERα 
luciferase pure 
compounds 
in 10% EtOH 
not needed  2.5-h  incubation 2.8 (E1), 0.28 (E2),  
0.29 (EE2), 35 (E3) 
Paper II 
  human urine 
(real 
samples) 
de-conjugation de-conjugation 45 min, 
2.5-h incubation 
0.38–3804 
(measured overall 
estrogenic 
concentration) 
Paper II 
Note: EtOH - ethanol; a measured as nM, converted by the authors; b LC-MS/MS - liquid chromatography-tandem mass spectrometry 
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TABLE 5.4.  Comparison of the yeast biosensor detection limits with chromatographic techniques described in the literature. 
Method Matrix Compound LOD (µg/L) Sample pre-treatment Recovery (%) Reference 
HPLC-UV water E1 
E2 
EE2 
E3 
330 
440 
510 
240 
SPE, enrichment 92 
95 
91 
75 
Stafiej et al. (2007) 
LC-MS/MS wastewater 
effluent 
E1 
E2 
EE2 
E3 
0.0001 
0.0007 
0.001 
0.005 
SPE, enrichment 105 
80 
43 
80  
Salste et al. (2007) 
HPLC-UV spiked human 
urine 
E1 
E2 
0.2 
0.1 
cloud-point extraction 87.9–104.3  
86.9–104.0 
Zou et al. (2012) 
Saccharomyces 
cerevisiae 
fresh and stored 
human urine 
overall estrogenic 
activity 
0.38 
 
de-conjugation - Paper II 
 10% EtOH E1 
E2 
EE2 
E3 
2.8 
0.28 
0.29 
35 
none - Paper II 
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Effect of Bioavailability of Estrogens in the Biosensor Application 
The bioavailability of the estrogens and the response of the biosensor was affected by the 
presence of estrogens as conjugates in urine, thus breaking up the conjugated bonds improved 
the sensitivity of the sensor strain. Time points of one and five months were selected in 
estrogenic activity testing due to the availability of samples. The overall, recommended time for 
urine storage is six months (WHO 2006) but shorter periods are commonly used (e.g. Akpan-
Idiok et al. 2012). 
As most of the estrogens (85–95%) are excreted as glucuronides (Table 2.7), it was reasonable 
to assume that use of β-glucuronidase was sufficient to break the conjugate bonds. Of course, 
if one would want to be absolutely sure to get the more accurate estrogen concentration and 
better hydrolysis, the additional use of sulfatase would be justifiable. Breaking down conjugated 
bonds in urine is important to gain knowledge on the amount of estrogens, as some soil 
microorganisms are capable of breaking down these conjugates – thus releasing active 
hormones (Ying and Kookana 2005, Kurisu et al. 2010, Goeppert et al. 2014).  
 
FIGURE 5.3.  Fold inductions (FI) of different urine samples using the bioluminescent yeast 
biosensor. The bars represent mean of three replicates with error bars showing 
standard error. β-gluc. = β-glucuronidase. A) FI values for the different fresh urine 
samples with and without different pre-treatments. B) FI values of fresh and stored 
urine (at room temperature in plastic jars with a tight lid, one or five months) with and 
without different pre-treatments. * indicates that urine samples were collected and 
analysed at the same time (measurement 2). (Paper II) 
Only unconjugated forms of estrogens and estrogenic compounds contributed to the ER activity 
when urine was measured without treatment (first and second bar, Figure 5.3A). Thus, the 
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bioavailability testing was conducted to get the response for all estrogenic activity present in 
the sample (measuring the sum of free and glucuronidated forms). Heat treatment at 80oC for 
half an hour resulted in increased activities (0.35–14 µg/L) when compared with urine without 
heating (0.05–0.29 µg/L). The addition of β-glucuronidase and incubation at 46oC for 45 
minutes increased the activity (1.4–10 200 µg/L, determined using standard for EE2), while 
incubation at 46 oC did not affect the activity as much as enzyme addition (Figures 5.3A and 
5.3B). Clearly, the method sensitivity was better with the β-glucuronidase addition, which was 
in accordance with previous results from testing a yeast biosensor with swine urine with pre-
treatment before analysis to break the conjugated bonds (incubation with a Helix pomatia 
solution) (Kaiser et al. 2010).  
The effect of urine storage on estrogenic activity was as speculated: the estrogenic activity in 
urine samples first increased from the 0.1 µg/L (< LOD) detected from fresh urine up to 9.5 
µg/L after one month of storage. This was expected since source-separated urine is never 
devoid of bacteria. The bacterial enzymatic (glucuronidases, estradiol dehydrogenases and 
sulfatases) and metabolic activity break the conjugated bonds, thus increasing the observed 
signal which reduces over time due to estrogen degradation. After five months of storage the 
estrogenic activity was still 6.2 µg/L, indicating the presence of ER binding compounds.  
Advantage of Yeast-Cell-based Biosensor over Chromatographic Techniques in Urine 
Analysis 
No adaptations of the biosensor for urine matrix were needed, which emphasized the 
applicability of the biosensor without pre-treatments on different matrices. Biological analysis 
can be advantageous over chemical analysis since the concentrations of single compounds 
are quite low and trace analytical techniques would have to be developed to detect only a 
fraction of pharmaceuticals and hormones present (Escher et al. 2006). Although the 
measurement of exact concentrations in urine is informative, measuring the overall estrogenic 
activity can be more useful regarding practical applications, such as fertilizer use. The 
biosensor measures the cumulative concentration of EDCs in urine, not just estrogens. 
Furthermore, the assay provides reasonable information on estrogenic activity in order to state 
when the activity has been reduced adequately in order to re-use urine, as urine application 
has been shown to enhance leaching and persistence of EDCs in the soil (study conducted 
with sheep urine, Lucas and Jones 2009). The yeast biosensor would not replace any standard 
methods, but could be used by authorities to screen a large number of samples for preliminary 
indications (Rodriguez-Mozaz et al. 2007). 
Biosensors are also suitable for the development for on-site tests because of their high 
specificity. Since estrogens have been shown to migrate and degrade in the soil (Ying and 
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Kookana 2005), this screening tool could be used to test estrogenic activity in soil samples after 
extraction to liquid. The yeast could also be used in pre-screening anthropogenic estrogen-like 
compounds which interact with the receptor, such as bisphenol-A or parabens (e.g. Leskinen 
et al. 2005). On the contrary to conventional chromatographic methods, the method has several 
advantages, including complementarity to traditional analytical chemistry analyses, a minimal 
sample pre-treatment need, the provision of analyte bioavailability information, and 
simultaneous analysis of multiple samples. The efficiency of the applied biosensor is due to the 
fast retrieval of results: compared to previous analyses which may take several days or include 
extensive sample pre-treatment (e.g. Routledge and Sumpter 1996), this yeast biosensor gave 
results in just three hours.  
5.3 Effect of Urine Storage on Pharmaceuticals (III) 
Behavior of eight pharmaceutical compounds during six-month storage of urine spiked 
individually, in therapeutic groups (antivirals, antibiotics, and anti-tuberculotics), and with 
different amendments (feces and urease inhibitor) was studied using CBZ as a reference 
pharmaceutical. In all assays, precipitates – either solid or both solid and floating – were visible 
at the bottom of the jars after six months, and in some cases already earlier. Only the liquid 
phase of the experimental jars was assayed: no precipitates were taken under examination.  
pH during Urine Storage in Pharmaceutical Amendments 
pH, which was followed as an indicator of biological and ureolytic activity, rose in jars where 
pharmaceuticals where applied individually to 8.7–9.6, whereas in therapeutic groups only anti-
tuberculotics had lower pH (7.9) (Table 5.5). This was expected to be due to the inhibitory 
effect of CIP and RMP on bacteria present in urine. Adding feces resulted in lower pH in the 
groups of antibiotics and anti-tuberculotics. The assays with urease inhibitor amendment 
resulted in the lowest final pH of 7.4–8.2 (Table 5.5), which was in correlation with the urease 
inhibitor delaying urea hydrolysis (Watson et al. 2008). In fact, pH of un-amended urine was >9 
after two months, whereas pH with urease inhibitor remained <7 for the first three months.  
Effect of Storage on Pharmaceutical Concentrations 
The overall pharmaceutical concentration reductions in the liquid phase without amendments 
were 41.9–99% for anti-tuberculotics, <52% for antivirals (except 3TC 75.6%), and <50% for 
antibiotic compounds. In assays with amendments, concentrations reductions remained <50%, 
except for RMP (>99%). RMP was completely removed in all assays (Table 5.6, Figure 5.4), 
indicating that the precipitation was not the major removal mechanism, but probably 
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biodegradation, which would be a novel finding as no information of RMP biodegradation could 
be found e.g. from WWTPs (Table 2.9). Co-precipitation of CBZ and other pharmaceuticals 
with struvite is not very likely as, using mass balances, it has been shown that pharmaceuticals 
remain in the solution (> 96% of CBZ, Ronteltap et al. 2007).  
 
FIGURE 5.4.  The concentration of rifampicin (RMP, left y-axis) and carbamazepine (CBZ, right y-
axis) in monthly samples during the six-month storage of urine with different 
amendments. Combined refers to the results of urine amended with therapeutic 
groups. The error bars represent the standard error between three replicates. (Paper 
III) 
In addition to bacteria not being able to break down some of the pharmaceuticals entering 
WWTPs (see e.g. Table 2.9 for WWTP removal percentages), transformation products are 
formed, which together with pharmaceuticals end up in the environment (Gao et al. 2012). The 
HPLC-UV chromatograms of monthly samples showed CIP and SMX producing a peak with 
almost similar spectrum to the parent compound, suggesting degradation (Figure 5.5). A 
qualitative LC-ESI-MS/MS (LC-electrospray ionization-MS/MS) applied on assays of individual 
compounds after a six-month storage showed no marked differences between different 
amendments. The removal of RMP was confirmed while four unidentified transformation 
products were observed in RMP assays. In addition, various transformation products for CIP, 
SMX, and 3TC were identified, while no transformation products for NVP, ZDV, and TRI 
(available in literature) were detected.  
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TABLE 5.5.  pH after six months of storage. Data are mean (± standard error), n = 3. The different background colors represent the 
subdivision into therapeutic groups. (Modified from Paper III) 
 pH 
  Separately Therapeutic groups Feces Urease inhibitor 
  Start 6 months Start 6 months Start 6 months Start 6 months 
antivirals 3TC 6.3 (0.0) 9.3 (0.2) 6.3 (0.0) 9.6 (0.0) 6.1 (0.0) 9.5 (0.0) 6.5 (0.0) 8.2 (0.1) 
ZDV 6.3 (0.0) 9.6 (0.0)       
NVP 6.3 (0.0) 9.5 (0.0)       
antibiotics TRI 6.4 (0.0) 8.7 (0.4) 6.4 (0.0) 9.2 (0.2) 6.2 (0.0) 7.8 (0.8) 6.5 (0.0) 7.4 (0.0) 
SMX 6.3 (0.0) 9.4 (0.2)       
anti-tuberculotics CIP 6.3 (0.0) 8.9 (0.1) 6.4 (0.0) 7.9 (0.2) 6.2 (0.0) 7.4 (0.2) 6.5 (0.0) 7.7 (0.5) 
RMP 6.3 (0.0) 9.4 (0.1)       
reference CBZ 6.4 (0.0) 9.6 (0.0) n.a. n.a. n.a. n.a. n.a. n.a. 
 Control 6.3 (0.0) 9.6 (0.0) 6.3 (0.0) 9.6 (0.0) 6.1 (0.0) 9.5 (0.0) 6.5 (0.0) 7.7 (0.0) 
Note: n.a. - not available 
 
 
TABLE 5.6.  Reduction of pharmaceuticals in liquid phase after six months of storage. Data are mean (± standard error), n = 3. The 
different background colors represent the subdivision into therapeutic groups. “Individually” refers to just one 
pharmaceutical amended in urine. (Modified from Paper III) 
  Reduction (%) in the liquid phase after six months Transformation products 
detected 
 Pharmaceutical  Individually Therapeutic groups Feces 
Urease 
inhibitor 
HPLC-UV LC-ESI-MS/MS 
antivirals 3TC 75.6 (7.8) 51.4 (8.3) 28.9 (22.3) < 1 n.d. + 
ZDV 51.5 (3.7) 45.6 (0.5) < 1 < 1 n.d. n.d. 
NVP 25.6 (6.2) 28.8 (3.1) 24.5 (2.9) 16.9 (5.0) n.d. n.d. 
antibiotics TRI 23.7 (1.7) 40.3 (4.8) 42.0 (3.6) 18.9 (1.6) n.d. n.d. 
SMX 24.0 (4.7) 32.2 (3.0) < 1 < 1 + + 
anti-tuberculotics CIP 51.1 (10.6) 41.9 (27.4) 38.5 (8.5) 44.2 (19.5) + + 
RMP > 99 > 99 > 99 > 99 n.d. + 
reference CBZ 26.8 (3.5) n.a. n.a. n.a. n.d. + 
Note: n.a. - not available; n.d. - not detected; + - transformation product(s) detected  
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The emergence of breakdown products in LC and LC-ESI-MS/MS analysis suggested 
(bio)transformation and implied paired compounds forming into potentially more harmful 
products; the environmental relevance of transformation products is still quite a new field of 
study, but the possibly higher risk of transformation products compared with the parent 
compound on human health and the environment is a fact (Haddad et al. 2015). However, 
chemical degradation also produces transformation products, which cannot be ruled out. 
 
FIGURE 5.5.  Chromatograms and spectra of CIP (A) and SMX (B) after five months of storage of 
urine amended with individual pharmaceuticals. The additional peaks are indicated 
with arrows. The spectra of the additional peaks resemble the original compounds. 
Note that the signal of SMX second peak is on the secondary axis. (Paper III) 
Biological removal was suggested by the disappearance of RMP parent compound and 
appearance of transformation products in LC-ESI-MS/MS analysis, but the degradation could 
also be chemically induced. The complete removal of RMP in each assay was strikingly 
opposite to the concentrations of the other seven studied pharmaceuticals which were reduced 
only moderately. The degradability rate of RMP, and partly SMX and CIP, may have increased 
with higher bacterial densities, and the diversity of microorganisms in urine could have 
increasingly affected the biodegradability as source-separated urine can support the growth of 
bacteria up to about 108 cfu (colony forming unit)/mL (Brooks and Keevil 1997). In comparison, 
closed bottle tests, which are common in biodegradation analysis, use low bacterial densities 
of 104–106 cfu/L (OECD 1992). On one hand, the pH increase suggested biological activity, but 
on the other, similar removals during storage were observed without pH change.  
 Based on the findings, six-month storage of urine reduces the pharmaceutical concentrations 
(23–75%), while storage may result in the formation of transformation products – suggesting 
that storage as recommended by WHO does not mean complete removal of the studied 
pharmaceutical risks. One has to bear in mind though that the results only apply to the eight 
pharmaceuticals and concentrations, which were quite high to replicate a worst-case scenario 
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of almost all people eating pharmaceuticals. If urine is to be utilized in fertilizer applications, 
other feasible treatment practices to enhance pharmaceutical removal should be considered. 
Some urine treatment processes and the removal of pharmaceuticals and hormones were 
presented in Chapter 2.2.2, but as discussed earlier, the techniques can be somewhat energy-
intensive. 
The presence of pharmaceuticals in separately collected urine and the possible degradation of 
pharmaceuticals has been speculated previously. Urine from a male urinal stored for several 
weeks contained many pharmaceuticals (e.g. lipid regulators and painkillers), but the measured 
concentrations were lower than calculated ones, suggesting that degradation processes might 
occur on some pharmaceuticals during storage (Winker et al. 2008b). Only few investigations 
on pharmaceutical behavior in source-separated urine have been performed: some in stored 
urine (Gajurel et al. 2007, Tettenborn et al. 2007) and some during precipitation of struvite 
(Ronteltap et al. 2007, Keemacheevakul et al. 2012). Most of them were focusing on lipid 
modifiers, painkillers, etc., while little or no data on fate of the compounds selected in this thesis 
was available. Based on the before-mentioned studies, however, it can be concluded that at 
least CBZ and TRI are not co-precipitating with struvite. 
Storage was conducted in similar conditions of 20oC in the dark. Summary of the storage results 
and comparison of the removal percentages of different pharmaceuticals is given in Table 5.7. 
The compounds tested in the experiments presented in Table 5.7 (except for CBZ) were 
different to aforementioned studies, as well as the formulation which was used to spike urine 
samples. Schürmann et al. (2012) used tablet formulations where the sample also contained 
additives such as lactose or starch, whereas only the pure compound was used in this thesis.  
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TABLE 5.7.  Effect of urine storage on pharmaceutical concentrations in different urine storage 
experiments reported in the literature. 
Pharmaceutical Specification Reduction Reference  
Bisoprolol beta blocker 19.3–38.3% Schürmann et al. (2012) 
Chloroquine prevention of malaria 14.3–71.6% Schürmann et al. (2012) 
Diclofenac anti-inflammatory 22.1–97.3% 
80–90%a 
Schürmann et al. (2012) 
Butzen et al. (2005) 
Tetracyclin antibiotic 80–90%a 
40%b 
Butzen et al. (2005) 
Butzen et al. (2005) 
Fenoprofen anti-inflammatory 20%b Butzen et al. (2005) 
Hydrochlorothiazide anti-hypertensive - Schürmann et al. (2012) 
Ibuprofen anti-inflammatory -3.9–66.7% Schürmann et al. (2012) 
Metoprolol beta blocker 27.3–77.5% Schürmann et al. (2012) 
Nebivolol beta blocker - Schürmann et al. (2012) 
Sulfadimidine veterinary antibiotic 59.1–94.3% Schürmann et al. (2012) 
Tramadolol opioid analgetic 20.9–57.7% Schürmann et al. (2012) 
Carbamazepine anti-convulsant 24.4–79.8% 
22.2–26.8% 
~20% 
20% 
Schürmann et al. (2012) 
Paper III 
Gajurel et al. (2007) 
Butzen et al. (2005) 
Lamivudine antiviral <1–71.6% Paper III 
Zidovudine antiviral <1–51.5% Paper III 
Nevirapine antiviral 16.9–28.8% Paper III 
Sulfamethoxazole antibiotic <1–32.2% 
45%a 
Paper III 
Butzen et al. (2005) 
  30%b Butzen et al. (2005) 
Trimethoprim antibiotic 18.9–42.0% Paper III 
Ciprofloxacin anti-tuberculotic 15.5–51.1% Paper III 
Rifampicin anti-tuberculotic >99% Paper III 
Note: Schürmann et al. (2012) results collected from a Figure representing elimination in pH-adjusted 
urine. a pH 2; b pH 9 
During storage period of a year, none of the tested pharmaceuticals (Table 5.7) were 
substantially removed in spiked urine (Gajurel et al. 2007). Although different pH’s (3, 4, 6.5, 7, 
8.5, 9, 9.5, 10, and 11: Butzen et al. 2005, Gajurel et al. 2007, Schürmann et al. 2012), storage 
temperatures (4 oC, 20oC, room temperature varying between 12 and 38oC, Gajurel et al. 2007, 
Schürmann et al. 2012), and storage periods (six months, Schürmann et al. 2012; a year, 
Gajurel et al. 2007) have been reported, no marked effect on pharmaceutical concentrations 
have been discovered. Although the concentrations used in the storage experiment were 
relatively high, they were in the same order of magnitude as in the experiment of Gajurel et al. 
(2007), who spiked their urine with 10 mg/L of pharmaceuticals. When the results from storage 
experiments (Table 5.6) are compared with the pharmaceutical concentration reductions in 
urine treatment processes (Table 2.8), it is obvious that storage alone is not as effective as the 
treatment techniques.   
Controversially, an earlier study (Butzen et al. 2005) has shown that low pH has a reducing 
impact on pharmaceutical concentrations during urine storage. After storage period of 3–4 
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months at pH 2, some compounds had reduced concentrations of 80–90%. It was 
acknowledged that the length of the storage period was not enough to remove these 
compounds, and the highest removal was achieved in acidic urine (Butzen et al. 2005). 
However, as discussed earlier (Table 5.1), pH of stored urine is elevated up to pH 9.6 – being 
far from acidic – and the costs of acidification would probably be too high in large scale 
applications. The prevention of urine hydrolysis, e.g. with urease inhibitors, is more economical 
than subsequent neutralization; e.g. hydrolyzed urine requires 11.3 g concentrated sulphuric 
acid per liter of urine (Maurer et al. 2006).  
Effect of Feces Presence on Pharmaceutical Behavior during Urine Storage 
The results clearly showed that with feces, the pharmaceutical concentration reductions were 
smaller than in therapeutic groups without additional amendments (<1–42% vs. 28–51%, 
respectively). Feces amendment did not enhance pharmaceutical removal, even though it was 
expected to increase microbial content in assay jars. This was interesting, as fecal 
contamination is prone to be present in collected urine but it had negative effect on 
pharmaceutical removal. Feces were added in urine samples containing pharmaceuticals in 
therapeutic groups to evaluate the effect of microorganism inoculum in pharmaceutical 
concentrations. The added concentration was 9 mgfeces/L, which has been found to be an 
average in source-separated urine (Schönning et al. 2002). It was hypothesized that the 
bacteria derived from feces would enhance biological removal of the compounds. Thus, the 
results imply that pharmaceutical removal may in fact be reduced in the presence of fecal 
contamination, but the mechanism is yet to be discovered and needs more research. Fecal 
microbes are inactivated at pH over 8.9 (Höglund et al. 2002), which could have affected the 
results.  
Effect of Urease Inhibitor Presence on Pharmaceutical Behavior during Urine Storage 
It appeared that the used urease inhibitor (2 mM, Tampere University of Technology et al. 2011) 
resulted in a low pH increase as anticipated, but however, it did not affect positively on 
pharmaceutical reduction. In fact, the pharmaceutical removal was lower in urine amended with 
urease inhibitor (<1–18.9%) than in control assays consisting of urine and pharmaceuticals 
(28.8–51.4%), except in the case of CIP (44.2%). Originally, the hypothesis was that lower pH 
generally enables better microorganism growth, thus enhancing biological removal of 
pharmaceuticals as bacterial extracellular enzymes can break down bonds in pharmaceutical 
molecules. Chemical precipitation/sorption of the studied pharmaceuticals was ruled out, as pH 
did not rise above 8, which is considered as a minimum pH prerequisite for the formation of 
struvite precipitates (pH optimum 9.4–9.7, Harada et al. 2006). The mechanism in 
pharmaceutical concentration reduction could well be biological and was inhibited by urease 
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inhibitor, leading to deduction that urease inhibitors could actually have negative effects on 
urine microbes and their functionality. However, contrary to this, in a greenhouse experiment 
where nBPT was applied in the soil, the soil urease activity was initially inhibited but recovered 
within 10 days (Watson 1998 and references therein). 
HPLC analysis (Paper I) demonstrated that 59% of the applied urease inhibitor was still present 
after six months of urine storage. It has been hypothesized that the degradation products of 
fertilizer formulations might have an inhibitory effect on soil ureases (Watson et al. 2008) and 
while the height of nBPT peak in HPLC chromatogram fell in time, additional peaks appeared. 
The addition of urease inhibitor might have co-affected the removal of compounds by 
preventing enzyme activity, thus explaining the poor concentration reductions.  
5.4 Microalgal and Biomass Growth in Human Urine (IV) 
Microalgal and Biomass Growth 
The use of diluted human urine as a sole nutrient source to grow biomass from microalga 
Chlorella vulgaris was studied using batch cultivations (21 days) in five different urine dilutions 
(1:25–1:300), in 1:100-diluted urine as such and with added trace elements (urine+TE), and as 
a reference, in artificial growth medium. First, the growth of C. vulgaris in 1:100-diluted urine 
was compared with growth in modified artificial Chu-10 medium and in Chu-10 medium where 
nitrogen and phosphorus sources were replaced with a corresponding amount of urine (set-up 
I) to investigate the potential of diluted urine as an algal nutrient source. Afterwards, the effect 
of different urine dilutions (1:25–1:300) on algal growth was assessed (set-up II). 
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FIGURE 5.6.  Biomass production as volatile suspended solids (VSS) in A) set-up I using 1:100-
diluted urine, urine+TE and Chu-10, and as VSS and calculated VSSalgae B) in set-up 
II with urine dilutions 1:25, 1:75 and 1:100, and C) urine dilutions 1:150 and 1:300. 
The error bars represent the standard error of three (A) and two (B, C) replicates. 
(Paper IV) 
C. vulgaris and related biomass grew better in urine than in the artificial medium (0.59 vs. 0.53 
g/L) (Figures 5.6A-C, Table 5.8). As biomass yields in 1:100-diluted urine were higher than in 
modified Chu-10 medium, the next step was to test the effect of different urine concentrations 
(set-up II). It was discovered that after 5–10 days, the algal biomass stabilized to approximately 
0.3 g/L, whereas total biomass continued to grow with similar growth rates and final biomass 
concentrations (0.5–0.6 gVSS/L) for all urine dilutions as well as for all reference cultures 
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(Table 5.8). Living algae dominated the biomass for the first 5–15 days – contributing about 
50–100% of the biomass (in 1:100-dilution < 30%) – after which the concentration of living algal 
cells stabilized, being at the end of the incubations (day 21) less than 40% of the VSS in all 
dilutions (Figures 5.6B and 5.6C). The high share of VSSalgae in the beginning of the cultivation 
suggested that in the beginning the conditions in all urine dilutions favored microalgal growth, 
while in the course of incubation bacteria became more competitive and the portion of dead 
algal cells increased. The obtained final biomass concentrations were in line with other results 
reported in the literature (Table 5.8), though not especially high. The growth in 1:100-diluted 
urine was, compared with other dilutions, unexpectedly poor in both replicates in set-up II, 
which could not be explained. 
The biomass growth was likely not limited by nutrients but rather light or CO2, as the 1:300 and 
1:25-dilutions resulted in similar final VSS concentrations (0.48 vs. 0.52 gVSS/L). The light 
intensity used was quite low (29 µmol photons/m2/s), and additional CO2/air sparging could 
have improved the results as cultures might have lacked sufficient light due to the increasing 
biomass concentration, as mutual shading of algae in batch cultivation decreases the average 
light supply per microalgae cell (Tuantet et al. 2014a). However, C. vulgaris has been cultivated 
previously at similarly low light intensities of 25–30 µmol photons/m2/s (de-Bashan et al. 2005, 
Moed et al. 2015).  
Availability of trace elements (e.g. iron, magnesium) is considered a potential limiting factor 
when cultivating algae with urine. (Liu et al. 2008, Sydney et al. 2010, Ilavarasi et al. 2011, 
Tuantet et al. 2014a, 2014b). The urine+TE medium also contained added vitamins, 
magnesium, and iron, whereas undiluted urine contained more magnesium and approximately 
the same concentration of total iron as Chu-10. Hydrolysis of urine leads to precipitation and 
depletion of Mg, thus decreasing its availability (Tuantet et al. 2014a), which is why the use of 
urease inhibitors for urine preservation has been suggested (Chapter 2.1.2). However, dilution 
of urine and thus decreased trace element concentrations did not affect overall biomass growth. 
The lower concentration of trace elements may have led to a bacterial dominance in the 
cultures because there may not have been enough magnesium or iron to support the growth 
of photosynthetic algae which require these elements e.g. for the production of chlorophyll and 
photosynthetic enzymes. However, it was demonstrated that urine without any additional 
vitamins or trace elements can sustain microalgal growth.   
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TABLE 5.8.  Comparison of different culture media and urine dilutions for algal growth in studies reported in the literature. Values given 
are averages. 
 
Cultivation set-up Nitrogen source 
Growth 
rate µ 
(1/d) 
Biomass 
production 
(g/L) 
Biomass 
productivity 
g/(Ld) Reference 
Algae grown in urine 
Arthrospira platensis 
(Spirulina platensis) 
bubble column photobioreactor 
nitrification 
CO2 addition 
2000 µmol photons/m2/s a 
16-day cultivation 
1:10-diluted synthetic urine 
1:10-diluted urine 
- 
- 
2.5 
2.30 
0.237 
0.206 
Feng et al. (2007) 
Spirulina platensis batch culture, 12 days 
continuous culture, 28 days 
synthetic urine - 
- 
1.25 
2.9–3.4 
- 
- 
Yang et al. (2008) 
Spirulina platensis bubble column photobioreactor 
5.6 L, nitrification 
2000 µmol photons/m2/s a 
1:10-diluted urine - 2.40 - Feng et al. (2008) 
Spirulina platensis photobioreactor  
CO2 addition 
1:120-diluted synthetic urine 
1:120-diluted urine 
0.171 
0.235 
0.25 
0.81 
- 
- 
Chang et al. (2013) 
Spirulina platensis bubble column photobioreactor 
1.2 L, aeration 
2000 µmol photons/m2/s a 
14-day cultivation 
1:180-diluted urine 
1:180-diluted synthetic urine 
- 
- 
2.32 
2.4 
0.266 
0.236 
Feng and Wu (2006) 
Scenedesmus 
acuminatus 
114-day cultivation, tank-scale 
30-day cultivation, tank-scale 
1:50-diluted urine - 
- 
0.133 b 
0.039 b 
- 
- 
Adamsson (2000) 
Chlorella sorokiniana CO2 addition 
photobioreactor  
controlled light intensity 
490–1550 µmol photons/m2/s 
1:2-diluted synthetic urine 
1:2-diluted urine 
- 
- 
8.1 
6.6 
7.5 
9.3 
Tuantet et al. (2014b) 
Chlorella sorokiniana 24-well microtiterplate 
105 µmol photons/m2/s 
concentrated urine 
synthetic urine 
0.104c 
0.116c 
- - Tuantet et al. (2014a) 
Chlorella sorokiniana 7 daily cycles  
6 L photobioreactor 
133 µmol photons/m2/s 
CO2 addition, pH adjustment 
non-filtered fresh urine 1.18 - - Zhang et al. (2014) 
Chlorella vulgaris 21-day cultivation  
batch bottles 
29 µmol photons/m2/s 
1:25-diluted urine 
1:75 
1:100 
1:150 
1:300 
0.38 
0.34 
0.20 
0.35 
0.38 
0.520 
0.570 
0.600 
0.570 
0.480 
0.06  
0.07 
0.07 
0.06 
0.05 
Paper IV 
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TABLE 5.8.  Continues 
 
Cultivation set-up Nitrogen source 
Growth 
rate µ 
(1/d) 
Biomass 
production 
(g/L) 
Biomass 
productivity 
g/(Ld) Reference 
Chlorella vulgaris grown in growth medium 
Chlorella vulgaris CO2 addition 
14-day cultivation 
Photobioreactor 
225 µmol photons/m2/s 
M8 (urea)d - 
 
0.53  0.052  Hulatt et al. (2012) 
Chlorella vulgaris CO2 addition 
14-day cultivation 
photobioreactor  
225 µmol photons/m2/s 
M8 (nitrate)d - 
 
0.54  0.046  Hulatt et al. (2012) 
Chlorella sp. 1 L photobioreactor 
CO2 addition 
600 µmol photons/m2/s 
Walne’s medium  
0.1 g/L urea 
0.058c 1.422 - Hsieh and Wu (2009) 
Chlorella vulgaris 12-day cultivation  
initial pH 5 
60–70 µmol photons/m2/s 
organic fertilizer  
 
0.270 0.51 - Lam and Lee (2012b) 
Chlorella vulgaris 21-day cultivation 
shake flasks 
29 µmol photons/m2/s 
Chu-10 (mod.) 
urine+TE 
0.370 
0.310 
0.529 
0.730 
0.056 
0.080 
Paper IV 
Note: - not reported; a 444.4 W/m2 converted to µmol photons/m2/s using conversion factor of 1 W/m2 = 4.5 µmol photons/m2/s; b calculated from 
cells/mL with a conversion factor by the authors; c growth rate reported as (1/h); d nitrogen limitation (1.33 mM) 
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Bacterial presence in the cultivations enhanced C. vulgaris flocculation, and clump formation 
in the presence of bacteria and their extracellular polymeric substances has been previously 
reported, although algal cells have naturally a negative charge on the cell surface which 
prevents aggregation (Lee et al. 2013). Non-sterile cultivation conditions are beneficial for 
nutrient removal over sterilized growth conditions (Chlorella sp. grown on secondary effluent, 
Zhang and Hong 2014) and bacterial (Bacillus licheniformis) presence in C. vulgaris cultivation 
has led to better ammonium and total phosphorus (Ptot) removal efficiency than in single algae 
or bacteria system in addition to promoting algal growth (Liang et al. 2013).  
The source for bacteria in algal cultivations was obvious as urine contains bacteria, the 
presence of which was microscopically confirmed in this study, and which in fact can be 
expected as urine contains organic carbon (Table 5.1) which enables growth of competitive 
microorganisms such as bacteria (Perez-Garcia et al. 2011a). The bacterial presence in 
sterilized and non-sterilized artificial algal growth media has been reported previously 
(Lakaniemi et al. 2012a, 2012b), but as urine contains bacteria, it was thought it might have a 
major impact on algal growth. Only two studies investigating the possible presence of bacteria 
in algal cultivations on urine have been conducted previously; C. sorokiniana grown with 
undiluted urine revealed heterotrophic bacteria growth in microscopical inspection (Zhang et 
al. 2014), while bacterial presence has also been estimated via chemical oxygen demand 
(COD) depletion (Tuantet et al. 2014b).  
pH and DOC Concentration during Cultivations 
Biomass growth was similar during the cultivations (Figures 5.7A and 5.7B) even though pH 
varied greatly between different cultivation batches (pH range 4.5 to 10). In urine dilutions 
1:25–1:100 the pH increased after an initial drop (Figure 5.7B) apparently due to CO2 
consumption (Chisti 2007), but the biomass growth was not limited by culture pH. With higher 
urine dilutions (1:150–1:300, Figure 5.7B) and with urine+TE (Figure 5.7A) pH remained 
lower during the whole incubation time, apparently due to ammonium uptake by algae (Brewer 
and Goldman 1976). Low pH values (<4) have resulted in cessation of C. vulgaris grown with 
ammonium (Hulatt et al. 2012), while the growth limiting pH for C. vulgaris is 3.5–4.5 (Huss et 
al. 1999); this supports the deduction of cultures not being affected by pH. Urea uptake by 
algae should not affect the culture pH (Brewer and Goldman 1976). Some urinary tract bacteria 
produce ureolytic enzymes (Krajewska 2009) which during the storage of urine increase the 
pH up to 9, leading to urea transforming into ammonium. The ureolytic activity of bacteria has 
likely caused the release of ammonium, which may also have increased the cultivation pHs.  
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FIGURE 5.7. Cultivation pH: A) set-up I with 1:100-diluted urine, urine+TE and Chu-10 medium, 
B) set-up II with different urine dilutions. Dissolved organic carbon (DOC): in set-up I 
(C) and set-up II (D) at different urine dilutions. The error bars represent the standard 
error of three (A, C) and two (B, D) replicates. (Modified from Paper IV) 
 
The DOC (initial concentration 8.4–114 mg/L) originated from the inoculum (Figures 5.7C and 
5.7D). In 1:25-diluted urine DOC decreased throughout the experiment, while the DOC in the 
other four dilutions began to rise after ten days (Figure 5.7D), which was expected, as all 
healthy algae release DOC during photoautotrophic growth (Puddu et al. 2003, Hulatt and 
Thomas 2010) and can also act as a substrate to heterotrophic microbes (Puddu et al. 2003 
and references therein, Hulatt and Thomas 2010). DOC normally rises during C. vulgaris 
growing process, which has been explained by the production of extracellular polymeric 
substances that cannot be degraded by C. vulgaris (Babel et al. 2002). In heterotrophic growth, 
the algae use organic carbon for their growth, resulting in declining DOC concentration (Miao 
and Wu 2004). In 1:25-diluted urine, the concentration of DOC originated from urine was so 
high that the DOC released by C. vulgaris could not be detected. High reduction of DOC in 
1:25-dilution was probably due to bacterial metabolism as it has been demonstrated that 
decrease of DOC in unsterilized wastewaters in C. vulgaris cultivation was due to bacterial 
activity (He et al. 2013a).  
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Effects of Nutrients on Biomass Growth 
Nutrient utilization of the biomass was 33–57% of total nitrogen (Ntot) and 94–99% of Ptot in 
set-up I and 40–79% of Ntot and 35–92% of Ptot in set-up II, respectively. Decreasing Ptot 
concentration in the cultivations followed the algal growth (Figures 5.8A and 5.8B) in both set-
ups slowing simultaneously, suggesting that the algae might have utilized phosphorus in their 
growth, while the dead algae might have released phosphorus for the bacteria to utilize.  
The Ntot, as well as organic nitrogen (Norg) concentration continued to decrease throughout the 
cultivation with diluted urine with increasing ammonium concentrations, while in cultivation 
where no urine was amended, no such obvious trend was seen (Figures 5.9A–F). C. vulgaris 
most probably utilized urea as it lacks ureolytic enzymes (Hodson and Thompson 1969) and 
metabolizes urea by urea carboxylase (Perez-Garcia et al. 2011b), while ammonium nitrogen 
(NH4-N) formation was likely of bacterial origin. Since VSSalgae reached a stationary phase after 
around ten days, it is reasonable to assume that part of the urea consumption after that was 
due to bacterial metabolism. The source of nitrogen (urea or nitrate) has been shown to have 
little effect on the protein and lipid content or maximum biomass production of C. vulgaris 
(Hulatt et al. 2012, Table 5.8). Comparison of cultivation of different microalgae in urine and 
their biomass yields and growth rates (Table 5.8) demonstrated that the obtained biomass 
yields in urine cultivation were comparable with previous studies. 
 
FIGURE 5.8. Phosphorus utilization (Ptot). A) set-up I with 1:100-diluted urine, urine+TE and Chu-
10 medium, B) set-up II with different urine dilutions. The error bars represent the 
standard error of three (A) and two (B) replicates. (Paper IV) 
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FIGURE 5.9. Nitrogen utilization as Ntot, Norg, and NH4-N in set-up I (A, B, and C) and with different 
dilutions in set-up II (D, E, and F). The error bars represent the standard error of 
three (set-up I) and two (set-up II) replicates. (Paper IV) 
 
The carbon to nitrogen (C:N) ratios in the cultivations ranged from 0.15 to 0.83 in cultivations 
with urine and artificial growth medium and from 0.74 to 1.3 in cultivations using diluted urine. 
The higher the C:N ratio is, the higher lipid production can be achieved in heterotrophic 
microorganisms (Silaban et al. 2014). Urea limitation (< 0.100 g/L) has been shown to increase 
Chlorella sp. lipid production while affecting negatively on the biomass concentration (Hsieh 
and Wu 2009). If the aim would be to use the produced biomass in biofuel production, 
optimization of the lipid content should be considered further, thus requiring a balance between 
sufficient nutrients while limiting the nitrogen concentration.  
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Especially the effects of urea from urine and thus ammonium as nitrogen source on the growth 
of algal cultures were of interest as previously it has been shown that ammonium uptake lowers 
the culture pH, thus affecting algal growth (Hulatt et al. 2012). Furthermore, unionized 
ammonia (as NH3) can be toxic to microalgae at concentrations over 28 mg/L at pH over 8 
when ammonium transforms into ammonia (Azov and Goldman 1982), as shown by Adamsson 
(2000) who reported decreased microalgal growth as ammonia concentration increased (2% 
urine was used). Contrary to this, C. vulgaris has been shown to prefer ammonium over nitrate 
and urea as a nitrogen source (Schuler et al. 1952, Perez-Garcia et al. 2011b). It was 
discovered that although ammonium was formed during cultivation in human urine (up to >59 
mg/L in set-up II), it did not affect the overall biomass (incl. bacteria) production. C. vulgaris 
has been reported to have grown in ammonium concentrations up to 207 mg/L, and the higher 
ammonium concentration resulted in increase in protein content but when applied in excess, 
carbohydrate productivity was reduced (He et al. 2013b).  
5.5. The Big Picture Based on the Results Presented in This Thesis 
Based on the findings presented in this thesis, it is convenient to speculate about the issues in 
a bigger picture. The following discussion highlights the selected aspects of the source-
separation of urine, analytical techniques on its characterization, pharmaceutical behavior, and 
utilization of urine. However, it is important to notice that the systems related to urine 
separation and use are complex, and they need more sophisticated approaches in order to 
assess e.g. the sustainability and safety of comparative systems. Currently, in the 
industrialized countries the sustainability of the sanitation practices needs to be assessed as 
the sewer infrastructure is on continuous development both in existing and new (residential) 
areas. As regards the less developed countries, necessity drives different sanitation customs 
and the threshold to employ sustainable and safe practices in order to protect people’s 
livelihood and the environment is a pressing matter.  
Pilot projects on urine collection and nutrient utilization are in operation in different parts of the 
world, as discussed in Chapter 2, and steps have been taken to make nutrient recovery from 
urine cost-effective while taking care of the hygienic quality. Yet, much needs to be done to 
improve the sanitation situation to the level where hygienic aspects are tackled with and focus 
can be directed to ecological aspects - therefore, in order to illustrate urine as a resource, an 
example scenario on urine collection and resource utilization in a Nordic climate is presented 
in Example 1. 
Example 1:  Collection and Storage of Urine in a Larger Scale 
In a community of 10 000 people, and urine production of 1.2 L/person/d, 12 m3/d 
urine is produced. On an annual level, this means 4380 m3 of urine. In a 
community, the joint collection of urine e.g. from adjacent or closely located 
buildings could be applied. From separate collection vessels, urine could be e.g. 
72 
 
transported to a larger collection facility. For example, three or four 1000 m3 tanks 
would be enough for six-month urine storage in appropriate environments before 
fertilizer application, and the tanks could be filled such that the order of filling 
rotates – as one tank is filled e.g. during three months, the second tank will start 
to fill after that and the tanks can be rotated in use. In this manner, the 
recommended six-month storage is applied on collected urine with minimum 
storage. For example, barley, wheat, and oats at Nordic climate require on 
average 100 kgN/ha and 38 kgP/ha (meta-analysis by Valkama et al. 2013). 
When applying the average nitrogen concentration in collected urine (Table 5.1, 
5.56 gN/L), the amount of N in 12 m3/d urine would be equal to 67 kgN/d. During 
six months, the amount of collected urine would contain approximately 12 tons N 
which would be enough to fertilize 120 ha field area equaling 240 ha field area 
per year. In the case of phosphorus, 12 m3/d urine would contain 6.2 kgP/d (0.513 
gP/L, Table 5.1) making it a little over 1 ton of P which could be used to fertilize 
29 ha field equaling 59 ha annually. Therefore, the amount of phosphorus in urine 
is limiting nutrient.   
The findings in urine nutrient concentrations (Papers II–III) suggest that while urine is a 
potential renewable fertilizer source, the pharmaceutical compounds and estrogenic activity 
present in urine after storage are an aspect that still needs to be addressed using e.g. 
enhanced treatment methods in order to promote both nutrient recovery and harmful 
compound removal. When considering controlling the use of urine in fields, the monitoring tools 
used in Papers I and II could come handy in faster analysis and preliminary screening for 
legislative bodies, research facilities and on-site inspectors. The HPLC method and 
bioluminescent yeast biosensor used for urine characterization in this thesis (Papers I and II) 
are quite robust. The HPLC method can be applied in places were access to more accurate 
systems (e.g. HPLC-MS/MS) is not available, as the method operates in the range of real 
pharmaceutical concentrations in urine. For lower concentration range and transformation 
product identification other tools are required.  As for the yeast biosensor, the portability is a 
prospective that could be true in the near future. Main advantage of these techniques would 
probably be for the monitoring personnel that control the fertilizer quality. 
The presence of feces during urine storage (Paper III) affected negatively on pharmaceutical 
removal as did the urease inhibitor. Feces are practically always present as contamination and 
it is probably quite difficult to prevent such contamination in practical use of separating toilets. 
The results presented in this thesis apply, however, only to the selected compounds and it is 
possible that in the case of other pharmaceuticals the concentration reductions could be 
higher. 
As for the urease inhibitor (Paper III), since it was still 59% present in urine after six months, 
it is quite possible that the bacterial activity of the urine was disturbed thus leading to the low 
concentration reduction results. The disruption of bacterial activity, on the contrary, could have 
affected the high remaining concentration of the urease inhibitor after the storage period. At a 
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practical point of view, if urine containing such a high concentration of urease inhibitor would 
be applied in agricultural fields, it might cause the disruption of bacterial enzymes in the soil, 
as was speculated by Watson et al. (2008). Therefore, before more is known about the urease 
inhibitor effect on soil activity, its use should probably be limited to urine which doesn’t contain 
pharmaceuticals, in order to achieve reduction in ammonia volatilization in the urine in the soil, 
as they are planned to do. In the scenario presented in Example 1, the use of urease inhibitors 
in preventing collection pipeline blockages due to struvite could be applied (see Tampere 
University of Technology et al. 2011). 
Microalgal systems are commercially available for bioactive compounds but not yet in a larger 
scale e.g. for high rate algal ponds in wastewater treatment (Jegathese and Farid 2014). The 
microalgal cultivation systems come in different shapes and sizes, but the scaling up is still in 
its infancy and more research is needed to make larger microalgal cultivations profitable. 
Reactor experiments with urine have shown promising results, but with the aid of multiple 
additives, the cost of which need to be considered.  
The nutrient and water sources can have a large impact on microalgal cultivations costs, as 
well as the selection of microalgal species, climate conditions, existing infrastructure, and 
logistic consideration (Rawat et al. 2013) as well as biomass harvesting and additional 
illumination (Cho et al. 2013). To give some perspective of the algal and related biomass 
production in a larger scale, the following example (Example 2) was constructed.  
Example 2:  Biomass Production Potential of Microalgae   
To estimate the produced biomass in a residential area of 10 000 inhabitants, 
each producing 1.2 L of urine per day was assumed. The results obtained in 
Paper IV and urine composition from set-up II (Table 5.1) were used in the 
calculations. The available Ntot and Ptot in liquid form for biomass growth would 
be 23.5 tons/a and 2.2 tons/a equaling 170 tons/a and 230 tons/a of biomass, 
respectively. This biomass would provide suitable feed e.g. for anaerobic 
digestion. 1 tonVS provides 200-400 m3 of methane (CH4) (in anaerobic digestion 
for different algal biomass sources, Gunaseelan 1997) and for C. vulgaris 286-
322 m3 CH4/tonVS (Lakaniemi et al. 2011, Lü et al. 2013), thus corresponding to 
approximately 170 tonsVS/a × 300 m3 CH4/tonVS = 50939 m3 CH4/a, which could 
be used e.g. in biofuel or biogas production, equaling 0.51 GWh. If lipids are 
extracted before anaerobic digestion, the potential methane yield is lower while 
the released ammonium is higher (Sialve et al. 2009). Yet, it must be kept in mind 
that biogas production itself also consumes energy while the digestate can be 
considered in fertilizer use. 
The water potentially needed for the dilution of urine for the algal cultivations needs to be 
considered as use, for instance, of drinking water seems questionable and more sustainable 
sources for water should be considered. The algae and other microorganisms would remove 
most of the nutrients in the cultivation medium, but it is possible some post-treatment for the 
74 
 
water would be required before release to the environment. As previously presented in this 
thesis, the possible flocculation of algae with bacteria, and overall bacterial contamination 
would probably render the dilution water useless to be reused as substances remaining from 
bacteria might cause algal clumping at the beginning of the next cultivation. A frequent cleaning 
of the cultivation vessel would be required to ensure the optimum growth of microalgae (Lam 
and Lee 2012b) due to bacterial presence. 
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6  Conclusions and Recommendations for Future 
Research 
Based on the results and findings presented in this thesis, the following conclusions and 
research recommendations can be constructed: 
 Properties of source-separated urine are favorable for fertilization purposes due to its 
relatively high nutrient concentrations (N, P, K) and renewability (Papers II, III, and IV). 
 Analysis of urine characteristics and pharmaceutical and estrogenic monitoring can be 
enhanced due to development of a HPLC method for simultaneous pharmaceutical 
detection (Paper I) and applicability of the yeast biosensor for urine analysis without 
the need for pre-treatment or adaptations of the biosensor for urine matrix (Paper II). 
 HPLC detection provides pharmaceutical detection range feasible for urine analysis of 
the selected pharmaceuticals (Paper I), while the yeast biosensor assay provides 
reasonable information on estrogenic activity in order to state the time when the activity 
has been reduced adequately in order to re-use urine (Paper II) and prevent possible 
migration into the soil or water bodies. 
 The yeast biosensor produces a cumulative signal which includes both natural and 
synthetic estrogens and estrogen-like compounds in urine (Paper II), therefore 
enabling exposure assessment of anthropogenic EDCs in urine. 
 Urine storage period of six months recommended by WHO is not enough to reduce the 
studied pharmaceutical concentrations (10–80 mg/L, three antivirals and four 
antibiotics) (Paper III). 
 Chemical or biological removal of antibiotic/anti-tuberculotic compounds can be 
expected to some extent in source-separated urine (Paper III), but the behavior of 
antivirals needs more investigation. In addition, antiviral resistance of viruses in the 
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environment has risen as one of the major concerns regarding pharmaceutical 
emissions from WWTPs. Methods for decreasing pharmaceutical concentrations in 
stored, source-separated urine should be studied further to enable its safe use. 
Additionally, the mechanisms affecting the removal require more research. 
 A potential for transformation product formation is evident (Paper III). Findings support 
the fact that using (stored) human urine directly in agricultural fertilization for edible 
plants may pose a risk. Thus, other feasible treatment practices or urine utilization 
methods should be considered.  
 Pharmaceutical concentrations are not reduced markedly during urine storage (Paper 
III). The treatment of the liquid phase remains a challenge for technical realization. 
However, separating urine from the municipal wastewater stream would no doubt aid 
in improving the effluent quality and the quality of the receiving waters, naturally 
depending on the place and/or use of urine being conveyed. 
 Presence of urease inhibitor, commonly used in fertilization applications to inhibit 
ammonia volatilization, affected negatively on pharmaceutical removal (Paper III). The 
effect of urease inhibitor on bacterial enzyme activity during urine storage needs thus 
more consideration. In addition, fecal contamination has negative impact on 
pharmaceutical removal, which can prove problematic in real-life applications. 
 Microalgae can grow in 1:25–1:300 times diluted human urine (Paper IV). The diluted 
urine is able to support biomass growth without additional trace elements or vitamins, 
thus having potential for sustainable use and recycling of nutrients.  
 Microorganisms present in the collected urine (Paper IV) can facilitate algal cell 
flocculation when re-using the urine-based cultivation medium. However, cultivation of 
C. vulgaris in more concentrated urine and the effect of the selected pharmaceuticals 
and estrogens on its growth need more research, as no studies on pharmaceutical-
containing urine on algal growth have been conducted. 
 The water coming for dilution of the algal cultivations is one major aspect. Microalgal 
(and related biomass) cultivation using only little diluted, source-separated urine could 
in the future be a sustainable way to re-use nutrients and generate biomass for energy 
production (Paper IV).  
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Simultaneous detection of three antiviral
and four antibiotic compounds in
source-separated urine with liquid
chromatography
An analytical method for the simultaneous screening of three antiviral agents (nevirapine,
zidovudine, lamivudine), four antibiotics (sulfamethoxazole, trimethoprim, ciprofloxacin,
rifampicin) and one reference compound (carbamazepine) in human urine was developed.
Separation was achieved with a Kinetex XB-C18 (75 × 4.6 mm, 2.6 m) column after the
extraction of pharmaceuticals from urine with SPE. Gradient elution with a mobile phase
consisting of acetonitrile and 10 mM KH2PO4 (pH 2.5), and diode array detection with
monitoring at 210 and 264 nmwas applied. The developedmethod was validated in terms of
selectivity, linearity, stability and sensitivity. Repeatability (n= 3) and between-day precision
(n= 3) revealed RSD<5%. The detection limits were estimated as 0.02–0.54 g/L (depending
on compound). The method was validated for human urine and successfully applied to
the simultaneous quantification of selected compounds. Strata-X cartridges provided good
recoveries ranging from81 to 109%. The limits of detection for urine varied between 0.04 and
1.61 g/L. Themethod is suitable for the fast determination of selected pharmaceuticals from
source-separated urine samples for further environmental risk assessment and degradation
potential evaluation. It provides a way to enhance safe nutrient recycling from wastewater
streams and promotes the safe use of urine as fertiliser.
Keywords: High-performance liquid chromatography / Pharmaceuticals / Solid-
phase extraction / Sustainable sanitation / Urine
DOI 10.1002/jssc.201300492
 Additional supporting informationmay be found in the online version of this articleat the publisher’s web-site
1 Introduction
In many countries, mixing all wastewater streams together
before treatment is common. Urine makes up only ∼1%
of the amount of wastewater arriving at wastewater treat-
ment plants but comprises the main portion of all the nu-
trients (80% N, 50% P, 90% K) [1–3]. Urine also contains
the residues of the consumed pharmaceuticals, either as a
parent compound or as metabolites. Pharmaceuticals may
not be removed during wastewater treatment or metabolites
can be transformed back into active compounds by bacterial
metabolism. A way to (i) enhance the nutrient recycling and
Correspondence: Sanna T. Pynno¨nen, Department of Chemistry
and Bioengineering, Tampere University of Technology, PO Box
541, 33101 Tampere, Finland
E-mail: sanna.pynnonen@tut.fi
Fax: +358-3-364-1392
Abbreviations: 3TC, lamivudine; CBZ, carbamazepine; CIP,
ciprofloxacin; DAD, diode array detector; NVP, nevirapine;
RMP, rifampicin; SMX, sulfamethoxazole; TRI, trimethoprim;
ZDV, zidovudine
(ii) remove the pharmaceuticals simultaneously is to collect
the urine fraction separately (source separation).
The pressure for resource recovery has made the fer-
tiliser use of source-separated urine an attractive alternative
to chemical fertilisers. Yet, the precautionary principle has
prevented the widespread use of urine as fertiliser, since the
fate of pharmaceuticals present in urine, when released to
the environment, is unclear. This problem overlaps with the
high prevalence of demand for low-cost nutrients, which is a
significant issue particularly in developing countries.
The environmental and health risks caused by pharma-
ceutical residues in urine are currently neglected. However,
from the perspective for future fertiliser use [4], it is im-
portant to monitor their presence in the potential nutrient
source. Therefore, if urine is used as a fertiliser it should
be ensured that the pharmaceuticals in human urine do not
pose a threat to humans or to the environment. Currently,
the main focus in related studies has been in either biologi-
cal fluids for bioanalytical purposes [5, 6] or in environmen-
tal analyses where pharmaceuticals are commonly dealt in
groups of similar analyte properties or each compound is
detected with a different chromatographic method [7]. Also,
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attention has been directed to compounds commonly associ-
atedwith the high standards of living, such as lipid-modifying
agents, analgesics and anti-rheumatics, and beta blockers [8],
but pharmaceuticals relating to HIV treatment have received
less consideration.
In developing countries, antiviral drugs to treat HIV and
antibiotics to treat tuberculosis are widely used. Three antivi-
ral drugs nevirapine (NVP), zidovudine (ZDV) and lamivu-
dine (3TC) are commonly used as fixed-dose combinations
to treat HIV [9]. Antibiotics sulfamethoxazole (SMX) and
trimethoprim (TRI) are used alongside antivirals to prevent
HIV-induced infections: approximately 76% of HIV patients
in sub-Saharan Africa use this combination called ‘cotri-
moxazole’ (http://www.aidsmap.com/TB-still-killing-4000-
people-with-HIV-each-day-WHO-reports/page/1543089/,
[10]). Antituberculotic pharmaceuticals rifampicin (RMP)
and ciprofloxacin (CIP) are commonly used to treat tubercu-
losis patients. Many HIV patients have latent tuberculosis
infection that is activated by HIV and lowered immunity.
Carbamazepine (CBZ) was selected in this study as a recalci-
trant reference compound. All pharmaceuticals are excreted
in urine at different percentages of the ingested oral dose,
which makes it interesting to monitor their concentrations
in urine. Since source-separated urine should be stored for
at least six months before use to remove pathogens [11], the
monitoring of pharmaceuticals is especially interesting if
urine is meant for fertilisation purposes.
These selected compounds have been detected in both
wastewater [12, 13] and surface water [14]. The detection of
some of these has been achieved using HPLC–MS [12,14–16]
and GC–MS [17]. To the best of our knowledge, there is
little information available regarding RMP detection from
wastewaters. Antiviral compounds have been recognised as
recalcitrant and persistent in the environment (for a review,
see ref. [18]). Antiviral compounds have been detected from
wastewaters using HPLC–MS [13]. However, pharmaceuti-
cals found in these waters are extensively diluted and the
compounds usually appear in the g/L to ng/L range and are
thus referred to as micropollutants [19]. In environmental
matrices, sample concentration is often necessary [20].
HPLC has been used to detect these compounds from
human serum [21,22] or plasma [23]. RMP has been detected
from antituberculotic tablets [24] and from human plasma
and blood spots [25]. Antiretroviral drugs have been detected
from plasma [26]. Some studies have also concentrated on
human urine [27–30]. In the case of human urine, most
pharmaceuticals are excreted in the mg/L range and can be
more easily analysed by using only HPLC with diode array
detection. However, to the best of our knowledge, there is
no method available that simultaneously detects all of the
selected pharmaceuticals from urine.
The detection of pharmaceuticals in plasma, urine and
medicinal products has been one of the basic analyses per-
formed in the medical industry. However, these analyses
have relied on methods that utilise porous C18 columns with
particle sizes of 3–5 m. The use of a core–shell column
enables fast gradient separations with a performance simi-
lar to ultra-performance liquid chromatography systems in
the 400 bar pressure limitation of conventional HPLC sys-
tems [31, 32]. According to Fekete and Fekete [33], the per-
formance achieved with 2.6–2.7 m core–shell particles is
comparable with results obtained with fully porous 1.7 m
particles when utilising fast gradient separations. Their re-
sults showed that this technology enables fast and efficient
gradient separations in routine pharmaceutical analysis.
Previous studies [34, 35] have demonstrated the good
performance of 2.6 m Kinetex-C18 particles under gradi-
ent conditions. The column selected for this study utilises a
XB-C18 phase (octadecyl silane) that, according to the man-
ufacturer, increases hydrogen bonding with hydrophobic se-
lectivity, which improves the peak shape for basic compounds
and increases the retention of acidic compounds.
Our preliminary studies showed that the chromatogram
of a urine sample contains several distinctive peaks created by
the urinematrix and therefore the sensitivity of themethod is
not sufficient at low concentrations. SPE provides a rapid and
easy means of extraction and purification of urine samples.
A previous study by Lai et al. [36] proved that urine samples
treated with SPE had less interfering peaks that could hin-
der the identification of compounds of interest in the chro-
matogram. Therefore, the analysis of urine samples with an
HPLC instrument without any sample pre-treatment is not
an option since the detector cannot distinguish individual
compounds from the interfering peaks caused by the urine
matrix.
The aim of this study was to develop a simple and rapid
HPLC gradient method utilising a core–shell column to
screen all the selected pharmaceuticals from human urine
simultaneously in the 0.05–500 mg/L range. This range is
relevant to the calculated predicted concentrations in urine.
The method enables the fast determination of selected phar-
maceuticals from collected urine samples for further environ-
mental risk assessment and degradation potential evaluation.
2 Materials and methods
2.1 Chemicals and materials
HPLC-grade acetonitrile (ACN) and methanol (MeOH) were
purchased from Sigma-Aldrich (Sweden). Potassium dihy-
drogen phosphate, ammonium hydroxide and acetic acid
were of analytical grade and purchased fromMerck. Phospho-
ric acid was purchased fromVWR (Prolabo). NVP, ZDV, 3TC,
RMP, CIP, SMX, CBZ and TRI were received from United
Corporation (Kenya). MilliQ-water was de-ionised water with
18.2 m cm conductivity (Millipore). The physicochemical
properties and type of usage of the analytes are presented in
Table 1. They range from acidic to neutral, basic and zwitteri-
onic compounds. The chemical structures of the compounds
are presented in Fig. 1. Stock solutions of 1.0 g/L were pre-
pared in MeOH, except CIP in MilliQ-water because of low
solubility in MeOH. CBZ stock solution concentration was
0.1 g/L. The stock solutions were stored in dark glass
C© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.jss-journal.com
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Table 1. Properties of the selected pharmaceuticals
Compound CAS Chemical
formulaa)
Ma) (g/mol) pKaa) ,b) logKowa) ,b) Water
solubilitya) ,b)
(g/L)
Typical usage
Lamivudine 3TC 134678-17-4 C8H11N3O3S 224.26 4.3 −1.29 2.76 Antiviral (HIV-treatment)
Zidovudine ZDV 30516-87-1 C10H13N5O4 267.24 9.96 0.05 16.3 Antiviral (HIV-treatment)
Nevirapine NVP 129618-40-2 C15H14N4O 266.89 2.8 1.75 0.105 Antiviral (HIV-treatment)
Sulfamethoxazole SMX 723-46-6 C10H11N3O3S 253.28 1.6; 5.7 0.89 0.459 Antibiotic
Trimethoprim TRI 738-70-5 C14H18N4O3 290.32 7.12 0.91 0.400 Antibiotic
Ciprofloxacin CIP 85721-33-1 C17H18FN3O3 331.35 6.09; 8.74 0.28 30 Antibiotic (tuberculosis)
Rifampicin RMP 13292-46-1 C43H58N4O12 822.94 1.7; 7.9 4.24 1.4 Antibiotic (tuberculosis)
Carbamazepine CBZ 298-46-4 C15H12N2O 236.27 13.9 2.45 0.0177 Antiepileptic
Data collected from
a) DrugBank (http://www.drugbank.ca/).
b) Toxnet (http://toxnet.nlm.nih.gov/).
Figure 1. Chemical structures
of the studied compounds. Pic-
tures obtained from DrugBank
(http://www.drugbank.ca/).
containers at about 4C, and they were usable for several
months. Urine samples were collected from healthy volun-
teers receiving no medication. The samples were combined
and carefully mixed, afterwards the samples were spiked.
Analysis was performed on the same day as samples were
collected.
2.2 Liquid chromatography
Analysis was performed using Hewlett-Packard Agilent 1100
HPLC (Agilent Technologies) consisting of a binary pump, a
vacuum degasser, an autosampler, a thermostatted column
oven kept at 40C, a standard flow cell (13L) and diode array
detector (DAD). The temperature of the column oven was set
at 40C to decrease the effect of room temperature variation
on the column performance and to achieve a lower operating
pressure due to the decreased viscosity of the mobile phase.
All capillaries were of 0.17 mm internal diameter. The dead
volume of the system was 24.4 L. The column used to per-
form analyses was Kinetex core–shell XB-C18, 2.6m (100 Å),
75 × 4.6 mm (Phenomenex, Denmark) equipped with Secu-
rityGuard ULTRA Pre-filter cartridge 0.2 m (Phenomenex).
Data analysis was conducted usingHPChemStation software
version B.01.03.
Themobile phasewas selected based onpreliminary stud-
ies conducted in our department earlier (data not shown
here). The mobile phase composition had been shown to
be effective in the detection of pharmaceutical compounds
from wastewater samples. The mobile phase consisted of
two parts: eluent A was ACN and eluent B 10 mM KH2PO4
buffer filtered through a 0.2 m filter (ME24, Schleicher &
Schuell, Germany), the pH of which was adjusted to 2.50
with 85% H3PO4. The peaks were detected using a DAD
at wavelengths 210 nm (3TC, TRI, ZDV, CIP, NVP, SMX,
CBZ) and 264 nm (RMP), and peak purity was determined
by running DAD from 190 to 600 nm during each analysis to
specify the spectra for each compound. The data acquisition
rate was set to the highest possible (<0.1 s). The injection
volume was 5 L, and the flow rate of the mobile phase was
2.5 mL/min. The high flow rate was selected with the core–
shell particle column to provide optimum performance and
sharp peaks with the Agilent 1100 system, but also to achieve
the separation of the compounds in a short analysis time. Col-
umn backpressure during the sample run was approximately
330 bar.
The method development was started with a linear gradi-
ent of 5–90% eluent A in the selected time and modified re-
peatedly to obtain the best selectivity between different phar-
maceuticals, resulting in the gradient presented here. Before
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running the samples, the UV signal at 210 nm was left to
stabilise with 5% eluent A flow. Gradient elution was used:
isocratic hold from 0.0 to 0.5 min at 5% eluent A, linear gra-
dient from 0.5 to 3.5 min from 5 to 70% eluent A, after which
an isocratic hold at 70% eluent A from 3.5 to 4.0 min was
applied. The gradient elution took place in 4.0 min and the
signal was left to stabilise for 2.0 min at 5% eluent A after
each sample. The total analysis time was 6.0 min.
2.3 Quantification
Each compound was identified by recording the retention
time and spectrum of the pure compound in MeOH and
comparing those to each peak in the sample. The calibration
curves were made in the range of 0.05–500 mg/L for each
compound from stock solutions straight into amber vials
by serial dilution. Internal standards were not used, since
the large variability of the therapeutic groups in one sam-
ple would cause difficulty in internal standards selection and
possibly hinder the analysis ofmultiple compounds from one
sample.
Standard curves were prepared by plotting peak areas
of the target analytes versus analyte concentrations. A linear
regressionmodel utilising the least-squares fitting (Microsoft
Excel 2007) was applied to the results and the calibration
curves were stored for further use of the method.
2.4 Application to urine matrix
Urine samples were spiked with a known amount of phar-
maceutical, vortexed and particles in the urine samples were
removed by filtering the spiked sample through a 0.2 m
nylon syringe filter (VWR, USA) to protect the column. The
first few drops of filtrate were discarded. Afterwards 1 mL of
sample was pre-treated by SPE.
2.5 SPE
Based on preliminary studies (data not presented here), a
choice from three different SPE sorbent types was made on
the basis of how well they removed interferences caused by
the urine matrix. Selected pharmaceuticals were extracted
from urine samples using Strata-X (1 cc/30 mg, 33 m) SPE
cartridges from Phenomenex, which enabled the simulta-
neous determination of selected compounds. Strata-X sor-
bent consists of chemically modified styrene-divinylbenzene
(mixed polymeric and reversed phase [37,38]). It has not been
as extensively used as some other sorbents, such as Oasis
HLB (Waters), but Strata-X has performed well, for example,
in bovine [39] and human urine pre-treatment [37].
SPE was conducted using a vacuum manifold (Supelco
Analytical, USA). The method was based on manufacturer’s
instructions for Strata-X (http://phx.phenomenex.com/lib/
tn75040410_l.pdf) in which the wash and elution steps were
modified. Extraction volume for urine was 1mL. SPE sorbent
tubes were conditioned with 1mLMeOH, equilibrated with 1
mLMilliQ-water, after which 1mL of sample was introduced.
After sample loading, the sorbent was dried under vacuum
for 1 min, eluted with 1 mL 2% NH4OH to collect 3TC and
dried under vacuum for 1 min. The second elution was con-
ducted with 1 mL of ACN/MeOH/acetic acid (50:50:2, v/v/v)
to collect the rest of the compounds. The flow rate was ap-
proximately 1 mL/min. The eluted samples were collected
into amber vials for analysis.
2.6 Method validation
To determine the instrumental quantification limit, the LOQ
and LOD were determined from standard solutions. In this
study,weusedS/N= 3 for the LODandS/N= 10 for the LOQ.
The LOD and LOQ were also determined for each compound
separately in the urine matrix.
The robustness of the method was tested by running
two different gradient slopes compared with the method.
The gradient was modified by adjusting the eluent A end-
concentration either to 60 or 85% and the changes in com-
pound retention times (tR) and peak areas were recorded.
In addition, the effect of eluent A starting percentage was
studied. The effect of temperature was monitored by testing
sample run temperatures ± 5C, and the same data was col-
lected as with gradient change. The effect of pH on selectivity
was also tested at pH values ± 0.5 units past the optimum
(pH refers to the pH of the aqueous buffer).
The reproducibility of the method was verified by statisti-
cally comparing the concentration found in the sample with
the one added. Statistical analysis was performed by conduct-
ing a two-tailed one-sample t-test (SPSS 15.0, IBM) using the
added concentration as test value and studying the p value
of the results. The null hypothesis (H0) was that there is no
difference between the added and found concentrations. If a
p value of >0.05 is observed, it verifies that the difference in
concentrations is not statistically significant.
The repeatability of the LC method was tested by trip-
licate injections of standard concentrations (1.0, 10.0 and
100.0 mg/L in MeOH and CIP in water) and spiked urine
samples (the pharmaceutical concentrations of 5.0, 10.0, 25.0
and 50.0 mg/L). Spiking was done to a urine sample that
did not contain pharmaceuticals with a mixture of selected
compounds; the sample was filtrated through a 0.2 m ny-
lon filter and the SPE procedure was performed as previously
described.
The recovery is the percentage of which known added
concentrations of compounds were obtained from a matrix
after pre-treatment and analysis. This was studied by using
concentrations of 5.0, 10.0, 25.0 and 50.0 mg/L for selected
compounds with three replicates each. The recoveries were
determined by comparing the peak area of the SPE-treated
sample to the peak area of the same compound at the same
concentration level dissolved in MeOH or MilliQ-water. The
LOD and LOQ were also determined for urine samples.
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Figure 2. Chromatographic peaks of the
selected compounds at 10.0 mg/L (stan-
dard solution, solid line) and SPE-
treated spiked sample of 25 mg/L
(dashed line, second elution with 50:50:2
ACN/MeOH/acetic acid). (a) lamivudine,
(b) trimethoprim, (c) zidovudine, (d)
ciprofloxacin, (e) nevirapine, (f) sul-
famethoxazole, (g) carbamazepine, (h)
rifampicin, (x) impurity caused by ri-
fampicin. Chromatographic conditions:
Eluent A acetonitrile, eluent B 10 mM
KH2PO4, pH 2.5. Flow rate 2.5 mL/min, UV
at 210 and 264 nm, injection volume 5 L,
column temperature 40C, isocratic hold
from 0–0.5 min at 5% A, gradient from 0.5–
3.5min 5–70%A, isocratic hold 3.5–4.0min
at 70% A.
3 Results and discussion
The developedmethod produced sharp peaks with acceptable
resolution. Injection volumes of 3, 4, 5, 6, 7 and 10 L were
tested:< 5 L injection volumes reduced the peak height too
much and injection volumes > 5 L caused less symmetric
peaks and the resolution between different peaks suffered.
Thus, a 5 L injection volume was selected. In addition, the
effect of the eluent flow rate was tested. At a flow rate of
2.0 mL/min the elution of the last peak (RMP) was delayed
markedly. Gradient elution was set to take place in 0.5 min
steps to decrease the analysis time. Subsequently, the flow
rate was adjusted to 2.5 mL/min, which further reduced the
analysis time to 4 min. DeStefano et al. [40] have demon-
strated that the flow rate of the mobile phase can be sub-
stantially increased and the separation time decreased with
only a small decrease in the column efficiency and separation
resolution when utilising new sub-3 m particle columns.
Figure 2 presents the order of the peak elution for the
stock compounds and for the urine sample (sample taken
from elution with 50:50:2 v/v/v, ACN/MeOH/acetic acid).
Between peaks g and h there is a smaller peak (x), which
is caused by RMP. Different gradient slopes and ACN end-
concentrations were tested but they did not have an effect
on the retention of CBZ and RMP. The retention times (tR),
the calibration curve R2 values,  (selectivity), k’ value (ca-
pacity factor), and LOD and LOQ of the instrument for each
compound can be found in Supporting Information Table
S1. Supporting Information Table S1 also describes the stan-
dard deviations of the calibration curves slope and intercept.
The R2 values were all ≥0.9992 and k′ and  were acceptable.
The standard deviations of the retention times were all < ±
0.02min. The LODandLOQvaried between 21–536g/L and
71–1786g/L, respectively, anddepending on the compound.
The linear range of the calibration varied depending on
the compound. The number of calibration points was seven
for 3TC, eight for CBZ and CIP, nine for TRI, SMX and NVP,
ten for RMP and 11 for ZDV. The capacity factor (k’) of a
peak should preferably be <12, and in this case the capacity
factor of 11.9 for RMP was accepted because of the highly
reduced sample run time. Also, the k′ value for 3TC was quite
low (<2), but this could not be affected even by changing the
gradient to start at 2%eluent A concentration. Any lowerACN
percentage would even be harmful for the performance of the
column. The selectivity () between peaks should preferably
be at least 1.2–1.3, but in our analysis three peak pairs had
selectivities of 1.0 (peak pairs b/c and c/d) or 1.1 (peaks e/f),
see Supporting Information Table S1.However, they resolved
well from each other. The reproducibility of the method was
acceptable. The RSDs for intra- and interday tests (not shown
here) were all <8%. A thinner particle shell means a smaller
surface area of particles. This causes smaller retention values
(k’) and reduced sample loading capacity [40], which might
explain the behaviour of 3TC and the variability in the largest
concentration level measurable at linear range, e.g. for TRI,
concentrations over 100 mg/L, which resulted in the loss of
linearity in the standard curve.
Supporting Information Table S2 presents the robust-
ness results. In Supporting Information Table S2a, the ef-
fect of alternative temperature is presented. When alternat-
ing the column temperature, the changes in peak areas were
within ± 10% and within ± 14% with temperatures higher
and lower than 40C, respectively. Supporting Information
Table S2b describes the effect of gradient slope change. The
gradient slope change did not affect the peak areas of the com-
pounds markedly. The variation percentage was between ±
5%, which is acceptable. When using a higher percentage of
eluent A (ACN), the peaks eluted approximately 0.1–0.4 min
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faster than when using 70% ACN end-concentration. With a
lower gradient, the tR did not change, except for RMP, which
eluted 0.4 min slower. However, the method was still capable
of separating RMP within the 4.0 min time limit. Supporting
Information Table S2c explains the effect of changing gradi-
ent start to 2% eluent A instead of 5%. The retention of the
problematic compound 3TC was not improved with a lower
starting ACN percentage. The changes in peak areas were
negligible when using a different gradient start when com-
pared with the gradient proposed in this article. The retention
time shifts either faster (2–85%ACN) or slower (2–60%ACN)
but the analysis could still be concluded within 4 min. The
order of peak elution did not change in any of the cases. Sup-
porting Information Table S2d describes the effect of eluent
pH change to peak elution and selectivity. At pH 2.0, the tR
of the compounds were in the range of ± 0.05 min except
for NVP (tR was shortened by 0.12 min). At pH 2.0, the selec-
tivity between peaks e and f (NVP and SMX) was increased,
for all the other compounds it remained the same. The peak
area changes were ± 7.2%. At pH 3.0, the retention times
varied ± 0.03 min, except for RMP (eluted 0.109 min earlier).
The selectivity of the peak pair e/f suffered and the peaks
began to merge with each other. The peak areas were affected
more, averaging at ± 9%, especially for 3TC (area increased
19.3%). In conclusion, pH 3.0 does not provide as good se-
lectivity as pH 2.5 or pH 2.0. The advantage of pH 2.5 is that
RMP elutes faster and its area is slightly larger. According
to Neue and Me´ndez [41], the retention changes between the
molecule’s ionised and non-ionised form depend weakly on
the amount of organic solvent in themobile phase and the re-
tention changes between charged and uncharged form of the
compound increases with increasing organic concentration.
The repeatability testing (Supporting Information
Table S3) with statistical evaluation showed somewhat sig-
nificant statistical differences (p < 0.05) or significant statis-
tical differences (p < 0.01) between the known added con-
centration and the acquired concentrations with the applied
method. The results varied depending on the compound:
two compounds (SMX and CBZ) had no statistical difference
between the added and acquired amounts, whilst most had
some statistically significant differences between the added
and recovered concentrations. These differences varied de-
pending on concentration levels. CIP is the only compound
with significant statistical difference (concentration level 1.0
mg/L). However, the different stock solution solvent (MilliQ-
water) might explain the variation at this low concentration,
even the recovery value with CIP at 1.0 mg/L is lower, which
supports this interpretation. Yet, the RSD for CIPwas<1.5%.
The recovery results for the proposed HPLC method (re-
peatability using stock compounds in eitherMeOHorMilliQ-
water) from the intraday tests show that the recoveries varied
between 90–108.8%. Variations in concentrations between
different days can be explained up to a point by the possible in-
stability of the old HPLC instrument. However, even though
somewhat larger or lower recoverieswere recorded, thanwhat
is recommended, the recoveries were accurate enough for the
purpose of this method and thus acceptable.
The results of the inter- and intraday testing of the
method for reproducibility are presented in Table 2. The
overall retention time for each compound did not change
markedly during interday analyses (standard deviations <±
0.01 min) except for RMP, whose standard deviation was
0.111 min.
The results for recovery testing are compiled in Table 2.
Thehighest recovery for 3TCwas obtainedusing 2%NH4OH.
The overall recoveries varied between 81.6–109.2%withRSDs
between 0.1–5.3%. 3TC gave quite low recovery when using
Strata-X sorbent: the best recovery was on 5 mg/L concen-
tration, with a recovery of 43.3%. The collection of the 3TC-
containing fraction separately was necessary to ensure at least
somewhat adequate recovery. The problem is mainly because
of the high polarity of 3TC (3TC also flushes out of the Kine-
tex XB-C18 column quite easily with c > 100 mg/L). Prasse
et al. [13] have stated that because of their high polarity, the
antiviral drugs are probably not effectively retained on SPE
sorbent materials (see Table 1, logKow of 3TC is −1.29) and
thus not on RP columns. The minimum requirement for an-
alyte logKow for Strata-X is −0.5. According to Rummel [42],
a general rule is that analytes with logKow < −1.0 are very
difficult to retain on many commercially available silica- or
polymer-based reversed-phase chemistries. This is in accor-
dance with our results.
In Table 2, the LOD and LOQ for the method using a
urine matrix are presented. The LOD and LOQ for urine var-
ied between 39–1610 and 129–5366 g/L, respectively. The
LOD as well as LOQ were higher for all compounds, except
for NVP, in SPE-treated urine samples than in standard solu-
tions, but not too high to prevent the utilisation of themethod
for the proposed purpose (detection from fresh urine samples
with concentrations from tens to hundreds of mg/L).
The poor retention of 3TC causes problems when
analysing water samples and with SPE while pre-treating
urine. Different SPE elution methods were tested to find
the optimum for all the compounds of interest: elution with
10% ACN, 50% ACN, 2% NH4OH and 2% Acetic acid was
tested. Of these 2% NH4OH was selected. The 3TC fraction
contained the interfering compounds from the urine sample
that were washed away in this step. If 3TC was the main an-
alyte of interest, it would be advisable to use another type of
column and/or SPE sorbent that increases the retention of
analytes with logKow < −1.0. However, the goal was to de-
velop a single method suitable for all the selected compounds
that might occur simultaneously in urine.
To compare our results with Strata-X to other similar
studies, some results fromprevious publications are collected
in Table 3. A comparison of data is challenging since either
the matrix or the SPE sorbent is not necessarily similar to
our study; however, some generalisations can be made. In
the case of TRI, ZDV, NVP and CBZ, the results are similar
to other studies that have used Strata-X as sorbent [5, 30,
42, 43], though, in many cases the matrix has been human
plasma [4, 44, 45]. For 3TC, the recovery obtained was better
than ours, but the SPE method was optimised for antiviral
pharmaceuticals. In that case [4], it was possible to adjust
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Table 2. Reproducibility of the method, and recovery and LOD and LOQ of the method in urine matrix
Compound
3TC TRI ZDV CIP NVP SMX CBZ RMP
Interdaya) c (mg/L)
(n = 3) 1 1.0 (0.05) 1.0 (0.003) 1.1 (0.02) 1.0 (0.04) 1.0 (0.02) 1.0 (0.02) 1.0 (0.02) 1.1 (0.06)
10 10.3 (0.20) 10.2 (0.05) 10.0 (0.06) 10.1 (0.08) 10.3 (0.05) 10.2 (0.13) 10.2 (0.01) 9.8 (0.10)
100 101.7 (1.56) 106.1 (0.63) 101.3 (0.24) 100.2 (0.22) 104.0 (0.50) 102.6 (0.48) 102.6 (0.12) 102.0 (0.30)
Intradaya) c (mg/L)
(n = 3) 1 0.9 (0.07) 1.0 (0.02) 1.1 (0.02) 1.0 (0.004) 1.0 (0.02) 1.0 (0.04) 1.0 (0.02) 1.1 (0.02)
10 10.3 (0.12) 10.3 (0.18) 10.1 (0.07) 9.9 (0.15) 10.7 (0.52) 10.1 (0.17) 10.3 (0.17) 9.9 (0.19)
100 102.0 (0.85) 105.9 (1.85) 102.0 (1.32) 99.5 (0.80) 105.6 (1.25) 104.8 (2.65) 105.0 (2.16) 102.3 (0.56)
Recoveryb) (%) c (mg/L)
(n = 3) 5 43.3 (3.1) 98.7 (2.7) 99.4 (2.7) 109.2 (2.4) 99.4 (2.9) 96.0 (3.1) 97.8 (1.0) 90.7 (2.5)
10 36.3 (3.0) 101.0 (1.4) 106.9 (0.5) 102.8 (3.6) 98.5 (3.4) 96.2 (5.3) 102.1 (3.3) 98.5 (2.6)
25 17.6 (1.4) 101.0 (1.9) 93.2 (3.8) 81.6 (3.1) 105.0 (1.5) 83.0 (3.1) 97.8 (1.7) 105.8 (1.9)
50 16.7 (1.0) 104.9 (0.2) 103.2 (0.4) 87.8 (0.5) 102.2 (0.1) 86.5 (0.7) – 101.2 (0.7)
LOD urinec) (g/L) 1610 39 189 189 71 115 41 503
LOQ urinec) (g/L 5366 129 630 631 237 383 136 1676
tR (min)d) Interday 0.490 (0.002) 1.917 (0.005) 1.978 (0.001) 2.038 (0.003) 2.333 (0.000) 2.450 (0.002) 2.908 (0.001) 3.548 (0.111)
a) Mean (±SD).
b) Mean (±RSD), analytes in same sample, 5–25 mg/L for CBZ.
c) Limits of detection and quantification of the method for urine matrix.
d) n = 9, mean (±SD).
Table 3. Comparison of recoveries obtained for the selected pharmaceuticals with different SPE sorbents and matrices
Compound SPE sorbent Matrix Recovery (%) References
Lamivudine (3TC) Strata-X plasma 96.8a) [6]
Trimethoprim (TRI) Bakerbond C18 urine 90–98b) [30]
Strata-X water 97.6 [43]
Strata-X water 123 [7]
BondElut Plexa urine 70–77b) [29]
Ciprofloxacin (CIP) Bakerbond C18 urine 45–83b) [30]
SPE-C18 plasma 72.3 [46]
3M-Empore MPC urine 61.9 [45]
Zidovudine (ZDV) Strata-X plasma 98.1a) [6]
Nevirapine (NVP) Strata-X plasma 97.4a) [6]
Bond Elute Certify plasma ≥88 [44]
Sulfamethoxazole (SMX) Bakerbond C18 urine 72–93b) [30]
Strata-X water 120 [7]
BondElut Plexa urine 86–90b) [29]
Carbamazepine (CBZ) LiChrolut DYE urine 105 [8]
Oasis HLB plasma 94–99.8b) [47]
Rifampicin (RMP) Strata-X plasma 55.8–72.9b) [25]
a) Method optimised for antiviral pharmaceuticals.
b) Recovery variation between different spiked concentration levels.
the sample in such way that 3TC was retained better in the
sorbent. In this method, the focus was on recovering all the
compounds simultaneously, which limited the sample pre-
treatment options. For CIP and RMP, the results show better
recoveries than that obtained in other studies (over 80% in
our case, only up to 72% in other studies). Also, in the case
of SMX, our results with Strata-X were better (96%) than
in the previous study. However, the matrix is different in
many cases. Overall, the results presented in Table 3 are in
accordance with our recovery values.
4 Concluding remarks
A rapid LC method utilising new core–shell column tech-
nology was developed to screen three antiviral agents and
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four antibiotics simultaneously from source-separated urine.
Also, the reference compound CBZ was successfully anal-
ysed. Instrumental LOD and LOQ varied between 21–
536 and 71–1786 g/L, respectively, for eight standard
compounds.
Recoveries obtained using Strata-X SPE-sorbent were
good although some compromises were needed in order to be
able to simultaneously analyse all eight compounds. Recover-
ies varied between 81 and 109% for all compounds except for
3TC (16–43%). In the case of 3TC, it is necessary to dilute the
urine sample with concentrations over 5.0 mg/L to guarantee
at least somewhat sufficient recovery. The recovery values us-
ing Strata-X are comparable with other previously published
results. The LOD and LOQ for urine varied between 39–1610
and 129–5366 g/L, respectively. However, while the LOD is
somewhat high for urine samples, the method enables the
detection of the selected pharmaceuticals from fresh urine
samples in the relevant range of concentrations from ten to
hundreds of mg/L.
The application of a core–shell column provides savings
in both time and mobile phase consumption, since the re-
duced analysis time greatly compensates the increased flow
rate of the eluent. Using two subsequent elutions from the
same SPE tube saves sorbent material. The repeatability and
recovery obtained using Kinetex XB-C18 column were in ac-
cepted ranges. The LOD and LOQ were low enough con-
sidering further uses of this method. The method offers an
easy and practical way to study the concentration of the eight
compounds belonging to therapeutic groups with different
physicochemical properties.
If urine is used as a fertiliser, it should be ensured that
the pharmaceuticals in human urine do not pose a threat
to humans or to the environment. The developed method
presented in this paper provides a useful tool for this. The
method fits for the fast determination of selected pharma-
ceuticals fromsource-separatedurine samples orwastewaters
for further environmental risk assessment and degradation
potential evaluation and enhances nutrient recycling from
wastewater streams. It also helps to promote the safe fer-
tiliser use of source-separated urine. The analytical protocol
also enables the further use of this method in environmental
and fertiliser use monitoring to promote sustainable sanita-
tion practices and the use in laboratories that do not have MS
detectors.
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Table S1. Results from the calibration with stock solutions
aMean (±SD), n = 9; bInstrumental detection and quantification limits when utilizing method presented in section “2.2 Liquid chromatography”.
Peak Analyte Calibration
range (mg L-1)
tR (min)a R2 Equation
 (±SD of slope and intercept)
LODb
(µg L-1)
LOQb
(µg L-1)
k’ Selectivity
between peaks
a 3TC 0.5-100 0.490 (0.003) 0.9999 y = 4.8365(±0.021)x-2.4327(± 0.823) 536 1786 0.8 α(a,b) = 7.5
b TRI 0.05-100 1.915 (0.002) 0.9992 y = 25.833(±0.278)x-9.3603(±9.614) 32 108 6.1 α(b,c) = 1.0
c ZDV 0.1-500 1.978 (0.001) 0.9997 y = 5.4836(±0.031)x-0.0058(±5.250) 66 661 6.3 α(c,d) = 1.0
d CIP 0.1-500 2.100 (0.004) 0.9999 y = 4.4385(±0.020)x-12.152(±3.755) 80 265 6.6 α(d,e) = 1.2
e NVP 0.05-250 2.336 (0.001) 0.9999 y = 13.042(±0.034)x-1.229(±2.945) 73 243 7.7 α(e,f) = 1.1
f SMX 0.1-250 2.446 (0.002) 0.9999 y = 11.399(±0.023)x-1.1715(±1.941) 106 353 8.1 α(f,g) = 1.2
g CBZ 0.05-100 2.908 (0.001) 0.9998 y = 26.667(±0.151)x-2.309(±5.373) 21 71 9.8 α(g,h) = 1.2
h RMP 1.0-500 3.483 (0.019) 0.9996 y = 2.8374(±0.019)x-7.8517(±3.561) 204 679 11.9
Table S2. Results of the robustness tests of the method: a) the effect of temperature, b) the
effect of gradient change, c) the effect of lower eluent A starting percentage, d) the effect of
different eluent pH
a 30 oC 45 oC
Compound
tR change
(min)
Peak area
change (%)
tR change
(min)
Peak area
change (%)
3TC 0.013 -0.1 0.007 -5.3
TRI 0.014 -1.8 0.002 0.0
CIP 0.015 9.4 0.002 13.9
ZDV 0.014 5.4 0.001 6.3
NVP 0.002 1.1 0.002 -0.1
SMX 0.027 -0.6 0.003 -1.0
CBZ 0.013 0.7 0.003 0.9
RMP 0.002 -9.1 0.002 -5.2
b 5 to70 % ACN 5 to 85 % ACN 5 to 60 % ACN
Compound
Current method
tR (min)
tR change
(min)
Peak area
change (%)
tR change
(min)
Peak area
change (%)
3TC 0.488 0.005 4.1 0.005 -0.6
TRI 1.917 -0.078 0.8 0.0 -0.5
CIP 1.975 -0.079 -2.5 0.001 0.2
ZDV 2.037 -0.106 5.1 0.0 -0.8
NVP 2.333 -0.138 0.7 0.0 1.0
SMX 2.446 -0.149 0.9 0.0 -0.3
CBZ 2.906 -0.243 0.1 0.0 0.6
RMP 3.494 -0.368 -1.6 0.455 -0.7
c 2 to70 % ACN 2 to 85 % ACN 2 to 60 % ACN
Compound
tR change
(min)
Peak area
change (%)
tR change
(min)
Peak area
change (%)
tR change
(min)
Peak area
change (%)
3TC 0.004 0.0 0.003 0.0 0.004 0.0
TRI 0.004 0.0 0.128 0.0 0.028 0.0
CIP 0.003 0.1 0.129 0.1 0.028 0.1
ZDV 0.003 0.1 0.113 0.1 -0.011 0.1
NVP -0.001 0.0 0.103 0.0 -0.052 0.0
SMX 0.005 0.0 0.105 0.0 -0.061 0.6
CBZ 0.001 0.0 0.076 0.0 -0.175 0.0
RMP -0.001 -0.1 0.044 -0.1 -0.321 -0.1
d pH 2.0 pH 3.0
Compound
tR change
(min)
Peak area
change (%)
tR change
(min)
Peak area
change (%)
3TC 0.013 0.0 -0.021 19.3
TRI 0.005 -2.3 0.004 2.0
CIP 0.009 0.3 0.010 3.2
ZDV 0.008 -0.2 0.004 3.3
NVP 0.120 6.5 -0.032 -8.9
SMX 0.027 -2.3 0.006 8.9
CBZ 0.008 7.2 0.009 5.4
RMP -0.050 -1.2 0.109 3.0
The tR change or peak area change refer to difference (either in minutes or percentages) compared to the proposed
method in this article.
Table S3. Statistical comparison of the concentrations added and found with the developed method and method recovery
aNull hypothesis: The concentrations added and recovered from samples are equal: p < 0.05 = almost statistically significant, p < 0.01 = statistically significant;
bMean recovery (± RSD)
Intraday 3TC TRI ZDV CIP NVP SMX CBZ RMP
p-valuesa C mg L-1
1 0.535 0.394 < 0.05 < 0.01 0.343 0.517 0.187 < 0.05
10 < 0.05 0.085 0.182 0.524 0.14 0.271 0.076 0.634
100 < 0.05 < 0.05 0.125 0.395 < 0.05 0.087 0.057 < 0.05
Method recovery %b
C mg L-1
1 90.0 (7.5) 101.2 (2.0) 108.3 (2.0) 96.6 (0.4) 98.7 (1.9) 101.8 (3.9) 102.0 (1.7) 108.8 (1.7)
10 103.2 (1.2) 103.3 (1.7) 100.8 (0.7) 99.3 (1.5) 107.1 (4.8) 101.5 (1.7) 103.4 (1.7) 99.4 (1.9)
100 102.0 (0.8) 105.9 (1.8) 102.0 (1.3) 99.5 (0.8) 105.6 (1.2) 104.8 (2.5) 105.0 (2.0) 102.3 (0.6)
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ABSTRACT
The objective was to demonstrate that a microbial whole cell biosensor, bioluminescent yeast,
Saccharomyces cerevisiae (BMAEREluc/ERα) can be applied to detect overall estrogenic activity
from fresh and stored human urine. The use of source-separated urine in agriculture removes a
human originated estrogen source from wastewater inﬂuents, subsequently enabling nutrient
recycling. Estrogenic activity in urine should be diminished prior to urine usage in agriculture in
order to prevent its migration to soil. A storage period of 6 months is required for hygienic
reasons; therefore, estrogenic activity monitoring is of interest. The method measured
cumulative female hormone-like activity. Calibration curves were prepared for estrone, 17β-
estradiol, 17α- ethinylestradiol and estriol. Estrogen concentrations of 0.29–29,640 μg L−1 were
detectable while limit of detection corresponded to 0.28–35 μg L−1 of estrogens. The yeast
sensor responded well to fresh and stored urine and gave high signals corresponding to 0.38–
3,804 μg L−1 of estrogens in different urine samples. Estrogenic activity decreased during
storage, but was still higher than in fresh urine implying insufﬁcient storage length. The
biosensor was suitable for monitoring hormonal activity in urine and can be used in screening
anthropogenic estrogen-like compounds interacting with the receptor.
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1. Introduction
Natural and synthetic estrogens and their analogues
have the ability to disrupt natural chemical processes
in the wildlife, for example, by causing ﬁsh feminiza-
tion.[1] Estrogens are excreted via human metabolism
into urine mainly as conjugates (sulfate or glucuronide
groups attached), which travel via the sewage to the
wastewater treatment plants (WWTPs) as extensively
diluted and mixed together with other types of waste-
waters. Bacterial metabolism and enzyme activity can
transform these conjugates back to their active forms
in the sewers (before wastewaters enter the WWTP),
[2,3] causing the distribution of estrogens into the
receiving waters.[4] The concentrations in the WWTP
efﬂuents vary depending on the type of estrogen,
from few to tens of ng L−1.[3,5] Wastewaters arriving
at WWTPs have been recognized as one of the main
pathways via which endocrine disruptors, including
estrogens, enter the environment. The degradation of
estrogens in WWTPs is not yet fully understood.[6]
The need for additional studies and cost-effective
alternatives for the removal and degradation of estro-
gens from efﬂuents has been noted.[7] The reduction
of estrogen discharges to WWTPs could minimize their
concentrations in efﬂuents to inactive levels
(concentration so low that no effect on environment
can be detected;[8]). The main compound of interest
regarding the environmental effects of estrogens has
been synthetic 17α-ethinylestradiol, used in contracep-
tives, but also natural estradiol, estriol and estrone are
of interest. Estrogen presence in WWTP efﬂuents is pri-
marily of domestic origin.[4] In addition, since estrogens
may migrate into and in soils [9] from wastewater pro-
ducts used as fertilizers, measuring the concentration
of estrogens prior to application is important. Thus,
the monitoring of estrogenic activity of source-separ-
ated urine is of interest.
Separate collection of urine from other household
wastewaters (source separation) is an environmentally
feasible way to remove the source of human originated
estrogens [4] from wastewater inﬂuents as well as to
recycle the nutrients (N, P, K and micronutrients) which
otherwise would burden the WWTP,[10] thus reducing
the treatment requirements. Urine comprises approxi-
mately 1% of the wastewaters arriving at municipal
WWTPs, but contains in liquid form 60% to 90% of N, P
and K a person ingests,[11] as well as many micronutri-
ents. Thus, source-separated urine is a good alternative
fertilizer, which adds major key nutrients into soil (e.g.
© 2016 Taylor & Francis
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phosphorus [12]). Source separation promotes decentra-
lized sanitation concepts which have received more
attention [13] as the need for sustainable fertilizer
sources has been recognized, and source separation is
practiced, for example, in Sweden,[14] Germany [15]
and Australia.[16] Source-separated urine should be
stored for 6 months to achieve the required hygienic
level regarding pathogens [17] and afterwards it can be
used in fertilization (for discussion on using human
excreta on plant production, see Ref. [18]). During
storage, urine typically undergoes ureolysis where urea
is transformed to ammonia and consequently pH is
raised greater than nine, leading to pathogen inacti-
vation. Application of sheep urine has been shown to
enhance the leaching of radiolabelled estrogens in soils
compared with application with distilled water.[19] In
addition, estrogens have been shown to de-conjugate
in soil.[20] If estrogens are not degraded already during
storage, they can cause harmful environmental effects
when leached in ground waters. Thus, estrogens
should be removed and/or degraded from urine before
fertilizer applications to mitigate their effect on the
environment.
In order to use source-separated urine in crop fertiliza-
tion, the use of a biosensor becomes a convenient
method for overall estrogenic activity detection to
demonstrate that the estrogenicity has diminished
from the urine. In this study, a genetically modiﬁed
yeast Saccharomyces cerevisiae was used.
Yeast cell biosensors have been regarded as a viable
alternative for ﬁrst-stage screening of endocrine disrupt-
ing compounds since they are easy and fairly inexpen-
sive to perform [21]; they have high speciﬁcity to
hormones due to the lack of endogenous steroid recep-
tors,[22,23] and can be grown on media devoid of
steroids.[24] Yeast cells are more resistant to environ-
mental contaminants compared with mammalian cells,
which make them advantageous for use in measuring
complex environmental samples.[21] Many applications
have utilized an extra-chromosomal reporter system
with β-galactosidase as a substrate-based reporter
protein (yeast estrogen screen, YES [25]), human breast
cancer estrogen-sensitive MCF-7 cells in E-SCREEN
assay [26] and estrogen-receptor mediated chemically
activated luciferase gene expression (ER-CALUX assay
[27]). Androgens have been detected from urine using
yeast with a modiﬁed androgen receptor.[22,23,28] The
application of yeast estrogen (and androgen) bioassay
to calf urine using green ﬂuorescent protein required
extensive pre-treatment steps involving solid phase
extraction and the use of organic solvents.[29,30]
However, mainly the aforementioned studies have
used a human androgen-receptor (male hormone)
based strain, whereas this paper focuses on the human
estrogen-receptor strain.
To our knowledge, no information is available on
using a bioluminescent yeast biosensor to monitor the
estrogenic activity of source-separated human urine.
The objective of this study was to demonstrate that a
bioluminescent yeast cell-based biosensor can be
applied as a rapid and simple screening tool in the
overall estrogenic activity detection from source-separ-
ated urine with and without storage without laborious
pre-treatments. The bioavailability of the estrogens was
studied by adding β-glucuronidase to the samples, as
estrogens are mainly excreted as conjugates. The aim
was to use the biosensor as a screening tool for studying
estrogenic presence in the samples in order to gain
knowledge on the safety of urine in agricultural use, as
well as to demonstrate the suitability of the biosensor
in urine and environmental sample monitoring as a
fast, stand-alone analytical tool.
2. Materials and methods
2.1. Chemicals and materials
Yeast nitrogen base w/o amino acids was purchased from
Difco, agar-agar from Merck, and D-glucose, adenine, L-
tryptofan, L-leucine, L-histidine and D-luciferin were
obtained from Sigma-Aldrich. Estrone (E1, ≥99%), 17β-
estradiol (E2, ≥98%), 17α-ethinylestradiol (EE2, ≥98%)
and estriol (E3, ≥97%) were purchased from Sigma and
used as standards for estrogenic activity measurements.
Sterile Octavia-water was provided by Fresenius Kabi Ag
(Germany). MilliQ-water (18.2 mΩ cm conductivity, Milli-
pore) was used in media preparation. Urease (jack bean
urease, lyophilized 5 U mg−1, EC 3.5.1.5) was obtained
from Merck and ionic strength adjusting (ISA) solution
was purchased from Thermo-Scientiﬁc. S. cerevisiae strain
BMAEREluc/ERα with modiﬁed estrogen receptor alpha
(ERα) was developed by Leskinen et al. [21]. Liquid
synthetic dextrose medium (SD-medium), AHL-medium
(containing essential amino acids adenine, L-histidine,
L-leucine aka AHL-medium) and AHL-agar were prepared
according to Välimaa et al. [31].
2.2. Yeast cultivation
S. cerevisiae BMAEREluc/ERα was cultivated in AHL-agar.
It was grown for 48 h at 30°C and subsequently one
colony was transferred into 5 mL of liquid medium
(two replicates) which was incubated at 30°C overnight
and 300 rpm shaking. Un-inoculated pure AHL-medium
was used as control. For bioluminescence and hormonal
activity assays, yeast cells were grown to an optical
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density (OD600) of 3.0 and subsequently the culture was
diluted with fresh AHL-medium to OD600 of 0.8 and used
in the assay.
2.3. Hormonal activity assay
Bioluminescence assay was performed according to the
method described by Leskinen et al. [21]. The method
was tested for each estrogen (stock solutions of 10 mM
in EtOH of E1, E2, EE2 and E3) by analyzing concentrations
from 0.027 ng L−1 to 29.6 mg L−1 (in 10% EtOH), in order
to create standard curves. The analyses were done in tri-
plicate with 10% EtOH as a reference blank.
A standard curve was constructed by pipetting 10 µL
aliquots of hormones into white 96-well plates (Thermo
Electron Corporation). As blank, 10 µL 10% EtOH was
used. Aliquots of 90 µL of the diluted yeast culture
(BMAEREluc/ERα) were then added into the wells con-
taining the samples. The plates were incubated at 30°C
for 2.5 h at 300 rpm. After incubation, 100 µL aliquots
of sterile ﬁltered 1 mM D-luciferin in 0.1 M Na-citrate
buffer (pH 5.0) were pipetted into the wells and biolumi-
nescence was measured immediately using Victor2
Wallac 1420 Multilabel counter (PerkinElmer Life
Sciences, Inc.).
2.4. Characterization of the matrix
The major constituents of fresh and stored human urine
(as indicators of storage; described in more detail below)
were determined in order to characterize the urine
matrix. pH and conductivity of both types of urine
samples were measured with Orion SA 720 pH-meter
and WTW LF95, respectively.
The sum of ammonium (NH+4 ) and ammonia (NH3)
was determined with an ammonia selective, gas-sensi-
tive membrane electrode (Thermo-Orion), which
measures the NH3 concentration. ISA solution was
added to the samples and standards to convert
ammonium to ammonia. Urea concentration was deter-
mined by measuring ammonia from the sample, then
adding the urease enzyme and afterwards letting the
sample stand for ca. sixteen hours in room temperature,
while urease catalyzed urea decomposition to ammonia.
Subsequently, ammonia was measured and the differ-
ence between the two ammonia concentrations equal-
led the amount of urea in the sample.
Ion chromatography (Dionex DX120) was used to
determine the anions of interest (PO3−4 , Cl
−, SO2−4 , NO
−
3 ,
NO−2 ) from the urine. The separating column was AS9-
HC (Dionex) equipped with pre-column AG9-HC
(Dionex). The eluent used was a buffer prepared of 12
mM Na2CO3 and 5 mM NaHCO3. Urine was diluted with
MilliQ water (1:100 v/v). The diluted urine was ﬁltered
(nylon 0.45 μm, VWR). Further analysis steps were
made according to standard SFS-EN ISO 10304-1:en.[32]
For the determination of cations, an atomic adsorp-
tion spectrophotometer was used. Na, K, Mg and Ca
were analyzed from urine with AA200 analyzer (PerkinEl-
mer) using air acetylene ﬂame. Before analysis, urine
samples were ﬁltered (0.45 μm nylon, VWR). The ﬁltered
samples were diluted at ratios from 1:50 to 1:5000 with
MilliQ-water using acid washed glassware. The dilution
for each sample depended on the cation and nature of
urine. A 0.18 M CsCl + LaCl3 solution (Merck) was added
to the samples of which Ca was analyzed to stop the for-
mation of substances that inhibit Ca atomization. The
analysis was done according to Finnish Standard Associ-
ation (SFS) standards 3018 [33] and 3044.[34]
Determination of dissolved organic carbon (DOC) was
conducted according to SFS-EN standard 1484.[35] Urine
samples were diluted with MilliQ-water and ﬁltered
through 0.45 µm prewashed syringe ﬁlter (nylon, VWR),
after which the samples were analyzed with a TOC-
5000 Analyzer (Shimadzu).
2.5. Detection of estrogenic activity in urine
For hormonal activity testing, triplicate urine samples
collected from a volunteer female taking oral contracep-
tives, a female not using synthetic hormones, and male
urine (two volunteers), child urine (both a boy and a
girl), mixed urine (a combination of the previous) and
stored urine (mixed, 1 or 5 months in polypropylene con-
tainers, in dark at room temperature) were used. The col-
lected urine samples were not spiked with estrogens, but
analyzed as such. The time points of 1 and 5 months
were selected in estrogenic activity testing to obtain an
understanding about the kinetics of hormone-like
activity and degradation. As blank, 10 µL 10% EtOH
and 10% EtOH in urine were used. Aliquots of 10 µL of
samples were pipetted in triplicate without any pre-treat-
ment into a white 96-well plate and analysis performed
as described earlier. Analysis was repeated thrice for
each urine sample. Concentrations of 0.027, 2.72, 272.4
and 27,238 µg L−1 of E2 were spiked in fresh and
stored urine to test the storage effect, and the recovery
was determined against the E2-standard in 10% EtOH.
Adaptations of the sensor for a different matrix were
not needed,[21] emphasizing the fact that the yeast bio-
sensor can be used without any pre-treatment of the
sample as a stand-alone tool in monitoring estrogenic
activity changes during urine storage.
The bioavailability of the estrogens was tested either
by heat treating samples at 80°C for 30 min (which is a
normal procedure to hydrolyze compounds) or by
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hydrolyzing them with β-glucuronidase enzyme (β-D-
glucuronoside glucuronosohydrolase from Escherichia
coli K12, EC 3.2.1.31, Fisher Scientiﬁc) at 46°C for 45 min
to break the conjugated bonds. β-Glucuronidase inter-
acts with the glucuronide group attached to the main
molecule and breaks the bond, thus releasing the orig-
inal estrogen in its bioactive form. Before hydrolysis
with β-glucuronidase, pH of the samples was adjusted
to 6.0–6.5 with 0.1 M NaOH or 0.1–1.0 M HCl. As a refer-
ence, the same samples were incubated at 46°C for 45
min without β-glucuronidase addition. The samples
were heated in water baths at the speciﬁc temperatures,
left to cool to room temperature and consecutively ana-
lyzed as previously described.
The impact of urine (fresh and stored) ﬁltration on bio-
sensor performance was not tested, as ﬁltration/steriliza-
tion is not feasible in practice on a large scale and thus
not considered feasible for applicability as a screening
tool to assess urine safety in agricultural use. Filtration
would be time-consuming and the costs would be
high, as well as all the bacteria responsible for estrogenic
degradation would be removed.
2.6. Analysis of obtained data
Light emission was measured as relative light units (RLU).
By normalizing the RLU values of the samples with the
background bioluminescence of the sensors, the data
obtained from different experiments and/or lumin-
ometers can be compared.[21] The induction of the
sensor by the sample was calculated as fold induction
(FI): FI = SLS/SLB, where SLS is the average biolumines-
cence of the yeast sensor (measured from three repli-
cates) and SLB is the bioluminescence of blank solvent
(at least four replicates). FI is a dimensionless unit. FI in
y-axis was plotted against log10 of the estrogen concen-
tration. The limit of detection (LOD) describes the lowest
measurable concentration and/or signal of the method.
The minimum response considered as positive (FILOD)
was determined according to Long and Winefordner
[36]: FILOD = 2(XB + 3SD)/XB, where XB is the average back-
ground bioluminescence value of the sensor (four 10%
EtOH blanks included in each assay) and SD is the stan-
dard deviation. The LOD was subsequently determined
from the standard curve using FILOD.
To evaluate the average estrogen concentration in
urine samples, an average estrogen calibration curve
was constructed based on four estrogens and their
average molecular weight (281.8 g mol−1). Although in
some cases the results were below FILOD, an estimation
of the estrogen concentration has yet been made. Of
course, it has to be kept in mind that the real urine
samples possibly contained other estrogenic
compounds which also induce a signal and thus the cal-
culated estrogen concentrations represent the concen-
tration of all estrogen-like compounds in the sample.
For FI values higher than the average estrogenic
response curve, the calibration curve of EE2 was used
(biosensor gave the best signal, as described later).
3. Results and discussion
The goal of this study was to investigate the applicability
of the bioluminescent yeast cell-based biosensor as a
fast, stand-alone analytical screening tool in estrogenic
activity monitoring in urine. In the present study, the
urine samples required no pre-treatment (e.g. ﬁltration,
extraction or centrifugation). The method could be
applied to urine as such.
3.1. Characteristics of the matrix
Source-separated urine contains amino acids, solids, sal-
inity and inorganic and organic constituents (urea, crea-
tinine, acids, etc.).[37] The measured characteristics of
human urine are presented in Table 1. Fresh urine
usually has pH ranging from 5.5 to 6.5, as described in
this study. Urine contains several grams per liter of
DOC (7.3 g L−1) and urea (4.9 g L−1), a compound
which transforms into ammonia during storage due to
bacterial ureases.[38] Urine contains macronutrients (N,
P and K) in relatively large quantities (g L−1), whereas
micronutrients up to tens of mg L−1 (Table 1). Therefore,
removing urine from wastewater streams not only
reduces the organic load arriving at WWTPs, but also
enables nutrient recycling. The collected urine can be
used as a liquid fertilizer, while WWTP efﬂuent is too
diluted in nutrients and contains more pathogens due
to the presence of fecal matter. The composition of
urine changes during storage: organic matter degrades,
Table 1. Characteristics of the urine matrix.
Urine composition (unit) Fresh Stored
pH 5.8 9.4
Conductivity (mS cm−1) 9.1 25.9
DOC (g L−1) 7.29 2.81
NH+4 + NH3 -N (g L
−1) 0.57 8.67
Urea (g L−1) 4.95 1.05
Anions
NO−3 (g L
−1) 0.16 n.d.
SO2−4 (g L
−1) 1.61 1.28
PO2−4 (g L
−1) 2.86 1.18
F− (mg L−1) 91.6 55.8
Cl− (g L−1) 2.67 2.40
Cations
Na (g L−1) 0.83 1.01
K (g L−1) 0.52 1.17
Mg (mg L−1) 76.0 n.d.
Ca (mg L−1) 88.0 3.1
Note: n.d. = not detected.
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Mg and Ca salts precipitate (e.g. as struvite) and the salt
content of urine decreases as a result of precipitation.
After storage, the pH increased from 5.7 to 9.0–9.5 and
urea transformed into ammonia.
3.2. Hormonal activity assay
Results obtained from constructing standard curves for
estrogens (E1, E2, EE2, E3) in 10% EtOH were as presented
in Figure 1(a). All the estrogens had similar standard
curves, with an exponential increase in the signal at a
speciﬁc concentration range. Similarly to Salste et al.,
[39] who studied WWTP efﬂuents with the same biosen-
sor, the yeast biosensor produced a signal with respect to
all of the studied estrogens in a concentration-depen-
dent way, thus demonstrating the repeatability of the
results produced by this particular yeast strain in a differ-
ent laboratory and matrix. The yeast response to estro-
gens varied depending on the estrogen (Figure 1(a))
with repeatable results, and mainly the response was
obtained with estrogen range from 0.29 to 29,640 µg
L−1. In order to estimate the overall estrogenic concen-
tration, an average of four estrogens was taken (Figure
1(b)) to approximate concentrations in urine.
The highest response with the biosensor was
obtained with the synthetic EE2. The FILOD for the biosen-
sor was 2.4, corresponding to approximately 2.8 µg L−1
E1, 0.28 µg L
−1 E2, 0.29 µg L
−1 EE2 and 35 µg L
−1 E3. The
LOD determined from the average concentration curve
corresponded to 0.29 µg L−1 estrogens. A comparison
of different yeast cell-based bioassays and their detec-
tion limits to the current bioassay is presented in
Table 2. A detailed comparison of the biosensors is
unequal as some of the studies have measured estrogen
equivalents, while some have used the bioassay only to
demonstrate estrogenic activity: in those cases concen-
trations have been measured with chromatographic
methods. One must bear in mind that practically all of
the previous biosensor analyses used sample enrichment
before analysis if the matrix has been some other than a
standard solution (e.g. EtOH). Overall, the LOD obtained
in this study is practical in monitoring real urine
samples and the analysis is relatively fast to perform. In
addition, as chromatographic methods usually require
sample preparation and clean-up before analysis, use
of this biosensor is well justiﬁable in simple and rapid
monitoring. Compared with the analysis using mass
spectrometer, which normally has LOD of few ng L−1
(e.g. Ref. [4]), the obtained LODs are higher; but com-
pared with conventional liquid chromatography in com-
bination with urine sample pre-treatment which has LOD
around 0.1–0.2 µg L−1, the results are comparable.[40]
Table 3 shows the typical excretion amount of estro-
gens per day in urine. The average amount of urine pro-
duced is ∼1.2 L person−1 d−1,[37] which dilutes the
estrogen concentrations in collected urine. Common
birth control pills contain approximately 30 µg of EE2.
When comparing the LOD of the yeast biosensor with
these excretion concentrations, it is obvious that the sen-
sitivity of the sensor is applicable in urine estrogenic
activity monitoring, especially, as the sensor reacts to
other estrogenic compounds as well.
Estrogenic concentrations spiked in fresh and 5-
month stored urine were different from the standards
(0.027, 2.72, 272.4 and 27,238 µg L−1). The results are pre-
sented in Figure 2(a),(b). The spiked E2 concentrations in
Figure 1. (a) Standard curves for estrone (E1), 17β-estradiol (E2), 17α-ethinylestradiol (EE2) and estriol (E3). (b) A standard curve calcu-
lated as the average of four estrogens from Figure 1(a) for the estimation of estrogenic concentration. The error bars represent the
standard errors from three measurements. Estrogenic concentration determination: FI < FILOD: estimated from average estrogen
curve; FI > FILOD: calculated from average estrogen curve; FI > average estrogen curve FI: calculated from EE2 standard curve.
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fresh urine gave reasonable signals, while the FI values
were lower than that in standards prepared in 10%
EtOH (0.5–6.2 FI units). This might be explained by
sample toxicity, which might have had an effect on the
yeast, thus decreasing the bioluminescence. However,
the reason for such spiked E2 behavior is not crucial
regarding the use of the biosensor to the suggested
application. The spiked E2 concentrations in stored
urine had high signals, with recovery comparable to
fresh urine, if standard error is taken into account. This
could be due to the purity of the estrogens, as they
were not glycosylated, thus making them more bioavail-
able. The urine blank induced quite high signal, which
caused a low FI value in stored urine. A high urine
blank signal in stored urine is explained by the release
of estrogenic compounds in urine in addition to the pres-
ence of other estrogenic substances.
Leskinen et al. [21] have already proven that yeast
estrogen strains have behaved and responded to
hormones (two androgens, E2) and xenoestrogens simi-
larly with yeast estrogen screen. Relative estrogenic
potencies determined with their assay seemed compar-
able to those determined using in vitro bioassays. Urine
always contains estrogens (even in urine from males);
thus, having urine blank is not possible. Even though
long enough stored urine might be devoid of estrogens,
the composition of the sample would be different and it
might still contain estrogen-like compounds that induce
a signal with the biosensor. The use of a different matrix
as blank seems inappropriate, for example, as a solution
of ammonia or water is not comparable with the compo-
sition of and the matrix effect caused by urine. However,
urine blank is not needed since all FI values are corrected
by dividing with the blank signal, and the aim of this
study was not to determine exact concentrations but
to monitor the overall change in estrogenic activity, in
which the biosensor performed accordingly.
3.3. Estrogen bioavailability
The bioavailability of the estrogens and the response of
the biosensor are affected by the presence of estrogens
as conjugates in urine (Table 3); thus, breaking up the
conjugated bonds should improve the sensitivity of the
sensor strain and provide knowledge on the magnitude
of de-conjugation potential in soil.
Figure 3(a),(b) describes the signal given by the yeast
biosensor in different urine samples without and after
different treatments (Table 4). As previously described,
time points of 1 and 5 months were selected in estro-
genic activity testing due to the availability of samples.
The overall recommended time for urine storage is 6
months,[17] but shorter periods are commonly used.
Table 2. Comparison of yeast cell-based bioassays.
Bioassay
Reporter
protein Matrix
Sample pre-
treatment Time needed for analysis LOD (µg L−1) Reference
S. cerevisiae
BMAEREluc/ERα
Luciferase Pure compound
in 10% EtOH
Not needed 2.5 h Incubation 0.008 (E2)
a Leskinen et al.
[21]
S. cerevisiae
(yEGFP)
Green
ﬂuorescent
protein
Spiked calf urine Solid phase
extraction, de-
conjugation
De-conjugation overnight, plate drying
overnight, 24 h incubation
1.0 (E2 and EE2)
a Bovee et al. [29]
S. cerevisiae β-galactosidase Pure compound
in EtOH
Not needed Three-day incubation 0.0015 (E2) Routledge and
Sumpter [28]
Yeast estrogen
screen (YES)
β-galactosidase River water Solid phase
extraction
Pre-treatment 120–150+ min, 3-day
incubation
0.0001 estrogen
equivalents (EE2)
Vermeirssen
et al. [46]
S. cerevisiae
BMAEREluc/ERα
Luciferase Wastewater
efﬂuent
Solid phase
extraction
Solid phase extraction 20+ min, freeze
drying 4.5 h, chromatographic
fractionation 28 min, LC–MS/MSb 15 min
2.5 h incubation
LOD was not
determined for yeast
assay
Salste et al. [39]
S. cerevisiae
BMAEREluc/ERα
Luciferase Pure
compounds in
10% EtOH
Not needed 2.5 h Incubation 2.8 (E1), 0.28 (E2), 0.29
(EE2), 35 (E3)
This study
Human urine
(real samples)
De-conjugation De-conjugation 45 min, 2.5 h incubation 0.38-3,804 (measured
overall estrogenic
concentration)
This study
aMeasured as nM, converted by the authors.
bLC–MS/MS = liquid chromatography–mass spectrometry.
Table 3. Typical estrogen concentrations in human urine and
their excretion.
Estrogen
Excretion in
urine (µg d−1)
Excretion as
glucuronides [47]
(%)
Excretion as free
form [47] (%)
Estrone (E1) 0.54–54
a 85–89 1–3
3.2–16.1b
Estradiol (E2) 0.54–16.3
a 90–95 1–3
4.6–269b
10.3c
Ethinylestradiol
(EE2)
7.1b 90–95 n.a.
Estriol (E3) 1.4–43.2
a 90–95 0–2
Note: n.a. = not available.
aU. Turpeinen, Helsinki University Central Hospital Laboratory, Helsinki,
Finland, personal communication.
bRef. [43], 269 µg E2 d
−1 for pregnant women.
cAverage concentration in human urine [48].
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Only unconjugated forms of estrogens contributed to
the ERα activity when urine was measured without treat-
ment (ﬁrst and second bar), and the results were repea-
table. Thus, bioavailability testing was conducted to get
the response for all estrogenic activities present in the
sample (measuring the sum of free and glucuronidated
forms). Bioavailability of estrogens is important as differ-
ent soil microorganisms [41,42] may break down the
conjugated bonds, thus releasing active hormones in
the soil.
Heat treatment at 80°C for half an hour resulted in
increased activities in urine from a female not taking con-
traceptives (FI value 18.5, 14 µg L−1) and a female child
(FI value 2.5, 0.35 µg L−1) when compared with urine
without heating (concentrations below average LOD,
0.05–0.29 µg L−1). The addition of β-glucuronidase and
incubation at 46°C for 45 min increased the FI values of
all urine samples, ranging from FI 7.8 (1.4 µg L−1) to FI
41.4 (10,200 µg L−1, a female without contraceptives,
determined using standard for EE2), except for the
Figure 2. Comparison of the storage effect with spiked samples. Fresh urine was collected on the previous day. Urine (mixed) was
stored for 5 months in plastic jars, at room temperature. Samples were spiked with four E2 concentrations and analyzed. The FI
values represent the mean of three replicates, with error bars showing standard error. (a) The higher FI values for fresh urine are
explained by the lower bioluminescence of the blank. The blank stored urine had a higher background signal, thus decreasing the
overall FI values. (b) Recovery of the added E2 concentration compared with the E2 standard in 10% EtOH. With fresh urine, the recovery
was better.
Figure 3. FI of different urine samples using the bioluminescent yeast biosensor. The bars represent the mean of three replicates, with
error bars showing standard error. β-gluc. = β-glucuronidase. (a) FI values for the different fresh urine samples with and without differ-
ent pre-treatments. (b) FI values of fresh and stored urine (at room temperature in plastic jars with a tight lid, 1 or 5 months) with and
without different pre-treatments. * indicates that urine samples were collected and analyzed at the same time (measurement 2).
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female taking contraceptives (FI 0.6, <LOD). Mere incu-
bation at 46°C did not affect the FI values as much as
enzyme addition, except in the case of the female
taking oral contraceptives and in stored urine. The high
FI value for the female not taking contraceptives can
be explained with the menstrual cycle and/or pregnancy:
during different phases, the excreted estrogen concen-
trations can vary markedly.[43] The observed signals cor-
responded to estrogen concentrations of 0.27–2,964 µg
L−1 (determined from the standard curves based on
measured FI, Figure 1(a),(b)), the highest of which
could be due to other estrogen-like compounds excreted
in urine and binding to the ERα receptor.
Estrogen excretion for men [43] has been calculated
to average 3.2 µg d−1, whereas our results using
heating and β-glucuronidase addition gave 15 µg L−1,
which adjusted to 1.2 L d−1 makes 18 µg d−1; however,
this estrogen concentration includes all estrogen-like
compounds excreted in male urine. Clearly, the
method’s sensitivity was better with β-glucuronidase
addition: the samples which earlier gave lower FI
values now showed more clearly estrogenic activity.
This was in accordance with the results published by
Kaiser et al. [44] who tested their yeast biosensor with
swine urine and noted that samples needed a pre-treat-
ment before analysis to break the conjugated bonds
(incubation with Helix pomatia solution), because estro-
gen conjugation reduced the method’s sensitivity. The
FI values were higher than the calculated LOD, except
in the case of the female taking contraceptives, which
could not be explained.
The effect of urine storage on estrogenic activity was
as hypothesized. Storing urine affected the bioavailabil-
ity of estrogens. After 1 month of storage, mixed urine
gave a markedly higher signal (FI value 17, 9.5 µg L−1)
than fresh urine (FI value 1.4, 0.1 µg L−1, <LOD). Urine
stored for 5 months gave an FI value of 4.3 (6.2 µg L−1),
indicating that some biotransformation had occurred.
This was expected since source-separated urine is
never devoid of bacteria and as previously stated, ﬁl-
tration of urine on a large scale is not feasible due to
economic reasons. The bacterial enzymatic (glucuroni-
dases, estradiol dehydrogenases and sulfatases) and
metabolic activity breaks the conjugated bonds, thus
increasing the observed signal, which reduces over
time due to estrogen degradation. After 5 months, the
estrogenic concentration was still higher than in fresh
urine (0.1 µg L−1, <LOD), indicating the presence of
estrogen-receptor binding compounds. According to
the review by Yu et al. [7] some microorganisms isolated
from the intestine can convert E2 to E1 and vice versa, or
degrade E1, E2 and E3; they can also co-metabolize EE2 in
the presence of other estrogens. Thus, further studies are
required to monitor how the estrogenic activity changes
and which enzymes are active during the 6-month
storage period. Furthermore, it might be interesting to
add certain microbial mixed communities known to
degrade estrogens to the urine.
The advantage of biosensors in estrogenic activity
monitoring is their capability to estimate the cumulative
estrogenic effects of a variety of chemicals in an environ-
mental sample [8] that correspond to the overall activity
of all ERα-binding chemicals present.[45] Although the
measurement of exact concentrations is informative,
measuring the overall estrogenic activity can be more
useful regarding practical applications, such as fertilizer
use. The yeast used in this study gave a positive response
to all major forms of estrogenic compounds and it could
also be used in pre-screening anthropogenic estrogen-
like compounds which interact with the receptor, such
as bisphenol-A or parabens (e.g. Ref. [21]). To be more
speciﬁc, the method applied in this experiment measures
the cumulative concentration of endocrine disruptor
compounds (EDCs), not just estrogens. Therefore, it is
very difﬁcult to make comparisons to other methods,
as the molecular diversity of such EDCs is so vast that it
is impossible to measure the accurate concentrations
of a single compound. In addition to the before men-
tioned, it is possible that degradation products of EDCs
are inducing a signal. As stated previously, the calculated
estrogenic concentrations in this study were only esti-
mates when calculation was based on average estrogen
molecular mass.
Biosensors are also suitable for the development for
onsite tests because of their high speciﬁcity. Since estro-
gens have been shown to migrate in soil, this screening
tool could be used to test estrogenic activity in soil
samples after extraction to liquid. This method may
Table 4. Different pre-treatments conducted to urine samples
presented in Figure 3.
Figure Pre-treatment
3A: Fresh
urine
Measurement 1: fresh urine only None
Measurement 2: fresh urine with
different pre-treatments,
indicated by*
None
Heat treatment 80°C (30
min)
Heat treatment 46°C (45
min)
Heat treatment with β-
glucuronidase addition 46°C
(45 min)
3B:
Stored
urine
Measurement 1: Stored urine (5
months)
None
Measurement 2: Stored urine (1
month) with different pre-
treatments, indicated by*
None
Heat treatment 80°C (30
min)
Heat treatment 46°C (45
min)
Heat treatment with β-
glucuronidase addition 46°C
(45 min)
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also prove useful in a quick screening of endocrine-dis-
rupting chemicals for the efﬁcacy of municipal WWTPs,
which has been previously performed, for example, by
Desbrow et al. [4] using a different reporter gene as
well as a selection of sample pre-treatment steps.
Contrary to the conventional chromatographic
methods, the method has several advantages, including
complementarity to traditional analytical chemistry ana-
lyses, a minimal sample pre-treatment need, the pro-
vision of analyte bioavailability information and
simultaneous analysis of multiple samples. The biolumi-
nescent yeast assay is easy to handle, robust, cost-efﬁ-
cient and needs no high-tech analysis equipment but
can be used with cheap portable detectors.
4. Conclusions
To our knowledge, this is the ﬁrst experiment where bio-
luminescent yeast biosensor S. cerevisiae with β-glucuro-
nidase addition has been used to monitor estrogenic
activity in source-separated urine. From the results
obtained in this study, we concluded the following:
. Estrogenic activity present in urine after storage
implied that the recommended length of urine
storage may be insufﬁcient in reducing the overall
estrogenic activity to agriculturally ‘safe’ levels.
. Four estrogens (E1, E2, EE2 and E3) could be detected
using the biosensor with an effective measuring
range of 0.29–29,640 µg L−1 and LOD corresponding
to 0.28–35 µg L−1 of estrogens.
. The yeast sensor produced a cumulative signal, which
included both natural and synthetic estrogens and
estrogen-like compounds.
. The addition of β-glucuronidase and heating for 45
min at 46°C enabled the assay to be used in monitor-
ing the change in the estrogenic activity of source-
separated urine.
. The yeast sensor can also be used in screening anthro-
pogenic estrogen-like compounds which interact with
the ERα receptor.
. The method has several advantages on conventional
chromatographic techniques, for example, a minimal
need for sample pre-treatment and the simultaneous
analysis of multiple samples in a short three-hour
analysis time.
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ABSTRACT
The behaviour of pharmaceuticals related to the human immunodeﬁciency virus treatment was
studied in the liquid phase of source-separated urine during six-month storage at 20°C. Six
months is the recommended time for hygienization and use of urine as fertilizer. Compounds
were spiked in urine as concentrations calculated to appear in urine. Assays were performed
with separate compounds and as therapeutic groups of antivirals, antibiotics and anti-
tuberculotics. In addition, urine was amended either with faeces or urease inhibitor. The
pharmaceutical concentrations were monitored from ﬁltered samples with solid phase extraction
and liquid chromatography. The concentration reductions of the studied compounds as such or
with amendments ranged from less than 1% to more than 99% after six-month storage. The
reductions without amendments were 41.9–99% for anti-tuberculotics; <52% for antivirals
(except with 3TC 75.6%) and <50% for antibiotics. In assays with amendments, the reductions
were all <50%. Faeces amendment resulted in similar or lower reduction than without it even
though bacterial activity should have increased. The urease inhibitor prevented ureolysis and pH
rise but did not affect pharmaceutical removal. In conclusion, removal during storage might not
be enough to reduce risks associated with the studied pharmaceuticals, in which case other
feasible treatment practises or urine utilization means should be considered.
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1. Introduction
The global target for sustainability and resource efﬁ-
ciency has raised the issue of developing the use of
urine especially as a fertilizer for crop production,[1] as
urine contains macronutrients (N, P, K) in relatively high
quantities. Urine comprises 60–90% of N, P and K
ingested by a person in liquid form,[2] in addition to
many micronutrients. The present fate of urine ranges
from discharges to the sewage, for example, in most
cities with a modern wastewater treatment system, to
conditions where urine is excreted into a hole in the
ground where it inﬁltrates through the soil. However,
in order to better manage the use of urine, the source
separation of urine is increasingly studied and proposed
as a method for promoting sustainable nutrient manage-
ment. Source-separated urine can replace a large portion
of nutrients applied in agricultural ﬁelds [3] and new
opportunities are opening as a nutrient source, for
example, in microbial electrochemical technologies [4]
and microalgal cultivation.[5] Source-separated urine is
typically stored before agricultural fertilizer use, and,
for example, six months storage is recommended by
World Health Organization [6] to remove pathogens
from urine before use in fertilization purposes.
However, urine may contain pharmaceuticals as in
humans they are to a great extent excreted in urine,
which may be disadvantageous to its use, and, for
example, in countries without proper sanitation, pharma-
ceuticals often end up straight in the environment.
Various types of pharmaceuticals are used globally.
Many studies have focused on compounds commonly
associated with the high standards of living (painkillers,
lipid modiﬁers, etc.) and the potential antibiotic resist-
ance of bacteria at wastewater treatment plants
(WWTPs). Their fate has been studied at WWTPs and
receiving waters (for a review, e.g. [7]), while to our
knowledge, pharmaceutical behaviour during long-
term storage (e.g. six months) has not been sufﬁciently
studied. Pharmaceuticals, which have been a little
studied, are antivirals, which are commonly used as a
combination in human immunodeﬁciency virus (HIV)
treatment (lamivudine, zidovudine and nevirapine).
[8–10] Antibiotics (trimethoprim and sulfamethoxazole)
are used in combination with selected antivirals;[11] as
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well as antibiotics (ciproﬂoxacin and rifampicin) that are
used to treat tuberculosis (referred to as anti-tuberculo-
tics). Latent tuberculosis may be activated during HIV-
infection which is why these pharmaceuticals are often
used together, especially in developing countries.
These pharmaceuticals have not been investigated as
extensively although they are administered in large
doses (hundreds of mg/d), but, for example, sulfa-
methoxazole, trimethoprim and ciproﬂoxacin have
been detected in WWTP inﬂuent and efﬂuents [12,13]
(antivirals are practically not at all studied). It is not poss-
ible to obtain the real yearly consumption data globally,
but the consumption goes hand in hand with the
amount of conﬁrmed HIV infections.
The behaviour of pharmaceuticals during storage is an
important factor to take account in order tominimize risks
when planning urine re-use options, such as fertilizer
applications. During the storage of urine, pharmaceutical
concentration reduction could occur either through pre-
cipitation and/or adsorption, but also via chemical and
biological pathways, the latter indicated by increased
pH and thus bacterial activity. During the storage, urea
in urine, typically in a few months, undergoes ureolysis
(mainly due to bacterial urease enzymes) where urea
transforms into ammonia with a simultaneous increase
in pH.[14] The increased pHmay result in ammonia volatil-
ization thus decreasing the fertilizing value of urine. Urine
contains bacteria from the urinary tract, and typically
those originating from faeces, which is commonly
present as contamination;[15] thus, bacteria may be
responsible for pharmaceutical degradation during
storage. However, from a practical point of view,
whether the compounds are biologically degraded or
remain in the storage vessel is not very crucial.
To study the effect of ureolysis and thus storage pH on
pharmaceutical removal, an urease-inhibiting compound
can be added into the urine, and subsequently urea
transformation into ammonia is avoided. The treatment
prolongs the fertilization impact and decreases the loss
as volatilized ammonia. The prevention of ureolysis
also prevents the pH rise in the urine, which might
prevent the decay of bacteria at high pH that might
play a role in the behaviour of pharmaceuticals during
urine storage. A urease-inhibiting agent nBPT [N-(n-
butyl)-thiophosphoric triamide] was found to decrease
ureolysis.[16] Thus, testing its effect on microorganism
survival via lowering the urine pH is of interest, as well
as its effect on pharmaceutical behaviour.
The aim of this study was to evaluate the effect of
urine storage of six months on selected pharmaceuticals,
which were studied as divided into three therapeutic
groups referred to as antivirals, antibiotics and anti-
tuberculotics, and as individual compounds with no
amendments. The effects of faecal contamination and
urease inhibitor to affect the compounds’ behaviour in
urine were also examined. The results obtained from
this experiment can be used to evaluate the safety
aspects of urine re-use options.
2. Materials and methods
2.1. Urine, chemicals and materials
Urine samples were collected from eight healthy volun-
teers, both male and female, receiving no medication,
while the initial pharmaceutical concentrations in col-
lected urine were not investigated. The samples were
stored in 0.5–1.0 L, sterilized polypropylene jars for a
maximum of one day (in 4°C) before they were all com-
bined and carefully mixed in a volumetric ﬂask, after
which homogenized urine was divided into 150 mL por-
tions in experimental jars. The adsorption onto polypro-
pylene jars was assumed to be negligible, since
polypropylene does not adsorb, for example, carbama-
zepine, trimethoprim or sulfamethoxazole.[17]
The eight studied pharmaceuticals (United Corpor-
ation Ltd., Kenya) were antivirals lamivudine (3TC), zido-
vudine (ZDV) and nevirapine (NVP); antibiotics
trimethoprim (TRI) and sulfamethoxazole (SMX); and
anti-tuberculotics ciproﬂoxacin (CIP) and rifampicin
(RMP), which belong to three therapeutic groups,
referred to as antivirals (3TC/ZDV/NVP), antibiotics (TRI/
SMX) and anti-tuberculotics (CIP/RMP). Carbamazepine
(CBZ) was included in this experiment as a well-studied
recalcitrant pharmaceutical reference compound.
Urease inhibitor nBPT dissolved in water-soluble
organic solvent was received as a ready-made Stabilu-
reN®-solution (Agra Group, Czech Republic). Faeces
were mixed with deionized water (MilliQ-water, Millipore;
18.2 mΩ cm conductivity) to produce a stock concen-
tration of 10 gfresh weight/L. Autoclaving, which is often
used to prevent biological activity, of the control was
not performed, since when tested it changed the compo-
sition of urine by transforming urea into ammonium.
The stock solutions of pharmaceuticals, 5.0 g/L, were
prepared in methanol, except CIP in MilliQ-water due
to low solubility in methanol. CBZ (antiepileptic) stock
solution (in methanol) was 1 g/L. Stock solutions of phar-
maceuticals were added in the sample jars to produce
concentrations (10–80 mg/L) which could be present in
source-separated urine originated from HIV and tubercu-
lotic patients (see Table 1). These concentrations were
calculated using typical pharmaceutical concentrations
used per person per day as described in WHO database,
[18] and as the literature indicates 2.7–70% of the admi-
nistered dosages of different pharmaceuticals (Table 1)
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are excreted in urine. Thus, the used concentrations illus-
trate conditions when pharmaceutical-containing urine
is not excessively diluted with urine containing no
pharmaceuticals.
2.2. Experimental set-up
The experiment consisted of the following four different
storage assays with pharmaceuticals, each performed
in triplicate (Figure 1): (1) eight pharmaceuticals were
stored separately and (2) in three therapeutic groups
(antivirals, antibiotics and anti-tuberculotics), which
were stored as such and with amendments of
(3) faeces (ﬁnal concentration of 9 mg/L, an average con-
centration shown to be present in source-separated
urine [15]) and (4) urease inhibitor (ﬁnal nBPT-concen-
tration of 2 mM, [manuscript in preparation]). In addition,
urine was stored as a control as such or with amend-
ments, but no pharmaceuticals were added (Figure 1).
All assays were performed as triplicates and altogether
60 jars were amended with 150 mL urine (jars closed
tightly with a lid) and were stored for six months in the
dark at room temperature.
The jar lids were opened once a month when samples
were taken thus resulting in the O2-depletion in the jar
head space and generating anoxic conditions before
next sampling. Sample volume was 3 mL and the total
volume of samples taken out during the experiment
was 21 mL per jar. The effect of volume reduction due
to volatilization in the jars was presumed to be small
due to tight lids.
2.3. Analyses
Before measurements and sampling (3 mL) the jars were
shaken vigorously a few times. The shaking of the sample
did not have an effect on the precipitates (remained in
the jars) and all samples taken for further studies were ﬁl-
trated (0.2 µm Nylon ﬁlter, VWR) before analysis. pH and
conductivity were measured from the sample jars; pH
with WTW 3210 pH-meter with a SenTix 41 pH electrode
and conductivity with WTW 3210 conductivity meter
with a Tetraﬂon 325 electrode.
The temperature was monitored with Data Loggers
(MSR Electronics GmbH, Switzerland) and data were ana-
lysed with MSR software (V5.12.04). The temperature was
19.5 ± 0.5 °C, (except peaks for 2–3 hours at 25°C during
ﬁve days) during six months.
Dissolved organic carbon (DOC) was determined
according to an SFS (Finnish Standard Association)
Table 1. The administered dosage (per person per day) for the selected pharmaceuticals in this study, their approximate excretion
percentages as a parent compound and the corresponding amount excreted into urine (per 1.5 L) per day.
Compound
Typical dosage (mg
d−1)a
Excretion to urine %
(unchanged)
Amount excreted in urine (mg L−1 d−1)
(1.5 L urine d−1)
Amount spiked in urine samples
(mg L−1)
Lamivudine (3TC)b,c 300 70.0 140 50
Zidovudine (ZDV)d 600 16.0 64 80
Nevirapine (NVP)e,f 400 2.7 7 10
Ciproﬂoxacin (CIP)e 1000 45.0 300 50
Rifampicin (RMP)e 600 15.0 60 70
Sulfamethoxazole
(SMX)e
320 20.0 43 50
Trimethoprim (TRI)e 1600 44.0 469 50
Carbamazepine (CBZ)g 1000 3.0 20 10
a[18], b[19], c[20], d[21], e[22], f[23], g[24].
Figure 1. Schematic of the experimental design. Pharmaceuticals
were added into urine as separate compounds and in therapeutic
groups as such and with different amendments. All 20 exper-
iments were performed as triplicate resulting in 60 experimental
jars.
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standard.[25] Urine samples, diluted with MilliQ-water
and ﬁltered through 0.45 µm prewashed syringe ﬁlter
(Nylon, VWR), were analysed with TOC-5000 analyser
(Shimadzu).
Anions (PO3−4 , SO
2−
4 , NO
−
3 , NO
−
2 ) were determined
with ion chromatography (Dionex ICS-1600) from ﬁltered
(0.45 µm nylon syringe ﬁlters, VWR) samples according to
standard SFS-EN ISO 10304–1:en.[26] The separating
column used was IonPac AS4A-SC anion exchange
column with ASRS-300 suppressor (2 mm). The eluent
was a buffer containing 1.9 mM Na2CO3 and 1.7 mM
NaHCO3.
The sum of ammonium (NH+4 ) and ammonia (NH3)
nitrogen concentrations was determined with an
ammonia-selective electrode (Thermo-Orion). The elec-
trode was calibrated with the standards of 100 and
1000 ppm solutions of (NH+4 )− N from ammonium chlor-
ide. The ionic strength-adjusting solution (Thermo-Orion)
was added to the samples and standards to convert
ammonium to ammonia. The gas-sensitive membrane
electrode measured the NH3 concentration of the sample.
Urea concentration was determined by measuring
ammonia from the sample, then adding the urease
enzyme (jack bean urease, EC 3.5.1.5, Sigma-Aldrich), and
afterwards letting the sample stand for ca. 16 hours in
room temperature, while the urease catalysed urea
decomposition to ammonia. Subsequently, ammonia was
measured and the difference between the two ammonia
concentrations equals the amount of urea in the sample.
For the analysis, 3 mL of ﬁltrated (0.2 µm Nylon ﬁlter,
VWR) sample was taken, of which 1 mL was pre-treated
for analysis and the rest was stored in the freezer (−18°
C) for LC-ESI-MS/MS. Pharmaceuticals were determined
from ﬁltrated samples, which were pre-treated with
solid phase extraction (SPE) and analysed with Hewlett-
Packard Agilent 1100 HPLC with UV detection using a
method optimized for the simultaneous detection of all
eight compounds, described by Pynnönen and Tuhka-
nen.[27] They also presented the method suitability for
the urine matrix and the recoveries for the present phar-
maceuticals as well as limit of detection (LOD) and
quantiﬁcation (LOQ) values (Table 4). The effect of
sample pH change on retention to SPE sorbent/HPLC
column was taken into account by testing pharma-
ceutical retention to the SPE sorbent in different pHs
(6–9) and constructing correction factors for different
pHs based in compound peak areas (data not shown
here). This was done as pH of the urine samples for
HPLC-analysis was not adjusted as the addition of pH-
adjusting agent into small sample volumes would have
caused sample dilution that should have been
accounted for. Monthly, the data from chromatographic
separation regarding each urine treatment were studied
and concentrations for pharmaceuticals were calculated
according to previously prepared external standards. The
HPLC-UV chromatograms were investigated to evaluate
the behaviour of the compounds during storage by
studying the parent compound peaks and screening
for peaks with similar spectra as parent pharmaceuticals.
Qualitative LC-ESI-MS/MS analysis (manuscript in prep-
aration) with the same pre-treatment as described for
HPLC-UV were used to evaluate possible transformation
products from assays as well as to verify the concen-
tration of the parent compound.
3. Results
Behaviour of eight pharmaceutical compounds during
the six-month storage of urine spiked with individually,
in therapeutic groups (antivirals, antibiotics and anti-
tuberculotics and with different amendments (faeces
and urease inhibitor) was studied using CBZ as a refer-
ence pharmaceutical. In addition, urine was stored as
such (Table 2) and with amendments. In all assays, pre-
cipitates, either solid or both solid and ﬂoating, were
visible after six months at the bottom of the jars, and
in some cases already earlier.
pH and conductivity were followed as indicators of
biological and ureolytic activity. During the six-month
storage, the pH rose up to 8.7–9.6 in urine as such and
with individual pharmaceuticals and in the groups of
antivirals and antibiotics while with group of anti-tuber-
culotics pH remained lower (7.9) (see Table 3). In the
presence of faeces, pH rise was similar or lower than
without, while the presence of the urease inhibitor miti-
gated pH rise in all three groups as well as in urine
control resulting in ﬁnal pH 7.4–8.2. Changes in conduc-
tivity followed in general, changes in pH: when pH rose
(up to 9) conductivity rose from initial ca. 9 up to 20–
25 mS/cm, while with assays where pH was lower (6.5–
8.2) conductivity remained lower as well (<15 mS/cm)
(data not shown).
The pharmaceutical concentrations in the liquid
phase were analysed once a month in all assays during
Table 2. Characteristics of fresh and six months stored urine.
Parameter (unit) Fresh urinea Stored urinea
pH 6.3 (0.0) 9.6 (0.0)
DOC (g/L)b 3.9 (0.0) 1.5 (0.0)
NH+4 + NH3 -N (g/L) 0.26 (0.02) 1.04 (0.03)
Urea (g/L) 0.89 (0.05) 0.05 (0.03)
Conductivity (mS/cm) 9.1 (0.0) 25.9 (0.3)
NO−3 (mg/L)
b 32.4 (5.6) n.d.
NO−2 (g/L)
b 0.04 (0.02) 0.77 (0.07)
PO3−4 (g/L)
b 0.93 (0.26) 0.35 (0.02)
SO2−4 (g/L)
b 1.61 (0.0) 0.91 (0.02)
Note: n.d. = not detected.
amean (± stdev), n = 3.
b
ﬁltrated samples.
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the six-month storage (Table 4). Sampling was per-
formed monthly as it was speculated that not much
difference can be observed in a shorter time span. In
all assays and with all amendments RMP concentration
reduced gradually during six months (Figure 2) below
the LOD while the other pharmaceuticals including CBZ
(Figure 2, shown as an example) exhibited 23–52%
removals and 3TC even up to 76% when incubated
alone or as therapeutic groups (Table 4). Faeces amend-
ment resulted in a similar or lower (even less than <1%)
reduction of the pharmaceutical concentrations than
without faeces. Urease inhibitor reduced the removal
of all pharmaceuticals except with CIP (Table 4).
The HPLC-UV chromatograms of monthly samples of
all ﬁve assays were screened for peaks with similar
spectra as parent pharmaceuticals to assess the presence
of the initial pharmaceuticals and/or transformation
compounds. For RMP, whose concentration reduced to
below LOD, no parent compound peak was detected in
the chromatograms (with or without different amend-
ments) after six months (small parent compound peak
was still present after ﬁve-month storage), which indi-
cated its complete removal from the liquid phase as
seen in Figure 2. As for 3TC, NVP, ZDV and TRI, no poten-
tial transformation product peaks were detected in chro-
matograms. On the contrary, anti-tuberculotic CIP
(Figure 3(a)) and antibiotic SMX (Figure 3(b)) both
produced a peak with almost similar a spectrum to the
parent compound, after three to ﬁve months depending
on amendment (additional peaks indicated with an
arrow) suggesting degradation.
In addition to HPLC-UV, a qualitative LC-ESI-MS/MS
technique was used to screen pharmaceuticals from
the assays of individual compounds after six-month
storage. The removal of RMP was conﬁrmed while also
four unidentiﬁed transformation products were
observed in assays with RMP. In addition, various trans-
formation products for CIP, SMX and 3TC were identiﬁed,
while not any transformation products for NVP, ZDV and
TRI (available in the literature) were detected (Table 4).
The qualitative analysis showed no marked differ-
ences between different amendments. For 3TC, one
degradation product was found in three amendments
while CIP had seven identiﬁed transformation products,
of which one was observed in every amendment. In
the case of SMX, one degradation product was seen in
every amendment.
4. Discussion
The present results show that storage of urine-contain-
ing pharmaceuticals for six months varies depending
on the compound and concentration reductions in the
liquid fraction of urine range from small to marked
Table 3. pH after six months of storage. Data are mean (±standard error), n = 3.
pH
Separately Therapeutic groups Faeces Urease inhibitor
Start 6 months Start 6 months Start 6 months Start 6 months
Antivirals 3TC 6.3 (0.0) 9.3 (0.2) 6.3 (0.0) 9.6 (0.0) 6.1 (0.0) 9.5 (0.0) 6.5 (0.0) 8.2 (0.1)
ZDV 6.3 (0.0) 9.6 (0.0)
NVP 6.3 (0.0) 9.5 (0.0)
Antibiotics TRI 6.4 (0.0) 8.7 (0.4) 6.4 (0.0) 9.2 (0.2) 6.2 (0.0) 7.8 (0.8) 6.5 (0.0) 7.4 (0.0)
SMX 6.3 (0.0) 9.4 (0.2)
Anti-tuberculotics CIP 6.3 (0.0) 8.9 (0.1) 6.4 (0.0) 7.9 (0.2) 6.2 (0.0) 7.4 (0.2) 6.5 (0.0) 7.7 (0.5)
RMP 6.3 (0.0) 9.4 (0.1)
Reference CBZ 6.4 (0.0) 9.6 (0.0) n.a. n.a. n.a. n.a. n.a. n.a.
Control 6.3 (0.0) 9.6 (0.0) 6.3 (0.0) 9.6 (0.0) 6.1 (0.0) 9.5 (0.0) 6.5 (0.0) 7.7 (0.0)
Note: n.a. = not available.
Table 4. Reduction of pharmaceuticals in the liquid phase after six months of storage. Data are mean (±standard error), n = 3.
‘Individually’ refers to just one pharmaceutical amended in urine.
Pharmaceutical
Reduction (%) in the liquid phase after six months
Transformation products
detected
Individually Therapeutic groups Faeces Urease inhibitor HPLC-UV LC-ESI-MS/MS
Antivirals Lamivudine (3TC) 75.6 (7.8) 51.4 (8.3) 28.9 (22.3) <1 n.d. +
Zidovudine (ZDV) 51.5 (3.7) 45.6 (0.5) <1 <1 n.d. n.d.
Nevirapine (NVP) 25.6 (6.2) 28.8 (3.1) 24.5 (2.9) 16.9 (5.0) n.d. n.d.
Antibiotics Trimethoprim (TRI) 23.7 (1.7) 40.3 (4.8) 42.0 (3.6) 18.9 (1.6) n.d. n.d.
Sulfamethoxazole (SMX) 24.0 (4.7) 32.2 (3.0) <1 <1 + +
Anti-tuberculotics Ciproﬂoxacin (CIP) 51.1 (10.6) 41.9 (27.4) 38.5 (8.5) 44.2 (19.5) + +
Rifampicin (RMP) >99 >99 >99 >99 n.d. +
Reference Carbamazepine (CBZ) 26.8 (3.5) n.a. n.a. n.a. n.d. +
Notes: For pharmaceuticals in urine [27]; LOD: 3TC 1.6 mg/L, ZDV 189 µg/L, NVP 71 µg/L, TRI 39 µg/L, SMX 115 µg/L, CIP 189 µg/L, RMP 503 µg/L, CBZ 41 µg/L.
LOQ: 3TC 5.4 mg/L, ZDV 630 µg/L, NVP 237 µg/L, TRI 129 µg/L, SMX 383 µg/L, CIP 631 µg/L, RMP 1.7 mg/L, CBZ 136 µg/L. + = transformation product detected.
n.d. = not detected. n.a. = not available.
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(from 23% to 75%) while RMP was removed >99% in all
assays. Furthermore, the potential for the formation of
transformation products, which can be also harmful, is
evident during storage. The concentration reductions
were lower with faeces amendment and the lowest
with urease inhibitor amendment. The results showed
marked reductions for some compounds but under the
studied conditions neither biological nor chemical mech-
anisms occurred to enable the complete removal of the
studied pharmaceuticals from the liquid phase (except
RMP). Thus, it appears that conditions in source separ-
ation and storage of urine do not favour the concen-
tration reduction and six-month storage as
recommended by WHO does not mean a complete
removal of the studied pharmaceutical risks. Therefore,
methods to actively decrease pharmaceutical concen-
trations in the source-separated urine should be
studied to enable its use.
Although source separation of urine is not a new
concept, there are currently only a few studies available
on pharmaceutical behaviour during urine storage,[28–
30] none of which has used the same pharmaceuticals
as the current study, except for CBZ. The concentration
reduction during 3–4-month storage of urine for CBZ
was reported to be 20–80% [28–30] and the highest
reductions for several pharmaceuticals (up to 80–90%)
were observed during pH-controlled storage (3–4
months [28]). It was discovered indicating that a low
pH facilitates concentration reduction during urine
storage. However, it was acknowledged that the length
of the storage period (3–4 months) was not enough to
completely remove the pharmaceuticals,[28] a ﬁnding
which concurred with the results presented in the
current study. In the current study, room temperature
and six-month storage were used, but parent com-
pounds were still present in urine afterwards. Varying
storage periods (from three months to a year), different
pHs (from pH 2 to 11) and temperatures (from 4°C to
38°C) have been tested, and somewhat marked effects
on pharmaceutical concentrations have been discov-
ered,[28–30] while complete removal has not been
observed. In a modern wastewater treatment system,
urine is ﬂushed to WWTPs along with the pharmaceuti-
cals, where conjugated pharmaceuticals can transform
back into their active forms by microbial metabolism
and be transported to watersheds; the transformation
can take place already in the sewer network (pressurized
sewer in anaerobic conditions, retention time 21 h [31])
where CIP was slightly degraded while SMX, TRI and
CBZ had negative removal implying a microbial or
Figure 3. Chromatograms and spectra of CIP (a) and SMX (b) after ﬁve months of storage of urine-amended individual pharmaceutical.
The additional peaks are indicated with arrows. The spectra of the additional peaks have resemblance to the original compound. Note
that the signal of SMX second peak is on the secondary axis.
Figure 2. The concentration of rifampicin (RMP, left y-axis) and
carbamazepine (CBZ, right y-axis) in monthly samples during
the six-month storage of urine with different amendments. Com-
bined refers to the results of urine amended with therapeutic
groups. The error bars represent the standard error between
three replicates.
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chemical breakdown of conjugated compounds.[31]
Source separation of urine removes this route of pollu-
tants. Yet, urine storage might not be enough to
reduce pharmaceutical risks in fertilizer use in which
case, other feasible treatment practices to enhance
pharmaceutical removal should be studied.
The complete removal of RMP, also with the two
studied amendments, was strikingly opposite to the
other seven studied pharmaceuticals. The main mechan-
ism for the removal of RMP from the liquid phase could
be biodegradation, which would be a novel ﬁnding as no
information of RMP biodegradation could be found. Bio-
logical removal was proposed, but not conﬁrmed, by the
disappearance of the RMP parent compound and
appearance of transformation products in the LC-ESI-
MS/MS analysis. Chemical degradation also produces
transformation products which cannot be ruled out.
However, as RMP is a very large molecule (823 g/mol)
compared with the other studied pharmaceuticals (a
range from 224 to 331 g/mol [27]), this is opposite to
the assumption that the smaller the molecule, the
easier it would be to degrade it. It might be, that
although pH with RMP alone rose >9, the different bac-
teria present in urine thrive at different stages and are
able to break down the compound gradually. While
RMP was similarly removed also in the presence of CIP,
and where pH remained 6.5–7.9 in all assays, the expla-
nation could be that urine contained bacteria that are
resistant to RMP/CIP but might not have ureases thus
causing lower pH. The disappearance of RMP in the pres-
ence of all amendments suggested that it is readily
biodegradable.
The concentrations of the seven other pharmaceuti-
cals reduced somewhat less indicating that neither bio-
logical nor chemical processes were sufﬁcient in
enabling the complete removal of the compounds. The
effect of antivirals and antibiotics can be seen in the
pH of the different urine assays: with antivirals, pH rose
close to or over 9 despite the urease inhibitor addition
whereas with antibiotics pH rise remained lower
(except for TRI/SMX and SMX individually, pH > 9.2). As
the pH of samples amended with faeces were similar
with urine amended with the urease inhibitor, it is poss-
ible that in the urease inhibitor assays the main affecting
factor in the pH was the urease inhibitor together with
pharmaceuticals. Therefore, in assays with faeces the
combination of two antibiotics and anti-tuberculotics
was probably still sufﬁcient in preventing bacterial
growth. The reason for the low or no (bio)degradation
could therefore also be the concentrations of antibiotic
compounds or the inhibitory effects on microbes
present in urine, as antibiotics are designed to prevent
bacterial growth. The inhibitory effect of therapeutic
groups on bacterial growth was seen, for example, as
lower pH rise with CIP and RMP, of which CIP is, in
addition to tuberculosis treatment, effective against
common bacteria found in urine, such as Proteus mir-
abilis, Escherichia coli and Klebsiella sp.[32] The aforemen-
tioned bacteria are also susceptible to TRI and SMX.[33]
In the case of antivirals, the high concentration could
lead to toxicity, but the antivirals ought not to affect
the bacteria as they are designed to stop virus infections.
Pharmaceuticals are excreted in urine in tens to hun-
dreds of mg/L (see Table 1), while in WWTPs the inﬂuent
typically contains ng/L to µg/L concentration of pharma-
ceuticals. Although these concentrations are orders of
magnitude lower than in urine, the bacteria in WWTPs
are not able to break down all of the pharmaceutical
compounds and addition to that, transformation pro-
ducts are formed, which together with pharmaceuticals
end up in the environment.[12] As inhibition is concen-
tration dependent, it is likely that the expected lower
pharmaceutical concentration in real-life urine storage
systems might enhance biological degradation;
however, no information is available on the toxicity
response of the studied pharmaceuticals. On the other
hand, the emergence of transformation products in the
LC-analysis suggested the (bio)transformation of the
pharmaceuticals and the emergence of breakdown pro-
ducts in the LC-ESI-MS/MS analysis implied the formation
of possibly more harmful products from paired com-
pounds. The environmental relevance of transformation
products is yet quite a new ﬁeld of study.[13] The degra-
dation products and their formation are currently
studied). Further determination and identiﬁcation of
the formed compounds will give indication regarding
the possibility of the compounds having more harmful
characteristics than the main compound. The removal
of the antibiotic compounds could be expected to
some extent in large-scale source-separated urine, but
the behaviour of the antiviral pharmaceuticals may
prove more problematic.
The current study showed that at least some of the
pharmaceuticals selected in this study underwent degra-
dation although only slightly, and the degradation could
either be chemically or biologically induced. Earlier
studies of pharmaceutical biodegradation using closed
bottle tests and lower pharmaceutical concentrations
have demonstrated that CIP (test concentration 5.95
mg/L [34]), SMX (3.8 mg/L [35]) and TRI (0.5 mg/L [36])
are not readily biodegradable. ZDV and NVP are also
recorded as not readily biodegradable (degraded 3–
4%), the same as 3TC, which have been found to pose
toxic effects on activated sludge (degradation −3%) (all
compounds 50 mg/L [37]). However, closed bottle tests
use low bacterial density: source-separated urine can
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support the growth of bacteria up to about 108 cfu/mL,
[38] while in closed bottle tests the recommended bac-
terial concentration ranges from 104 to 106 cfu/L.[39]
The current study used pharmaceutical concentrations
of 10–80 mg/L which are similar or higher than in pre-
vious tests, yet the bacterial density in urine was prob-
ably quite high. Thus, the biodegradability rate of these
compounds may have increased with higher bacterial
densities and the diversity of microorganisms in urine
could have increasingly affected the biodegradability,
as it was probably with SMX, which has been shown to
be degradable by bacteria in WWTPs (89% removal
[12]). Biological activity was proposed by pH increase,
but on the other hand, similar removals during storage
were observed without pH change and the conﬁrmation
of the affecting mechanisms (biological and chemical)
require more research.
The study proposed that chemical (precipitation/sorp-
tion) of the studied pharmaceuticals was low or insignif-
icant in all studied storage conditions, which was
supported by the fact that, for example, in the groups
of antibiotics and anti-tuberculotics in most assays the
pH did not rise above 8, which is considered as a
minimum pH prerequisite for the formation of struvite
precipitates, with a pH-optimum of 9.4–9.7.[40] Pre-
viously, when the coprecipitation of CBZ and other phar-
maceuticals (CBZ was the only same pharmaceutical as in
the current study) with struvite in urine was investigated,
it was proved using mass balances that the studied phar-
maceuticals remained in the solution (> 96% of CBZ).[41]
RMP was completely removed when pH was 9.4 (indivi-
dually) as well as in pH 7.4 (urease inhibitor addition),
suggesting that the precipitation with struvite was not
the major removal mechanism. Adsorption on particu-
late matter, which is abundant in source-separated
urine and was removed when samples were ﬁltrated,
was also regarded as a possibility. In practice, the role
of adsorption could differ depending on adsorption
sites in different conditions. Stability studies for the phar-
maceuticals, for example, with puriﬁed water were
chosen not to be conducted, since although they
might have given some indication of the compound
stability, ionic strength and other properties of human
urine (see Table 2) are quite different from plain water,
making comparison unequal.
Hypothesis was that the addition of faeces would sup-
plement urine with additional bacteria thus improving
compound removal. However, the results clearly
showed that faeces did not enhance pharmaceutical
removal even though they were expected to increase
microbial content in assay jars. Faeces are practically
always present in source-separated urine,[15] and it
was hypothesized that the bacteria derived from faeces
would enhance the biological removal of the com-
pounds. Thus, the results imply that pharmaceutical
removal may in fact be reduced in the presence of
faecal contamination, but the mechanism is yet to be
discovered.
It appeared that the used urease inhibitor resulted in a
low pH increase as anticipated, but it did not, however,
affect positively on pharmaceutical reduction. This indi-
cates that the mechanism in pharmaceutical concen-
tration reduction could well be biological and was
inhibited by the urease inhibitor. Originally, the hypoth-
esis was that lower pH generally enables better microor-
ganism growth thus enhancing the biological removal of
pharmaceuticals as bacterial extracellular enzymes can
break down bonds in pharmaceutical molecules. In
addition, the HPLC analysis showed that 59% of the
urease inhibitor was still present in the sample after six
months (data not shown). To our knowledge, no infor-
mation is available regarding the urease inhibitor’s
effect on bacterial enzyme activity besides ureases. The
addition of the urease inhibitor might have co-affected
the removal of compounds by preventing such activity
thus explaining the poor concentration reductions.
4. Conclusions
From the present study, we conclude that during the six-
month storage of source-separated urine
. the pharmaceutical concentration reductions ranged
from less than 1% to more than 99%: without amend-
ments reductions were for anti-tuberculotics 41.9–
99%; for antivirals <52% (except with 3TC 75.6%)
and for antibiotic compounds <50%.
. in assays with amendments, the reductions were all
<50% (except with RMP >99%). Transformation pro-
ducts were detected for 3TC, CIP and SMX, but the
parent compounds were still present in urine after
six months.
. RMP concentration reduced to below LOD in all assays
and four unidentiﬁed transformation products were
detected.
. faeces and urease inhibitor amendments resulted in
similar or lower reduction than without them which
was contradictory to the anticipation that the bacterial
activity should increase and therefore improve
concentrations reductions. The urease inhibitor
prevented ureolysis and subsequent pH rise, but did
not enhance pharmaceutical concentration reduction.
. biological activity was proposed by increased pH
during storage, but similar removal during storage
was observed without pH change. Thus, the
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conﬁrmation of the affecting mechanisms (biological
and chemical) requires more research.
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ABSTRACT
Our aim was to study the biomass growth of microalga Chlorella vulgaris using diluted human urine
as a sole nutrient source. Batch cultivations (21 days) were conducted in ﬁve different urine dilutions
(1:25–1:300), in 1:100-diluted urine as such and with added trace elements, and as a reference, in
artiﬁcial growth medium. The highest biomass density was obtained in 1:100-diluted urine with
and without additional trace elements (0.73 and 0.60 g L−1, respectively). Similar biomass growth
trends and densities were obtained with 1:25- and 1:300-diluted urine (0.52 vs. 0.48 gVSS L−1)
indicating that urine at dilution 1:25 can be used to cultivate microalgal based biomass.
Interestingly, even 1:300-diluted urine contained sufﬁciently nutrients and trace elements to
support biomass growth. Biomass production was similar despite pH-variation from < 5 to 9 in
different incubations indicating robustness of the biomass growth. Ammonium formation did
not inhibit overall biomass growth. At the beginning of cultivation, the majority of the biomass
consisted of living algal cells, while towards the end, their share decreased and the estimated
share of bacteria and cell debris increased.
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1. Introduction
Microalgae have been studied extensively for production
as feedstock for bioenergy and biofuels (for reviews and
discussion, see [1–4]). More sustainable cultivation of
microalgal biomass can be achieved if the nutrients are
obtained from recycled resources or waste materials.[5–
7] Source separated urine is one possible waste-derived
nutrient source for microalgae, as large amounts of nitro-
gen (25–35 g d−1 per person) and phosphorus (2–2.5 g
d−1 per person) are excreted into human urine although
N and P produced by an individual per day are highly
dependent on the person and the diet.[8] The production
rate of urine has been estimated to be 0.6–2.5 L person−1
d−1.[8] Decentralized sanitation concepts where waste-
water is source separated and collected for use have
gained more attention. They provide an alternative to
recycle the nutrients in urine and can be considered to
promote sustainable sanitation practices in some cases
compared with centralized wastewater treatment
systems.[9] The advantage of growing microalgae on
urine is that they both treat urine by removing nitrogen
and phosphorus from it and also produce high yield of
biomass [10] which can be used in the production of,
for example, biofuel applications.
The cultivation of microalgae in human urine has only
recently started to gain more interest and not many
studies are available that use real, non-sterilized urine.
In algal cultivations with urine, the presence of bacteria
(originated from urine) which might have a major
impact on algal growth has neither been explicitly
reported nor studied. In addition, to our knowledge
microalga Chlorella vulgaris, which is considered a prom-
ising strain in biotechnology applications, has not been
previously used in algal growth experiments with urine
as a nutrient source. The growth of different microalgae
in real and synthetic human urine has previously been
studied using cyanobacterium Spirulina platensis [11,12]
and microalgae Chlorella sorokiniana [13,14] and
Scenedesmus acuminatus.[15] For example, Tuantet
et al. [14] grew C. sorokiniana in 1:2–1:3-diluted human
urine to produce biomass and obtained a high biomass
productivity of 9.3 g L−1 d−1 (per reactor volume) with
a continuous reactor design. All of the studies have
demonstrated microalgae’s ability to use nutrients (nitro-
gen and phosphorous) from urine. Interestingly, when
using real human urine, cultivations have been inocu-
lated with algae and supplemented with non-sterilized
urine which most likely leads to bacterial contamination
of the cultivations. A large variety of bacteria have been
detected from C. vulgaris cultures grown on both steri-
lized and non-sterilized artiﬁcial growth media,[16,17]
emphasizing the fact that bacteria have likely been a sig-
niﬁcant part of algal cultures grown on urine.
Production of nitrogen fertilizer has been noted as an
important ﬁnancial and a sustainability factor in microal-
gal cultivations and its effect on chemical biomass
© 2015 Taylor & Francis
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composition has been investigated in many publications.
Different nitrogen sources (ammonium, nitrate and urea)
have been studied for cultivating different microalgae.
[10,18] Most of the nitrogen in urine is originally in the
form of urea (∼85% [8]), which however, during
storage of urine, is hydrolysed resulting in the release
of ammonium and ammonia. Hulatt et al. [18] showed
that cultivation of Chlorella vulgaris with medium con-
taining urea as the nitrogen source had a slightly
higher maximum biomass growth rate and yield than
with nitrate, while no growth occurred with ammonium.
The reason for latter was that ammonium utilization
caused a signiﬁcant decrease in culture pH (from 6.8
to 4) and resulted in the cessation of C. vulgaris
growth. However, according to tests conducted by
Schuler et al.,[19] C. vulgaris prefers ammonium over
nitrate as the nitrogen source suggesting that urine
would make a preferable nitrogen source in algal cultiva-
tions. In previous studies,[10,11,14,15] microalgal growth
in diluted human urine has been studied successfully
using additional trace elements to enhance growth,
which has raised a research need regarding growth
without trace element supplementation to produce
algal biomass more sustainably and cost-efﬁciently.
To promote further studies on the realization of micro-
algal cultivation in source separated urine, at least two
types of scenarios for full-scale systems can be specu-
lated. The ﬁrst scenario would entail quite concentrated
urine diluted with water [13,14] with high light intensities
(>1000 µmol photons m−2 s−1) and a continuous reactor
design with CO2 and trace elements additions to sustain
growth. In the second scenario more diluted urine (e.g.
dilution 1:25) would be used [10,11,15] in batch mode
without CO2 and trace element addition, and at low illu-
mination. It can be speculated that the second scenario
would be more economical as in the ﬁrst scenario the
additions would increase costs, energy requirements
and environmental impacts. On the other hand, these
impacts could be compensated at least partly by the
increased biomass productivity. Thus, case-related econ-
omic and life cycle analyses (LCA) should be used to
enable more conclusive comparison. To our knowledge,
LCA of cultivation of microalgae on source separated
(hydrolysed) urine is only shortly discussed while LCAs
on algae cultivation on wastewaters has recently been
reported [20,21]; thus, an economic comparison of the
two scenarios is not possible at the moment. In practice,
several factors affect the realization and localization of
these kind of systems such as the scale of the system
(urine volume, etc.), availability of light, dilution water
and CO2,[22] and required reactor structures as well
availability of land. Furthermore, algal cultivation is
only part of the system and both processes would
require biomass harvesting, processing and utilization
as well as ﬁnal treatment of the diluted urine.
Based on the second scenario presented above, the
aim of this study was to evaluate the biomass growth
of microalga C. vulgaris using diluted human urine as a
sole nutrient source. The hypothesis was that
C. vulgaris can grow in diluted human urine without
trace element additions, and thus the trace element
addition, CO2 supplementation and high degree of
culture optimization could be avoided. Urine used in
the experiments was not autoclaved and thus contained
bacteria. No CO2 addition was used and the illumination
was kept low to study the growth in less optimized con-
ditions. First, C. vulgaris was cultivated in 1:100-diluted
urine as such and with trace elements and as reference
in artiﬁcial growth medium with nitrate as the nitrogen
source. Subsequently, the effect of urine dilution on
algal growth was studied. The experiments included
the analysis of total biomass as dry weight (algae and
bacteria) and algal cell count to reveal the share of
living algae of the total biomass (referred to as microbio-
logical composition). To our knowledge, the microbiolo-
gical composition of biomass grown in human urine has
not been previously studied. Yet, it is of particular inter-
est regarding biomass utilization options, for example,
anaerobic digestion.
2. Materials and methods
2.1. Microalga, maintenance and urine
C. vulgaris (SAG 211-11b) was obtained from the Culture
Collection of Algae (SAG) at the University of Göttingen.
Maintenance cultures and two inoculum cultures of
C. vulgaris were grown in modiﬁed Chu-10 medium,[23]
where Na2SiO3, H2SeO3, Na2EDTA and citric acid were
left out as they were not required for growth of
C. vulgaris. Chu-10 medium was chosen as the reference
medium (to compare algal growth in urine vs. artiﬁcial
medium) since Ilavarasi et al. [24] compared ﬁve different
typical microalgal growth media for the cultivation of
C. vulgaris (Modiﬁed Hoagland’s medium, Bold’s Basal
medium, Acidiﬁed Bold’s Basal medium, Half strength
Chu-10 medium and BG 11 medium) and reported the
highest biomass production using half strength Chu-10.
Themodiﬁed Chu-10medium for themaintenance cul-
tures and inoculum growth was prepared in MilliQ-water
and contained (mg L−1): Ca(NO3)2 × 4H2O (57.56), K2HPO4
(10.0), MgSO4 × 7H2O (25.0), Na2CO3 (20.0), FeCl3 × 6H2O
(1.334), H3BO3 (2.86), MnCl3 × 4H2O (1.81), ZnSO4 × 7H2O
(0.222), CuSO4 × 5H2O (0.79), Na26MoO4 × 2H2O (0.39),
Co(NO3)2 × 6H2O (0.0494) and vitamins – thiamin B1
(0.2), biotin B7 (0.001) and cyanocobalamin B12 (0.001).
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The total concentrations of N and P in the modiﬁed Chu-
10 medium were 0.49 and 0.06 mM, respectively. The pH
of the medium was set to 6.4 with 1 M HCl and the
medium was sterilized by autoclaving. Maintenance cul-
tures were transferred into fresh sterile medium at four-
week intervals to maintain the culture. Maintenance cul-
tures were grown in 250 mL Erlenmeyer shake ﬂasks at
135 rpmmixing, 24 ± 1.0°C and under a constant illumina-
tion of 29 µmol photons m−2 s−1 (5 ﬂuorescent OSRAM L
18W/965 Biolux-lamps, light intensity measured with a
DeltaOHM HD 9221 lux meter). This light intensity is rela-
tively low, but light intensities of similar magnitude (39–
70 µmol photons m−2 s−1) have successfully been used
for microalgal cultivation.[15,25,26] No air or CO2 was
added to the cultivations by sparging. The only source
of carbon was the surrounding air, the introduction of
which to the cultures was enhanced by shaking of the cul-
tures. No CO2 addition was used since our previous ﬁnd-
ings have demonstrated that the culture pH with the
fresh water strain C. vulgaris is markedly lower when
CO2-enriched air is fed to the cultures, unless the culture
medium is well buffered.[17]
Two inoculum cultures (to grow sufﬁcient amount of
inoculum) of C. vulgaris were grown in 500 mL of modi-
ﬁed Chu-10 medium in similar conditions as the main-
tenance cultures. The urine used in the experiments
was collected from a healthy male volunteer receiving
no medication. Two different batches of urine were
used, one for each experimental set-up (Table 1).
2.2. Growth experiment set-ups
Two experimental set-ups were used: in set-up I different
growth media were compared and in set-up II different
urine dilutions were studied. Both growth experiments
were conducted in 1 L Erlenmeyer ﬂasks for 21 days in
similar conditions (mixing, temperature and light
intensity) as the cultures used as inoculum. Experiments
were conducted as triplicate (set-up I) and duplicate (set-
up II), as is typically done in microalgal studies employing
batch cultivations.[12,15] The temperature was 25.5 ±
1.3°C during set-up I and the dissolved oxygen (DO)
varied between 7.9 and 9.5 mg L−1 (saturation 96.7–
106.9%). The temperature in set-up II was 24.2 ± 1.4°C
and DO varied between 7.9 and 9.3 mg L−1 (saturation
95.6–109%). To inoculate the experimental cultures, an
aliquot (60 mL) was harvested during the exponential
growth phase from the inoculum cultures into 600 mL
of selected experimental growth medium.
In set-up I, C. vulgaris was grown in three media (i–iii)
having the concentrations of Ntot and Ptot 5.0 mM (70.6
mg L−1) and 0.2 mM (6.4 mg L−1), respectively (N:P ratio
of 25:1). The growth media were (i) 1:100-diluted urine
(C:N 0.15), and as reference (ii) 1:100-diluted urine with
trace elements from Chu-10 medium (referred to as
‘urine+TE’, C:N 0.75) and (iii) modiﬁed Chu-10 medium,
where the concentrations of Ntot and Ptot were adjusted
to match that of 1:100-diluted urine (an additional
amendment of Ca(NO3)2 × 4H2O and K2HPO4 to obtain
the Ntot and Ptot concentrations corresponding to the
levels of 1:100-diluted urine, C:N 0.83). This adjustment
was done to ensure a similar concentration of N and P
in all cultures. The pH of all three media preparations
was adjusted to pH 6.4 with 1 M HCl after which the
media were autoclaved without urine present, after
which urine was added in relevant shake ﬂasks.
In set-up II, the effect of urine dilution was investi-
gated. C. vulgaris was grown for 21 days in urine dilutions
of 1:25 (C:N 0.74), 1:75 (C:N 0.76), 1:100 (C:N 0.88), 1:150
(C:N 1.2) and 1:300 (C:N 1.3). The pH of MilliQ-water
used for diluting the urine was adjusted to pH 6.4 with
1 M HCl to correspond the pH-adjustment in set-up I
before autoclaving. Urine was added after autoclaving
of the MilliQ-water into each ﬂask to obtain relevant
dilution.
2.3. Analyses and calculations
DO was measured using a WTWMultiline P3 meter with a
WTW CellOx 325 electrode and pH was measured using a
WTW 3210 pH-meter with a SenTix 41 pH-electrode.
Optical density (OD) was determined by measuring
absorbance at 600 nm using a Shimadzu UV-1700 Phar-
maSpec spectrophotometer. OD measurement was
used to calculate the growth rate since it required only
small sample volume. If necessary, the samples were
diluted with MilliQ-water to give OD below 1. Growth
rate was calculated as µ = (ln N2−ln N1)/(t2−t1), where
N1 is the OD at time t1 and N2 is OD at t2. Calculations
were based on the following: In set-up I, OD increased
Table 1. The characteristics of undiluted urine used in the two
experimental set-ups.
Urine composition (as mg L−1 where appropriate) Set-up I Set-up II
pH 5.8 5.7
Ntot 6800 4320
NO3
−–N <5 <2
NO−2 -N <1 <1
NH+4 -N 520 275
Norg 6275 4042
Ptot 670 355
DOC 4830 2405
Fe
a
<1 n.a.
Mg 50 n.a.
Ca 77 n.a.
Na 710 n.a.
K 717 n.a.
Note: n.a. = not available.
aBelow AAS detection limit.
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from 0.099 to 0.640 (days 0–5) in modiﬁed Chu-10; from
0.074 to 1.15 (days 0–9) in urine+TE; from 0.067 to 0.762
(days 0–9) in 1:100-diluted urine. In set-up II, OD
increased from 0.086 to 1.26 (days 0–7) in 1:25; from
0.085 to 0.93 (days 0–7) in 1:75; from 0.53 to 1.46 (days
11–16) in 1:100; from 0.086 to 0.408 (days 0–7) in
1:150; from 0.081 to 1.18 (days 0–7) in 1:300.
Volatile suspended solids (VSS) were determined by
ﬁltering a measured volume of culture solution through
a glass ﬁbre ﬁlter (Whatman GF/A), followed by drying
the ﬁlter at 105°C for 20 h and igniting it at 550°C for
2 h. Assumption was that VSS measures the algal
biomass and the dead algal cells and bacteria present
in the cultures. Algae cell counting (including only
intact algal cells) was performed with phase contrast
microscopy (Zeiss Axioskop 2) using a Thoma counting
chamber (0.02 mm depth, Fischer Scientiﬁc). However,
a slight uncertainty to algal biomass calculations comes
from the fact that at the midpoint of the cultivation
(around days 7–11), in all dilutions but most visibly in
1:100-diluted urine (in set-up II), the algal cells formed
larger clumps, that could not be enumerated in cell
counting thus decreasing the calculated cell concen-
tration. This is not, however, believed to have a signiﬁ-
cant effect on the share of algae in the cultivations
(max. 10% by rough estimation). The algal cell count
was converted to VSSalgae by multiplying average algal
cell count with an average C. vulgaris cell mass of 25.7
pg [27] to estimate which part of the total biomass
(VSS) was composed of algae. By using this value in cal-
culations, it was conﬁrmed that the algal cell weight was
not underestimated, as other cell masses found in the lit-
erature for C. vulgaris in different growth phases and
experimental set-ups were lower than the average
reported by de-Bashan et al.[27] The fraction of bacterial
biomass and dead algal cells was calculated as VSS-
VSSalgae. The method for calculating VSSalgae was the
same as previously used by Perez-Garcia et al. [25] to esti-
mate dry weight of C. vulgaris in batch cultivations.
Measurements of proteins, lipids and hydrocarbons
from the produced biomass were out of scope of this
study. Previous study [18] has demonstrated that lipid
and protein content at different stages of C. vulgaris’
growth are not markedly affected by the nitrogen
source, which is why the effect of urea as the nitrogen
source on cell composition was not examined further.
Ion chromatography (IC, Dionex ICS-1600) was used to
determine the anions of interest (PO3−4 , NO
−
3 , NO
−
2 ) from
the ﬁltered (0.45 µm nylon syringe ﬁlters, VWR) culture
samples. The separating column applied was an IonPac
AS4A-SC anion exchange column with ASRS-300 sup-
pressor (2 mm). The eluent used was a buffer containing
1.9 mM Na2CO3 and 1.7 mM NaHCO3. Analysis of the
samples was done according to the ion chromatography
standard SFS-EN ISO 10304–1:en.[28]
Fe, Na, K, Mg and Ca were analysed from urine with an
atomic adsorption spectrophotometer (AAS) AA200 ana-
lyser (Perkin Elmer) and air acetylene ﬂame. The ﬁltered
samples were diluted at ratios ranging from 1:10 to
1:1000 with MilliQ-water using acid washed glassware.
A 5% (v/v) CsCl–LaCl solution (10 g L−1 CsCl + 100 g
L−1 La, Merck) was added to the samples of which Ca
was analysed to stop the formation of substances
which inhibit Ca atomization. Fe analysis was performed
from samples diluted in 0.07 M HNO3 to prevent iron oxi-
dation. The analysis was done according to the SFS stan-
dards 3018 [29] and 3044 [30].
Dissolved organic carbon (DOC) was determined
using a Shimadzu TOC-5000 Analyzer according to the
Finnish standard SFS-EN 1484:en [31] from ﬁltered
samples. Total phosphorus (Ptot), ammonium nitrogen
(NH+4 -N) and total nitrogen (Ntot) were analysed from ﬁl-
tered samples using HACH Lange cuvette tests and
HACH spectrophotometer DR 2800. The organic nitrogen
(Norg) in the samples was calculated by subtracting the
concentrations of NO−3 -N, NO
−
2 -N and NH
+
4 -N from Ntot.
The C:N ratios at the beginning of the cultivations (day
0) were calculated from the DOC and Ntot concentrations
to provide insight on the culture conditions. The C:N ratio
has been shown to have a signiﬁcant effect on lipid pro-
duction at least with heterotrophic microorganisms.
3. Results and discussion
3.1. Biomass growth
Growth of biomass in C. vulgaris-inoculated cultivations
were studied in 1:100-diluted urine and as a reference
in 1:100-diluted urine with additional trace elements
from Chu-10 medium and in Chu-10 medium with artiﬁ-
cial N and P (Figure 1(a)) as well as in different urine
dilutions (1:25, 1:75, 1:100, 1:150 and 1:300, Figure 1(b)
and 1(c)).
The biomass growth, measured as VSS thus including
both living and dead algae and bacteria at least in
cultivations containing urine (in both set-up I and II),
followed similar growth rates and ﬁnal biomass concen-
trations (0.5–0.6 gVSS L−1, Table 2) for all urine dilutions
as well as for all reference cultures. Somewhat higher
VSS concentrations were obtained with 1:100-dilution
(Figure 1(b)) and urine+TE (Figure 1(a)), and slightly
lower with 1:300-diluted urine (Figure 1(c)).
Based on algal counts (set-up II), which in maximum
ranged from 8.0 × 106 to 6.0 × 106 cells mL−1 (dilutions
1:25–1:300), living algae dominated the biomass for the
ﬁrst 5–15 days in the incubations contributing about
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50–100% of the biomass (in 1:100-dilution <30%, Figure
1(b)) after which the concentration of living algal cells
stabilized while total VSS continued to increase. At the
end of the incubations (day 21), the estimated portion
of microalgae was less than 40% of the VSS in all
dilutions (Figure 1(b) and 1(c)). However, it should be
taken into account that this algal dry weight is only an
estimate. It is acknowledged that the algal cell weight
varies depending on the growth phase.[32]
The high share of algal VSS in the beginning of the
cultivation (Figure 1(b) and 1(c)) suggests that in the
beginning the conditions at all urine dilutions favoured
microalgal growth while in the course of incubation, bac-
teria became more competitive and also the portion of
dead algal cells increased. The trend was clear even
though the share of algae in the biomass may be some-
what underestimated due to clump formation which
complicated cell counting. This is not believed to have
a signiﬁcant effect on the estimated share of algae in
the cultivations. Clump formation in algal cultivations
in the presence of bacteria and their extracellular poly-
meric substances has been previously reported.[33] In
addition, the intracellular substances released by dead
algae might have affected clump formation. These are
likely reasons for clumping observed in the present
study, since clump formation coincided with the begin-
ning of the stationary phase in algal growth (Figure 1
(b) and 1(c)) and increasing share of bacteria in the
biomass. The growth in 1:100-diluted urine was com-
pared with other dilutions unexpectedly poor in both
replicates in set-up II, which cannot be explained.
The percentage of living algae of the produced
biomass was larger in less diluted urine (1:25 and 1:75,
Figure 1(b)) although it could be assumed that in that
case also the amount of added bacteria was the
largest. The use of less diluted urine seems to be the
most beneﬁcial to microalgal growth since the nutrients
are the most abundant and the algal biomass growth
rate is the highest. This deduction is also supported by
results of Tuantet et al.[14] who concentrated on the
optimization of C. sorokiniana cultivation in photobior-
eactors with a very short light path using, for example,
trace mineral additions.
As the microalgal and bacterial growth (VSS) was
almost similar in all urine dilutions (Figure 1(a) and 1(c)),
and VSS was similar when comparing 1:100-diluted
urine with Chu-10 medium, it seems that all cultivation
media sufﬁciently contained elements for the growth of
algae and/or bacteria. For example, the 1:300 and 1:25-
dilutions (Figure 1(b) and 1(c)) resulted in similar ﬁnal
VSS concentrations (0.48 vs. 0.52 gVSS L−1, Table 2)
suggesting that the used culture conditions were poss-
ibly growth limited either by light or by CO2 rather than
nutrients. After the initial growth of algae, their further
growth was likely constrained by the limited CO2 avail-
ability or light transfer (29 µmol photons m−2 s−1) due
to increasing biomass concentration (microalgal VSS
remained a little lower than 0.3 gVSS L−1 even at the
lowest urine dilution, Figure 1(c)) or different kinetics of
algae and bacteria. Apparently the dead algal cells,
which were also observed through microscopical obser-
vations (‘empty shells’), released substrate/carbon for
the growth of bacteria in the course of the incubations
and are also present in the biomass portion not consisting
of living algal cells.
Figure 1. Biomass production as VSS in (a) set-up I using 1:100-
diluted urine, urine+TE and Chu-10, and as VSS and calculated
VSSalgae (b) in set-up II with urine dilutions 1:25, 1:75 and
1:100, and (c) urine dilutions 1:150 and 1:300. The error bars rep-
resent the standard error of three (a) and two (b, c) replicates.
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In previous studies on the cultivation of microalgae
in human urine,[10,11,15] the microbiological compo-
sition in the biomass has not been investigated (Table
3); cultivations were inoculated with microalgae and it
was assumed that the obtained biomass consisted of
algae only. In the current study, the colour of the culti-
vations was dark green typical for algae cultivations;
however, it did not ensure that only algae were
present. Biomass growth in previously mentioned
studies has been measured with OD and dry weight
(biomass ﬁltered and dried overnight at 105°C), which,
to our knowledge measure, both living and dead
algae and bacteria. In the previous study performed
by Tuantet et al. [14] on algal growth in urine, the
observed 71% COD removal was reasoned to be due
to bacterial presence, while the concentration of bac-
teria was not estimated, for example, by microscopy
examination, cell counting or molecular biology
methods. However, Chlorella is capable in growing het-
erotrophically by using DOC,[34] but the presence of
dissolved organic substrates likely leads to increased
competition with other microorganisms, for example,
bacteria,[25] which is probably one of the reasons for
low algal biomass in this study.
The source for bacteria in cultivations is obvious as
urine contains bacteria, whose presence was microscopi-
cally conﬁrmed in this study. The presence of bacteria in
the urine containing growth medium was not prevented,
for example, by autoclaving since it was found that auto-
claving enhanced the urea transformation to ammonium
thus signiﬁcantly changing the urine composition. In
addition, it was deemed that sterilization of urine
would not be possible in a real scale process utilizing
urine due to the high costs and energy requirement of
autoclaving. The avoidance of bacterial growth, in fact,
is not needed if the produced biomass is considered
for methane production, as previous research has
shown that the biomass consisting of bacteria and micro-
algae can give even higher methane yields than pure
microalgal biomass. For example, Lü et al. [35] showed
that in batch system 17–24% higher methane yields
(376 to 403 mL CH4·gVS
−1) were obtained from
Table 2. Results from C. vulgaris growth experiments.
Reduction percentage (%)
µ (d−1) Biomass (gVSS L−1)b Biomass productivity (gVSS L−1 d−1)bNtot Ptot NH4
+-Na Norg
a
Chu-10 33 >99 −128 −11 0.37 0.53 (0.02) 0.06 (0.02)
urine+TE 45 >99 92 45 0.31 0.73 (0.08) 0.08 (0.03)
1:100-diluted urine 57 94 −86 70 0.27 0.59 (0.04) 0.06 (0.03)
1:25 40 35 −366 71 0.38 0.52 (0.11) 0.06 (0.03)
1:75 55 54 −166 80 0.34 0.57 (0.02) 0.07 (0.03)
1:100 74 80 −70 84 0.20 0.60 (0.03) 0.07 (0.04)
1:150 77 84 25 80 0.35 0.57 (0.04) 0.06 (0.03)
1:300 79 92 42 81 0.38 0.48 (0.01) 0.05 (0.03)
Note: The reduction percentage of the main nutrients describes to what extent it was used. µ is the speciﬁc growth rate of the algae, biomass describes the
biomass concentration in the end of the experiment and the average biomass production (calculated from days 0 to 21) represents the biomass produced
on a daily basis.
aNegative value means that nutrient was released from the microorganisms.
bMean (standard error).
Table 3. Comparison of culture conditions and biomass production in this study and other microalgal cultivation studies conducted
using human urine.
Alga Substrate Cultivation conditions
Biomass
(g L−1)
Biomass growth
measured
Microorganism
composition
determined Reference
C. sorokiniana 1:3-Diluted
urine
Continuous ﬂat plate reactor, short light path (10 mm)
CO2, Mg, Fe supplementation, antifoaming agent
addition, N and P optimization, 1550 µmol photons
m−2 s−1
15.4 Optical density no [14]
S. platensis 1:120-
Diluted urine
1.2 L Photobioreactor (batch), CO2 supplementation,
2000 µmol photons m−2 s−1 a
0.81 Optical density no [10]
S. platensis 1:180-
Diluted urine
1.2 L photobioreactor (batch), CO2 supplementation,
2000 µmol photons m−2 s−1 a
2.32 Dry weight
chlorophyll
no [11]
S. acuminatus 1:50-Diluted
urine
Batch bottles (200 mL), Mg, Fe supplementation, 39–
47 µmol photons m−2 s−1
0.16b Optical density dry
weight
no [15]
C. vulgaris 1:25–1:300-
Diluted urine
Batch bottles (600 mL), 29 µmol photons m−2 s−1 0.60 Optical density dry
weight
Microscopical cell
enumeration
Yes This study
a444.4 W m−2 converted to µmol photons m−2 s−1 using a conversion factor of 1 W m−2 = 4.5 µmol photons m−2 s−1.
bCalculated. The author converted dry weight to million cells mL−1 (115 mg dry weight·L−1 = 1 × 106 cells mL−1).
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biomass containing both algae (C. vulgaris) and bacteria
(1–10%) than biomass containing only algae.
In this study, the obtained biomass production
rates (0.05–0.07 g L−1 d−1, µ 0.20–0.38 d−1) and ﬁnal
biomass concentrations 0.48–0.60 gVSS L−1 (diluted
urine, Table 2) were in line with other algal growth exper-
iments reported in the literature, although not especially
high. Lam and Lee [26] obtained 0.29–0.51 g L−1 biomass
and µ of 0.23–0.27 d−1 in a 12-day cultivation period
using organic fertilizer medium, continuous aeration
with compressed air and light intensity of 60–70 µmol
photons m−2 s−1. A biomass production rate of 0.05 g
L−1 d−1 and maximum biomass concentration of 0.53 g
L−1 were obtained when C. vulgaris was grown on urea
in a column photobioreactor at a light intensity of 225
µmol photons m−2 s−1.[18] However, in that study, the
concentration of nitrogen (urea) was kept low (1.33 mM)
to induce lipid accumulation inside the cells and this
can have slowed down the growth. Higher biomass con-
centrations (15.4 g L−1) have been obtained on urine sup-
plemented with trace elements using high light intensity
(490–1550 µmol photons m−2 s−1) in laboratory scale
(∼1 L) with a continuous reactor design (Table 3, [14]).
However, the design of the reactor and process
conditions, including the addition of trace elements, dif-
fered from the present experimental design, making the
comparison of biomass production and scalability of the
systems inequitable.
Availability of trace elements is considered a potential
limiting factor when cultivating algae with urine. The
addition of trace elements such as iron and magnesium
was shown to improve biomass production in human
urine.[13,14] The present studied urine+TE medium
also contained added vitamins, magnesium and iron.
Undiluted urine contains more magnesium and approxi-
mately the same concentration of total iron as Chu-10
(Table 1). Dilution of urine and thus decreased trace
element concentrations did not affect overall biomass
growth in this study. The lower concentration of trace
elements may have led to bacterial dominance in the cul-
tures because there may not have been enough mag-
nesium or iron to support the growth of
photosynthetic algae, which require these elements, for
example, for the production of chlorophyll and photo-
synthetic enzymes. However, when comparing biomass
growth in 1:100-diluted urine without additional vita-
mins and trace elements (set-up I) with modiﬁed Chu-
10 medium, it was demonstrated that urine without
any additional vitamins or trace elements can sustain
microalgal growth.
3.2. pH and DOC
In all cultures, the starting pH was 6.2–6.6 (Figure 2(a)
and 2(b)) from which in urine dilutions 1:25–1:100 the
pH increased after an initial drop (5–6) up to 8–10
within 5–10 days while some decrease towards the end
of the incubation was seen (Figure 2(b)). Contrary to
those, pH remained lower (5–6) during the whole incu-
bation time with higher urine dilutions (1:150–1:300,
Figure 2(b)) and with urine+TE (Figure 2(a)). The fact
that biomass growth was similar during the cultivations
even though pH varied greatly between different cultiva-
tion batches indicates the robustness of the biomass pro-
duction since the growth was not limited by the culture
pH. The decreased pH at the beginning of cultivations
with urine (Figure 2(a) and 2(b)) was apparently due to
ammonium uptake by algae, which results in H+ pro-
duction lowering pH.[36] This is supported by the obser-
vation that no such decrease was seen in Chu-10
medium since nitrogen was added as nitrate and in
higher dilutions, in which the starting concentration of
ammonium was quite low. The increased pH in the culti-
vations after a few days was likely due to algal assimila-
tion of HCO−3 via photosynthesis.
Plummeting pH values have been detected in the
batch cultivation of C. vulgaris grown with ammonium
Figure 2. Cultivation pH: (a) set-up I with 1:100-diluted urine,
urine+TE and Chu-10 medium, (b) set-up II with different urine
dilutions. The error bars represent the standard error of (a)
three and (b) two replicates.
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in a photobioreactor where low pH (drop from pH 6.8 to
less than 4) resulted in the cessation of algal growth,[18]
while the growth-limiting pH for C. vulgaris has been
reported to be 3.5–4.5.[37] Urea uptake by algae
should not affect the pH.[36] Some bacteria that
inhabit the urinary tract produce ureolytic enzymes
[38] which during the storage of urine increase the pH
up to 9 leading to urea transformation into ammonium.
Since urine amended was not sterile, the ureolytic
activity of bacteria present in the urine has likely
caused the release of ammonium which may also have
increased the cultivation pHs.
The initial DOC (Figure 3(a) and 3(b)), which originated
from the inoculum and the urine, ranged between 8.4
and 114 mg L−1 and was the highest with the highest
urine concentration. DOC in 1:25-diluted urine decreased
throughout the experiment, while the DOC in the other
four dilutions began to rise after 10 days. The DOC in
1:100-diluted urine rose 60%, whereas in the urine+TE
it remained unchanged (Figure 3(a)). After the microalgal
growth reached its peak based on algal cell counts, DOC
seemed to follow VSS in cultures with urine diluted 1:75
or more (Figure 1(b) and 1(c)). This was probably due to
the decay of algal cells, which was followed by enhanced
bacterial growth. In 1:25-diluted urine, the concentration
of DOC originated from urine (Figure 3(b)) was so high
that the DOC released by C. vulgaris could not be
detected.
3.3. Nutrient effects
Dissolved Ptot concentration (Figure 4(a) and 4(b))
decreased in 5–11 days below 50 µg (detection limit)
in modiﬁed Chu-10 medium and in urine+TE and in
1:300-diluted urine while with less diluted urine, Ptot
also decreased until day 11, but after that remained
unchanged. In 1:25-diluted urine ﬁnal Ptot concentration
was 9.4 mg L−1 (Table 2, Figure 4(b)). The different evol-
ution of Ptot for the two 1:100-diluted urine in the two
set-ups (Figure 4(a) and 4(b)) is likely due to the differ-
ences in the urine as in set-up I, for example, phos-
phorus concentration was almost double to that of
set-up II (Table 1). Based on the algal cell counts,
decreasing Ptot concentration in the cultivations fol-
lowed the algal growth (Figure 4(b)). When the algae
cell counts reached a stationary phase, the Ptot con-
sumption also slowed down. Thus, the algae might
have utilized phosphorus in their growth in the station-
ary phase and the dead algae might have released
phosphorus for the bacteria to utilize (Figure 4(b),
Figure 3. Dissolved organic carbon (DOC) in set-up I (a) and set-
up II (b) at different urine dilutions. The error bars represent the
standard error of three (a) and two (b) replicates.
Figure 4. Phosphorus utilization (Ptot). (a) set-up I with 1:100-
diluted urine, urine+TE and Chu-10 medium, (b) set-up II with
different urine dilutions. The error bars represent the standard
error of (a) three and (b) two replicates.
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around day 12). It appears that Ptot did not limit the
overall biomass production as VSS continued to increase
(Figure 1(b) and 1(c)). Most microalgae can grow even at
as low concentrations as 50 µg L−1 phosphorus.[39]
However, in the present study, overall biomass was
not composed of algae alone.
In cultivations with urine, Ntot (dissolved, Figure 5(a)
and 5(d)) was initially mainly Norg while with Chu-10
medium nitrogen was added as nitrate (Figure 5(b)).
During the cultivations, Ntot concentration (and calcu-
lated Norg by subtracting other nitrogen compounds
from Ntot) reduced in all dilutions likely due to algal
assimilation of urea (and/or bacterial metabolism).
However, after 5–10 days of incubation, ammonium
concentrations (Figure 5(c) and 5(f)) began to rise
suggesting that bacteria, which started to dominate
the cultures as discussed above, began to transform
urea to ammonium.
The NH+4 − N (Figure 5(f)) concentration increased in
all dilutions rising up to 19 mg L−1 (1:75-diluted urine)
but after 16–18 days the concentration started to level
off except in 1:25-diluted urine, where the ammonium
transformation continued due to high initial urea con-
centration (>50 mg L−1 NH+4 − N by day 21, Figure 5(f)).
In cultures to which urine was added, the urea concen-
tration (Norg) decreased in all cultivations when the
Figure 5. Nitrogen utilization as Ntot, Norg and NH4–N in set-up I (a, b, and c) and with different dilutions in set-up II (d, e, and f). The
error bars represent the standard error of three (set-up I) and two (set-up II) replicates.
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concentration of ammonium started to increase, which
was as expected as bacteria released ammonium from
Norg in addition to algae and bacteria utilizing Norg in
their growth. In the modiﬁed Chu-10 culture, nitrate
(NO−3 ) was used as the nitrogen source and was con-
verted into nitrite (NO−2 ) (93% decrease in nitrate con-
centration), the concentration of which increased up to
level of 28 mg L−1 by the end of the incubation (data
not shown). The concentration of nitrite remained
below 5 mg L−1 in 1:100-diluted urine and in urine+TE
cultures in set-up I and in set-up II nitrate was not
detected during cultivation suggesting that nitriﬁcation
did not take place. The absence of nitrite in algal cultiva-
tions on urine indicated that nitrifying bacteria were
likely not introduced in the cultures via urine to
convert urea to nitrite, whereas in modiﬁed Chu-10
culture nitrite was the logical product of nitrate (nutrient
source) utilization.
The concentration of dissolved Ntot followed with the
decline in Norg which indicated that the algae and bac-
teria utilized Norg (Figure 5(b) and 5(e)). According to
Hodson and Thompson,[40] C. vulgaris converts urea to
ammonium without enzymatic reactions. This suggests
that C. vulgaris does not have ureolytic enzymes and indi-
cates that in the present study C. vulgaris utilized urea as
the nitrogen source, but ammonium formation was likely
of bacterial origin. As stated previously, the ureolytic
activity of bacteria found in urine can also have caused
the decrease of Norg in the cultures. Since VSSalgae
reached a stationary phase after around 10 days
(Figure 1(b) and 1(c)), it is reasonable to assume that
part of the urea consumption after that is due to bacterial
metabolism.
Especially, the effects of ammonium containing urine
as the nitrogen source on the growth of algal cultures
were of interest as previously it has been shown that
ammonium uptake lowers the culture pH thus affecting
algal growth. Furthermore, unionized ammonia (as
NH3) can be toxic to microalgae [41] as shown by Adams-
son [15] who reported decreased microalgal growth as
ammonium concentration increased (2% urine was
used). However, in the present study, the biomass con-
centration showed no signs of decline suggesting that
overall biomass (including bacteria) growth continued
despite the increasing ammonium concentration (after
day 10, Figure 5(c) and 5(f)). The utilization of ammonium
was different in the two set-ups: whereas in set-up I the
concentration of ammonium rose rapidly after day 5, in
set-up II it only began to rise after day 11 (Figure 5(c)
and 5(f)). This was likely due to different initial
ammonium concentrations in the two experiments, as
the initial concentration of NH+4 − N in set-up II was
about half of that in set-up I (Table 1).
4. Conclusions
From the present study, we conclude that in a batch
system using non-sterilized urine
. At the relatively low light intensities used, similar
biomass yields of C. vulgaris and associated bacteria
were obtained with 1:25- and 1:300-diluted urine
(0.52 vs. 0.48 gVSS L−1) as in artiﬁcial media previously
found optimal for C. vulgaris cultivation.
. The highest biomass yields were obtained in 1:100-
diluted urine with (0.73 gVSS L−1) and without trace
element additions (0.60 gVSS L−1).
. Even 1:300-diluted urine contained sufﬁciently nutri-
ents and trace elements to support biomass growth.
. The cultures were ﬁrst dominated by living microal-
gae, while in the course of incubation bacteria
became more competitive and also the portion of
dead algal cells increased.
. Biomass growth was similar in comparative cultiva-
tions although pH varied from <5 to 9.
. Ammonium formed (>59 mg L−1) during cultivations
did not inhibit biomass production.
Acknowledgements
The authors are grateful to M.Sc. Viljami Kinnunen for the co-
operation during the laboratory experiments.
Disclosure statement
No potential conﬂict of interest was reported by the authors.
Funding
The ﬁnancial support provided by TUT Doctoral Programme
in Engineering and Natural Sciences, Finnish Doctoral
Programme in Environmental Science and Technology
(EnSTe) and Maa- ja vesitekniikan tuki ry. are highly
appreciated.
References
[1] Lakaniemi A-M, Tuovinen OH, Puhakka JA. Anaerobic con-
version of microalgal biomass to sustainable energy car-
riers – a review. Biores Technol. 2013;135:222–231.
[2] Lam MK, Lee KT. Microalgae biofuels: a critical review of
issues, problems and the way forward. Biotechnol Adv.
2012;30:673–690.
[3] Abdelaziz AEM, Leite GB, Hallenbeck PC. Addressing the
challenges for sustainable production of algal biofuels:
I. Algal strains and nutrient supply. Environ Technol.
[Special Issue: Sustainable Technologies: Bioenergy and
Biofuel from Biowaste and Biomass]. 2013;34:1783–1805.
[4] Abdelaziz AEM, Leite GB, Hallenbeck PC. Addressing the
challenges for sustainable production of algal biofuels: II.
1168 S. JAATINEN ET AL.
D
ow
nl
oa
de
d 
by
 [T
am
pe
re 
Un
ive
rsi
ty 
of
 T
ec
hn
olo
gy
] a
t 0
4:0
2 2
7 M
ay
 20
16
 
Harvesting and conversion to biofuels. Environ Technol.
[Special Issue: Sustainable Technologies: Bioenergy and
Biofuel from Biowaste and Biomass]. 2013;34:1807–1836.
[5] Ahmad AL, Yasin NHM, Derek CJC, Lim JK. Comparison of
harvesting methods for microalgae Chlorella sp. and its
potential use as a biodiesel feedstock. Environ Technol.
2014;35:2244–2253.
[6] Rawat I, Bhola V, Kumar, RR, Bux F. Improving the feasi-
bility of producing biofuels from microalgae using waste-
water. Environ Technol. [Special Issue: Sustainable
Technologies: Bioenergy and Biofuel from Biowaste and
Biomass]. 2013;34:1765–1775.
[7] Pittman JK, Dean AP, Osundeko O. The potential of sus-
tainable algal biofuel production using wastewater
resources. Biores Technol. [Special Issue: Biofuels – II:
Algal Biofuels and Microbial Fuel Cells]. 2011;102:17–25.
[8] Harper HA, Rodwell VW, Mayes PA. Review of physiologi-
cal chemistry. 17th ed. Lange Medical Publications; 1979.
Chapter 39, The kidney and the urine; 702 p.
[9] Winker M, Vinnerås B, Muskolus A, Arnold U, Clemens J.
Fertiliser products fromnewsanitation systems: their poten-
tial values and risks. Biores Technol. 2009;100:4090–4096.
[10] Chang Y, Wu Z, Bian L, Feng D, Leung DYC. Cultivation of
Spirulina platensis for biomass production and nutrient
removal from synthetic human urine. Appl Energy.
2013;102:427–431.
[11] Feng D-L, Wu Z-C. Culture of Spirulina platensis in human
urine for biomass production and O2 evolution. J Zhejiang
Univ Sci B. 2006;7:34–37.
[12] Yang C, Liu H, Li M, Yu C, Yu G. Treating urine by Spirulina
platensis. Acta Astronaut. 2008;63:1049–1054.
[13] Tuantet K, Janssen M, Temmink H, Zeeman G, Wijffels RH,
Buisman CJN. Microalgae growth on concentrated human
urine. J Appl Phycol. 2014;26:287–297.
[14] Tuantet K, Temmink H, Zeeman G, Janssen M, Wijffels RH,
Buisman CJN. Nutrient removal and microalgal biomass
production on urine in a short light-path photobioreactor.
Water Res. 2014;55:162–174.
[15] Adamsson M. Potential use of human urine by green-
house culturing of microalgae (Scenedesmus acuminatus),
zooplankton (Daphnia magna) and tomatoes
(Lycopersicon). EcolEng. 2000;16:243–254.
[16] Lakaniemi A-M, Hulatt CJ, Wakeman KD, Thomas DN,
Puhakka JA. Eukaryotic and prokaryotic microbial commu-
nities during microalgal biomass production. Biores
Technol. 2012;124:387–393.
[17] Lakaniemi A-M, Intihar VM, Tuovinen OH, Puhakka JA.
Growth of Chlorella vulgaris and associated bacteria in
photobioreactors. Microb Biotechnol. 2012;5:69–78.
[18] Hulatt CJ, Lakaniemi A-M, Puhakka JA, Thomas DN. Energy
demands of nitrogen fertiliser supply in mass cultivation
of two commercially important microalgal species,
Chlorella vulgaris and Dunaliella tertiolecta. Bioenerg Res.
2012;5:669–684.
[19] Schuler JF, Diller VM, Kersten HJ. Preferential assimilation
of ammonium ion by Chlorella vulgaris. Plant Physiol.
1953;28:299–303.
[20] Clarens AF, Resurreccion EP, White MA, Colosi LM.
Environmental life cycle comparison of algae to other
bioenergy feedstocks. Env Sci Technol. 2010;44:1813–
1819.
[21] Medeiros DL, Sales DA, Kiperstok A. Energy production
from microalgae biomass: carbon footprint and energy
balance. J Clean Product. 2015;96:493–500.
[22] Soares FR, Martins G, Seo ESM. An assessment of the econ-
omic aspects of CO2 sequestration in a route for biodiesel
production from microalgae. Environ Technol. [Special
Issue: Sustainable Technologies: Bioenergy and Biofuel
from Biowaste and Biomass]. 2013;34:1777–1781.
[23] Chu-10 (Modiﬁed by J. Acreman, CPCC). Canadian
Phycological Culture Centre. [Internet]. Available from:
https://uwaterloo.ca/canadian-phycological-culture-centre/
cultures/culture-media/chu-10
[24] Ilavarasi A, Mubarakali D, Praveenkumar R, Baldev E,
Thajuddin N. Optimization of various growth media to
freshwater microalgae for biomass production.
Biotechnology. 2011;10:540–545.
[25] Perez-Garcia O, Bashan Y, Esther Puente M. Organic
carbon supplementation of sterilized municipal waste-
water is essential for heterotrophic growth and removing
ammonium by the microalga Chlorella vulgaris. J Phycol.
2011;47:190–199.
[26] Lam MK, Lee KT. Potential of using organic fertilizer to cul-
tivate Chlorella vulgaris for biodiesel production. Appl
Energy. 2012;94:303–308.
[27] de-Bashan LE, AntoundH, Bashan Y. Cultivation factors and
population size control the uptake of nitrogen by the
microalgae Chlorella vulgaris when interacting with the
microalgae growth-promoting bacterium Azospirillum bra-
silense. FEMS Microbiol Ecol. 2005;54:197–203.
[28] Finnish Standard Association. SFS-EN ISO 10304–1:en.
2009. Water quality. Determination of dissolved anions
by liquid chromatography of ions. Part 1: Determination
of bromide, chloride, ﬂuoride, nitrate, nitrite, phosphate
and sulfate (ISO 10304–1:2007).
[29] Finnish Standards Association. SFS 3018. 1982. Metal
content of water determined by atomic absorption spec-
troscopy, atomization in ﬂame. Special guidelines for
calcium and magnesium.
[30] Finnish Standard Association. SFS 3044. 1980. Metal
content of water, sludge and sediment determined by
atomic absorption spectroscopy, atomization in ﬂame.
General principles and guidelines.
[31] Finnish Standard Association. SFS-EN 1484:en. 1997.
Water analysis. Guidelines for the determination of total
organic carbon (TOC) and dissolved organic carbon DOC.
[32] Zhang X, Amendola P, Hewson JC, Sommerﬁeld M, Hu X.
Inﬂuence of growth phase on harvesting of Chlorella
zoﬁngiensis by dissolved air ﬂotation. Biores Technol.
2012;116:477–484.
[33] Lee J, Cho D-H, Ramanan R, Kim B-H, Oh HM, Kim H-S.
Microalgae-associated bacteria play a key role in the ﬂoccu-
lationofChlorella vulgaris. Biores Technol. 2013;131:195–201.
[34] Miao X, Wu Q. High yield bio-oil production from fast
pyrolysis by metabolic controlling of Chlorella protothe-
coides. J Biotechnol. 2004;110:85–93.
[35] Lü F, Ji J, Shao L, He P. Bacterial bioaugmentation for
improving methane and hydrogen production from
microalgae. Biotechnol Biofuels. 2013;6:92–102.
[36] Brewer PG, Goldman JC. Alkalinity changes generated
by phytoplankton growth. Limnol Oceanog.
1976;21:108–117.
ENVIRONMENTAL TECHNOLOGY 1169
D
ow
nl
oa
de
d 
by
 [T
am
pe
re 
Un
ive
rsi
ty 
of
 T
ec
hn
olo
gy
] a
t 0
4:0
2 2
7 M
ay
 20
16
 
[37] Huss VAR, Frank C, Hartmann EC, Hirmer M, Kloboucek
A, Seidel BM, Wenzeler P, Kessler E. Biochemical
taxonomy and molecular phylogeny of the genus
Chlorella sensu lato (Chlorophyta). J Phycol. 1999;35:587–
598.
[38] Krajewska B. Ureases I. Functional, catalytic and kinetic
properties. J Mol Catal B: Enzymatic. 2009;59:9–21.
[39] Becker EW. Microalgae. Biotechnology and microbiology.
Irthlingborough: Cambridge University Press; 1994. p. 293.
[40] Hodson RC, Thompson JF. Metabolism of urea by Chlorella
vulgaris. Plant Physiol. 1969;44:691–696.
[41] Azov Y, Goldman JC. Free ammonia inhibition of algal
photosynthesis in intensive cultures. Appl Env Microbiol.
1982;43:735–739.
1170 S. JAATINEN ET AL.
D
ow
nl
oa
de
d 
by
 [T
am
pe
re 
Un
ive
rsi
ty 
of
 T
ec
hn
olo
gy
] a
t 0
4:0
2 2
7 M
ay
 20
16
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Dedicated to my dad 
I know you are always proud of me 
I love you 
ISBN 978-952-15-3765-3
ISSN 1459-2045
Tampereen teknillinen yliopisto 
PL 527
33101 Tampere
Tampere University of Technology
P.O.B. 527
FI-33101 Tampere, Finland
